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ABSTRACT 
N-deoxyribosyltransferase catalyses the transfer of 2-deoxy-I 2., 3-dideoxy- 
and 2,5-dideoxyribose sugars between purine and pyrimidine bases. In this 
work, a crude extract of N-deoxyribosyltransferase from Lactobacillus 
leichmannii was used in the chemoenzymatic synthesis of nucleoside 
analogues with potential antiviral activity, in particular, 9-P-D-2', 3'- 
dideoxyribofuranosyl 2-aminopurine which had anti-HIV activity. 
The immobilisation of a crude extract of N-deoxyribosyltransferase on a 
variety of support matrices is described. The most successful matrices were 
octyl Sepharose and Poly(acrylamide-co-N-acryloxysuccinimide) (PAN- 
550) gel. However, the PAN method gave higher and more sustained 
levels of activity, was easier to handle and incubate, and provided a 
general batch reactor method for the large scale synthesis of nucleosides 
such as 2-thio-2'-deoxyuridine. 
As the synthesis of Y-subs titute d-2,3'-dide oxynucleo sides was not possible 
by the enzymatic transfer method, an investigation into the 
conformations adopted by the nucleosides, which were and were not 
glycosyl donor nucleosides in the transfer reaction, was undertaken using 
variable temperature 1H NMR. Little is known about the active sites of the 
N-deoxyribosyltransferases from lactobacilli, but major factors accounting 
for this lack of reactivity may be steric hindrance or dipolar effects that 
inhibit the binding of a substrate to the transferase. Another factor which 
may be important is the conformation and flexibility of the deoxyribose 
ring, because a substrate which adopts a "rigid", unfavourable shape may 
not bind to the active site of the transferase and may be inactive as a 
substrate. Analysis of the variable temperature 1H NMR data led to 
information about the conformer populations, the equilibrium constants 
and, the free energy, enthalpy and entropy of each system. The 
temperature dependance of the coupling constants yielded quantitative 
information with regard to the position of the dynamic equilibrium 
between the two principal conformers of the sugar ring and determined 
the flexibility of sugar rings in nucleosides. It was found that only 
"'flexible" sugar rings without extremes of conformation were active as 
glycosyl donors in our system. 
The modified nucleoside, (±)-l-[(2'P, 4'p)-2"-(hydroxymethyl)-4'- 
dioxolanyllthymine, [(±)-Dioxolane-T], in which the Y-carbon atom is 
replaced by oxygen, was prepared. Its ability to act as a glycosyl donor for N- 
deoxyribosyltransf erases from lactobacillus was investigated but 
unfortunately its extreme conformation prevented it from being an active 
glycosyl donor. 
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CHAPTER I 
INTRODUCTION 
1.1: Background 
Viruses were discovered in the 1890's following studies on the tobacco leaf 
mosaic diseasel. At that time bacteria were believed to be the organisms 
responsible for disease. However, it was found bacteria-free filtrates were 
still able to induce disease in healthy plants and the causative agents were 
called viruses. 
In 1898 "Filterable Viruses" were confirmed when foot and mouth disease 
was transmitted from the bacteria-free lymph of infected cattle2. Viral 
infections such as influenza, herpes, hepatitis, rabies, chicken pox, and 
mumps account for about sixty per cent of all illness in developed 
countries. In 1941 the introduction of penicillin transformed medicine, 
giving physicians a powerful and versatile weapon against infectious 
bacteria, which only account for fifteen per cent of all diseases. Over forty 
years on there is still no comparable remedy for viral infections, but the 
threat of other viruses has been overshadowed by the spread of aquired 
immune deficiency syndrome (AIDS). 
Viruses consist of a genetic component (DNA or RNA) contained in a 
protein coat (capsid) made up of glycoproteins and/or lipids. The structure 
of the viral coat, type of nuclei acid, mode of entry into cells and the 
mechanism of repli-cation all vary depending on the virus. 
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There are few effective treatments for viral diseases (none for 
retroviruses) since viruses (unlike bacteria, which are independent of the 
host cell with unique enzymes and substrates and therefore effective 
therapies can be targetted) always commandeer the host cells' genetic 
machinery in order to reproduce. This obligate, intracellular nature of 
viruses produces an intimate involvement between host and virus which 
makes selective inhibition of viral replication difficult without affecting 
the host cells. Indeed, until the beginning of the 1960's the problem of 
distinguishing viral functions from cellular ones for selective attack of the 
virus was thought to be insurmountable. Instead the main strategy for 
controlling viral infections was (and still is to a large extent) the 
development of vaccines, which forestall infection by stimulating the 
immune system in advance rather than attack the virus directly. 
1.2: Antiviral Therapy 
Since the advent of AIDS, first described in the early 1980'S, 3 the search for 
new antiviral drugs has intensified rapidly. As yet there is no cure for 
AIDS or a vaccine for the Human Immunodeficiency Virus (HIV) which 
is the cause of the disease and the epidemic continues to spread. Therefore, 
there is an increased demand for more potent drugs, not only to inhibit 
and prevent the replication of the HIV, but also to treat the many life 
threatening opportunistic infections associated with this 
immunosuppressive condition3,4. 
An effective antiviral agent must either kill or stop the pathogen from 
multiplying without harming the infected host significantly. Selective 
agents exert their favourable effects through one or more of the following: 
2 
9 they are accumulated principally by the infected cell; 
*they utilise differences in the systems: attacking a biochemical 
pathway that is unique to the pathogen or infected cell; 
*they react exclusively with a structure that exists only in the virus. 
The replication of viruses is intimately connected with the biochemical 
mechanisms of the host cell and so there are few unique functions for 
selective attack. In the replication of viral nucleic acids there exist certain 
enzymes that are specifically coded for by the virus. These processes are 
therefore unique to infected cells and so offer an ideal opportunity for 
6 selective chemotherapy', . 
Nucleoside Analogues 
1.3.1: Inhibitors of DNA Syntheses 
Herpes viruses are a class of double-stranded DNA viruses which cause a 
variety of diseases in humans: e. g. cold sores, eye infections (keratitis), 
genital sores, chicken-pox, shingles and glandular fever (infectious 
mononucleosis). The different viruses include herpes simplex virus 
(HSV-1 and HSV-2), Varicella zoster virus (VZV), cytomegalovirus 
(CMV), and Epstein Barr virus (EBV)7-10. 
There are many nucleoside analogues targetted at the herpes virus because 
11,12 
it codes for many enzymes required in its replication and metabolism 
This produces some selectivity for the drug action. An example of an 
effective drug is 9-(2-hydroxyethoxymethyl) guanine (ACV, acyclovir, Fig. 
1 
3 
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Fig. 1.1 The chemical structure of Acyclovir 
Acyclovir has a low toxicity as it is only metabolised in cells infected with 
the herpes viruses, where 'it has a much higher affinity for the virus 
induced deoxythymidine kinase than for the corresponding kinase of the 
host cells. This kinase phosphorylates the acyclovir into acyclovir 
monophosphate which is further phosphorylated into the triphosphate. 
Once again the DNA polymerase of the herpes virus has a much higher 
affinity for the acyclovir triphosphate than the cellular polymerase; hence 
they are added to viral DNA in preference to cellular DNA. The drug is 
incorporated into the growing DNA strand where it acts as a chain 
terminator due to the lack of the Y-hydroxyl group. Furthermore, it also 
15-17 acts as a suicide substrate for the DNA polymerase 
However, as the replication cycle of each class of virus is unique there are 
few broad-spectrum antiviral agents, unlike the broad spectrum 
antibiotics. An example is phosphonoformate18. Any drug which affects 
more than a single viral species is likely to impair a fundamental 
biochemical pathway and therefore have inevitable host cell toxicity. 
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There are only a few antiviral drugs licensed for use: 
DRUG 
Amantadine 
Rimantadine 
5-Iodo-2'-deoxyuridine 
5-Trifluoromethyl-2'-deoxyuridine 
Adenine arabinoside 
Acyclovir 
Gancyclovir 
5-Ethyl-2'-deoxyuridine 
5-Iodo-2'-deoxycytidine 
Ribavirin 
3'-Azido-2', 3"-dideoxythymidine 
2', 3'-dideoxyinosine 
VIRUS 
Influenza A 
Influenza A (USSR) 
HSV 
HSV 
HSV 
HSV, VZV 
Cytomegalovirus 
HSV (Germany) 
HSV (France) 
Respiratory syncytial virus 
HIV-1 
HIV-1 
Table 1.1 Licensed antiviral drugs19 
Most of the promising drugs have been nucleoside analogues and the 
majority of current successes have been centered around interrupting 
11,15,20-23 nucleic acid synthesis 
There are many other antiviral compounds which owe their effects to 
their resemblance to nucleosides. They can act as chain terminators24-26, 
inhibit the viral-specific mRNA capping enzymes, guanyl transferase and 
N-7 methyl transferase20,21,27, or they can be suicide substrates for some 
polymerases13. 
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The AIDS Virus 
AqUired immune deficiency syndrome (AIDS) is believed to have spread 
from central Africa to the Caribbean and then the U. S. and Europe. In 1984 
the disease -was shown to be caused by a retrovirus known as the human 
immunodeficiency virus (HIV)3 
Fig. 1.2 Diagramatic representation of HIV28 
HIV is a member of the lentivirus family 
(a sub-class of retrovirus) and 
like other viruses, cannot replicate without taking over 
the biosynthetic 
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apparatus of the host cell and exploiting it for its own ends. The HIV 
virion is a sphere that is roughly 1000 A units across. The virus particle is 
covered by a membrane, made up of two layers of lipid material, that is 
derived from the outer membrane of the host cell. Studding the 
membrane are glycoproteins: each has two components; gp4l spans the 
membrane and gp120 extends beyond it. The membrane-and-protein 
envelope covers a core made up of proteins designated p24 and p18. The 
viral RNA is carried in the core, along with several copies of the enzyme 
reverse transcriptase, which catalyzes the assembly of the viral DNA28- 
The virus possesses no energy-producing or protein-synthesizing 
machinery of its own. In order to reproduce., it must therefore become 
absorbed to a host cell on specific cell-surface receptor molecules, be 
transported across the cell membrane., penetrate the cell cytoplasm, and 
uncoat in order that its viral genes can be expressed. The genome may 
require transportation to the cytoplasm or the nucleus. In retroviruses the 
genetic information is encoded on RNA and in order for them to replicate 
this must be transcribed into DNA. Once the RNA has been injected into 
the host cell, a virally encoded enzyme, reverse transcriptase, exploits the 
viral RNA as a template to assemble a corresponding molecule of DNA. 
The viral DNA then travels to the nucleus of the host cell and integrates 
itself into the genome of the host. The integrated viral genome, known as 
a provirus may remain latent until it is activated to replicate. The proviral 
DNA is then transcribed into mRNA, which directs the synthesis of viral 
proteins. The provirus also gives rise to other RNA copies which will 
serve as the genetic material of viral progeny. The proteins and the 
genomic RNA congregate at the cell membrane and assemble to form new 
HIV particles, which then bud from the cell16. 
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Fig. 1.3 Stages in the life-cycle of HIV which can be targetted by drugs29 
1.5: AIDS Therapy 
The wealth of knowledge that has now been gained about HIV enables the 
groundwork for treatment and prevention to be laid. The HIV life-cycle 
offers many potential targets for antiviral agents to inhibit such as: 
I 
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adsorption, penetration,, uncoating, reverse transcription, proviral DNA 
circularization and integration, viral mRNA transcription, maturation 
(capping, splicing, polyadenylation), and translation,, viral protein 
precursor cleavage and glycosylation, virus assembly and release (budding) 
30-34 
The most tempting drug target in the HIV replication cycle is reverse 
transcription, a step both crucial to viral replication and irrelevant to host 
celIS35-37. There are several non-nucleoside inhibitors of the reverse 
transcriptase enzyme33,38,39. The first class, while being inhibitors of the 
reverse transcriptase process, achieve their activity through inhibition of 
virus attachment to the celIS40. The second class interact noncompetitively 
with a specific allosteric binding site of the reverse transcriptase36 
However, most of the compounds are nucleoside analogues which bind 
competitively to the binding site of reverse trans crip tas e36. 
Of these inhibitors of reverse transcriptase, nucleoside analogues appear to 
affect a more potent and more selective action than the other classes of 
compounds. They do this by exerting a competitive action with respect to 
the normal substrates. Many 2', 3-dideoxynucleosides25,26,41,42 and 2', 3'- 
substituted nucleosideS43-48 have been synthesised but the most potent of 
these chain terminating nucleoside analogues are 2', 3'-dideoxycytidine 
(ddC )25,3/ - azido- 2', 3'- di deoxythyrni dine 
dideoxyinosine (ddj)51. 
(AZT)24,49,50 and 2", 3'- 
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Fig. 1.4 The chemical structures of some antiviral nucleosides 
The nucleosides must first be converted intracellularly to the 
corresponding 5'-triphosphates before any interaction with reverse 
transcriptase can occur. There is no difference in the ability of uninfected 
and virus-infected cells to phosphorylate the 2', 3'-dideoxynucleosi des - 
Therefore, the selectivity of these nucleoside analogues must be based 
upon their interaction with the reverse transcriptase: to which it has an 
affinity 100 times greater than its affinity for cellular DNA polymerase. 
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The analogue is incorporated into the growing DNA chain (Fig. 1.5 B) but 
as the Y-hydroxyl group of the analogue has been replaced by a hydrogen 
or other substituent, subsequent elongation of the DNA chain is 
prevented. 
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Fig. 1.5 Chain termination of the growing DNA by AZT3,16 
II 
Strategies for the design of inhibitors of reverse transcriptase have been 
advanced greatly by the recent structural elucidation of the HIV-1 reverse 
transcriptase/DNA complex at 7A resolution showing active site 
locations52. 
However, drug-resistant variants of HIV, resulting from mutations within 
the virus genome, have been recovered from patients undergoing long- 
term treatment with antiviral compoundS53-55. The resistant variants arise 
from selective amino acid mutations in the reverse transcriptase which 
prevent the antiviral nucleoside analogues from binding. The analogues 
are therefore not incorporated into the growing chain of DNA and no 
chain termination occurs. This means that the need for more clinically 
useful therapeutic agents has heightened. 
1.6: Nucleoside Synthesis 
1.6.1: Chemical Synthesis 
There are three main categories for the chemical synthesis of nucleoside 
analogueS56-60: 
* the modification of a preformed nucleoside; 
* the formation of the glycosidic bond by the fusion of a preformed 
base onto a sugar; or 
, *the de novo synthesis of a heterocyclic 
base onto a preformed 
nitrogen or carbon substituent at C-1 of the sugar moiety. 
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1.6.1.1: Formation of the Glycosidic Bond 
1.6.1.1(i): Koenigs-Knorr Procedure 
In the case of ribose sugars this reaction utilises the presence of an acyloxy- 
substituent at C-2 to produce selectively only the P-ribonucleosides. 
The initial sugar halide is formed from the reaction of either the cc- or P-D- 
ribofuranose tetraacetate with hydrogen bromide in acetic acid to give 
2,3,5-tri-O-acetyl-(x-D-ribofuranosyI bromide (Scheme 1.6). 
0 
AcO HO OH AC2 0 AcO OAC HBr 
Br 
H OH Ac Ac AcO OAc 
Scheme 1.6 Synthesis of 2,3,5-tri-O-acetyl-(x-D-ribofuranosyI bromide 
Under these conditions the (x-anomer of the bromide usually 
predominates because of the powerful anomeric effect. The anomeric 
effect is due to stereo-electronic factors arising from the more favourable 
dipolar interaction between the dipole associated with the ring-oxygen and 
the dipole associated with the substituent at C-1 in the axial position. This 
is shown by the Newman projection along the C-1 to 0-5 
bond: 
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Fig. 1.7 Newman projection 2,3,5-tri-O-acetyl-cc-D-ribofuranosyI bromide 
along the C-1 to 0-5 bond 
The (x-anomer is thermodynamically more stable as the dipoles are not in 
opposition and thus represent a lower energy configuration. The extent of 
the anomeric effect depends upon the nature of X substituent and the 
solvent. Non polar solvents favour the cc-anomer whereas polar solvents 
favour the P-anomer. 
Heavy metal salts of the bases catalyse the nucleophilic displacement of 
the halogen substituent from the C-1 of the protected sugar to give the 1,2- 
trans product despite the fact that the reaction is unimolecular. The 
formation of only the P-product is due to the shielding of the (x-face of the 
sugar by the neighbouring trans-acetoxyl group at C-2. 
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Scheme 1.8 Koenigs-Knorr displacement of halide 
The stabilisation of the carbonium ion by neighbouring group 
participation is confirmed by the production of both cc- and P-anomers 
when the C-2 group is lacking (Scheme 1.9). 
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Scheme 1.9 Formation of both (x- and P-anomers in the absence of a 
functional group at C-2 
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With pyrimidines, the initial product is an 0-glycoside (kinetic product) 
which then reacts with another mole of sugar halide in the presence of 
mercuric chloride to form the N-glycoside (thermodynamic) product of 
the required P-nucleoside58. 
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Scheme 1.10 Pyrimidine nucleoside synthesis 
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BzO 
In purine nucleoside synthesis the initial N-3 glycosyl derivative 
undergoes an intermolecualr rearrangement to give the N-9 product. 
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Scheme 1.11 Purine nucleoside synthesis 
However, in the synthesis of 2'-deoxynucleos ides and 2', 3'- 
dideoxynucleosides the lack of the 2/-acyl substituent means there is no 
stereochernical control. There is no neighbouring group participation to 
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protect the exo-face of the sugar moiety. This results in anomeric mixtures, 
so for their synthesis other methods are favoured which will be expanded 
on later. 
1.6.1.1(ii): Hilbert-Johnson and Silyl Procedures 
O-substituted pyrimidines are sufficiently nucleophilic to react directly 
with halogeno-sugars without any need for electrophilic catalysis. In the 
alkylation of a 2-alkoxypyrimidine with a halogeno-sugar the initial 
product is a quaternary salt which can then be reacted to give several 
nucleosides with different base moieties. 
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Scheme 1.12 Hilbert-Johnson synthesis of nucleosides 
Owing to the mechanism of the reaction, a mixture of anomers is often 
produced, even with a ribose derivative bearing a 2-acyloxy-substituent. 
The relative contributions of carboxonium ion to the overall reaction 
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determines the ratio of products. In the basic reaction mechanism there is 
little neighbouring group participation, however, by altering the reaction 
conditions, such as the use of mercuric bromide, the proportion of 
anomer can be increased. 
The halogenoses used in these preparations are rather unstable so the use 
of peracylated sugars in combination with silylated bases has the 
advantage of easy preparation, homogeneous reaction mixtures, and 
intermediate products which can be converted into a variety of 
nucleosides with modified bases. The use of mercuric oxide as a catalyst 
gave way to Lewis acid catalysts such as tin (IV) chloride and mercuric 
acetate, which have now been superseded by the use of silyl esters of 
strong acids, e. g. trimethylsilyl triflate, trimethylsilyl nonaflate or 
trimethylsilyl perchlorate. These Friedel-Crafts-catalysed reactions of a 
peracylated sugar and a silylated heterocycle in 1,2-dichloroethane, 
dichloromethane, or acetonitrile room temperature are fast and high 
61-63 yielding 
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Scheme 1.13 Friedel-Crafts-catalysed nucleoside synthesis 
With ribose sugars only the P-nucleoside is formed. However, some 
stereochemical control can be gained in the synthesis of deoxynucleosides 
by using suitable reaction conditions. The ratio of cc and P products varies 
with the solvent used. A polar solvent, such as acetonitrile, will promote 
an SNI reaction mechanism which will lead to a mixture of both (x and 0- 
nucleosides. The use of a non-polar solvent, such as carbon tetrachloride, 
promotes the SN2 mechanism, thus giving predominately P-nucleosides64. 
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These fusion methods work well to produce a large number of nucleoside 
analogues, including unnatural configurations., which have modified 
bases and sugars that maybe difficult to prepare by other methods. The 
modified sugar moeity can be synthesized from a carbohydrate or 
noncarbohydrate precursor65. However, the lack of precise control of regio- 
and stereoselectivity and the need for protecting groups in convergent 
syntheses can result in substantially reduced yields. 
1.6.1.2: Transglycosylation 
Transglycosylation is the transfer of a sugar residue from one base to 
another. The reaction is particularly effective for transferring sugars from 
pyrimidines (which are n-deficient heterocycles) to the more basic purines 
(n-excessive heterocycles). 
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Scheme 1.14 Synthesis of nucleosides by transglycosylation 
Its use in the synthesis of ribonucleoside derivatives has been 
demonstrated 66. The reaction products imply an SN1 reaction mechanism. 
As with other chemically catalyzed reactions, these products require 
chromatographic separation. 
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Construction of the Base onto the Sugar at C-1 
The advantage of building the base onto the sugar moeity is that the 
position of attachment of the glycosyl residue is unambiguous and if the 
C-1 substituent has a P-configuration then the product nucleoside will also 
have this stereochernistry. There are many examples of this type of 
synthesis which were used historically as a method for proving structures 
or for the preparation of analogues (ususually aza- or deaza-nucleosideS)58. 
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Scheme 1.15 Synthesis of a nucleoside by constructing the base onto the 
sugar67 
Nowadays, this route is often employed for the synthesis of C-nucleosides 
and carbocyclic nucleosides which can therefore have starting materials 
other than sugars or carbohydrates56. 
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Modification of Naturally-Occuring Nucleosides 
There are literally hundreds of reactions which can be used to transform 
the base of a preformed nucleoside57,58,68-72 but unfortunately the 
reactions available for the transformation of the sugar moiety are far less 
common and are often multistep procedures involving protection and 
57,60 deprotection steps to introduce some stereo- and regioselectivity 
Recently the interest in synthesising nucleosides with novel sugar 
moeities has resulted in several improved methods for the introduction 
of substituents into the sugar. The introduction of a fluorine substituent at 
various positions in the sugar moiety has produced many promising 
antiviral compounds. The fluorine atom is the most electronegative atom 
that can be introduced in an organic compound and has a van der Waals 
radius (1-35A) comparable to that of hydrogen (1.17A). Substitution of 
fluorine for hydrogen has a strong effect on the electronic configuration of 
a molecule, often reflected by a dramatic change in biological activity73. 
Presently., the most popular fluorinating agent is diethylaminosulphur 
trifluoride (DAST). The dialkylamino sulphur trifluorides are easy-to- 
handle fluorinating reagents for replacing hydroxyl and carbonyl oxygen 
with fluorine under very mild conditionS74. The many different 
fluorinating agents and methods will be discussed in Chapter 4. 
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1.6.2: Enzymatic Synthesis 
Many nucleoside analogues exhibiting antiviral properties are difficult to 
synthesise chemically owing to the presence of both modified base and 
sugar residues. These multistage processes are often difficult and time 
consuming and can produce mixtures of products in poor yields. With this 
in mind, chemists have been aware for a long time of the advantages that 
the use of enzymes as catalysts would have over purely chemical methods. 
Enzymes demand attention chiefly because of their efficiency, selectivity 
and mildness with which they catalyse reactions. For example, enzymatic 
glycosyl transfer reactions usually lead exclusively to the "natural" P- 
anomer of the nucleoside and only one site in the heterocyclic base is 
glycosylated75. The unique properties of enzymes can be exploited either, 
to replace existing chemical processes or in combination with chemical 
steps to improve existing methods. 
The broad substrate specificities of some enzymes often enables reactions 
to be performed on analogues of natural substrates in both aqueous and 
non-aqueous solvents. The mild conditions of these enzyme-catalysed 
reactions can give good yields and are useful methods for preparing a large 
range of produCtS76-80. However, some enzymes are strongly influenced by 
the concentration of substrates, products or other species present in 
solution which can cause problems in the scale-up for the production of 
large quantities of product. The problem of low solubility of some 
substrates and products has been addressed; for example, by the use of 
adenosine deaminase to convert a soluble diaminopurine nucleoside into 
an insoluble guanine nucleoside as the last step of a synthesis8l. 
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The use of immobilised enzymes means that a small amount of enzymes 
can be use repeatedly to produce more substantial quantities of product. 
Immobilisation can also enhance the thermal, mechanical, and chemical 
stability of the enzyme so that it becomes a recoverable catalyst. The 
immobilised enzyme is prevented from diffusing freely through the 
reaction medium by being adsorbed physically or attached chemically to a 
support material. Therefore, the reaction consists of two phases; the bulk 
solution and the immobilized enzyme with its support environment82. 
In the search for new drugs with antiviral activity many compounds have 
been screened. Vast effort has gone into defining and improving syntheses 
for nucleoside analogues with potential antiviral activity. The use of 
enzymes, which accept analogues as well as the natural substrates, give a 
convenient method for the small-scale synthesis of a huge range of highly 
modified base and sugar nucleoside analogues. The use of enzymes can 
thus be used to improve the current methods available for synthesising 
nucleoside analogues which are to be used in the screening programmeS78. 
1.6.3: Enzymatic Synthesis of Nucleoside Analogues 
1.6.3.1: Enzymatic Modification of Sugar or Base Residues 
Enzymes have been used to modify existing nucleosides by selective 
protection and deprotection of hydroxyl groUpS83-85. The synthesis of 
sugar-modified nucleosides such as 2'-O-acyl esters of araA86, and 
base 
modified nucleosides 87 have been described. By far the most useful 
application has been the resolution of nucleoside analogues 
by sugar 
88,89 
modification , or base modification using adenosine 
deaminase81,90. 
25 
Enzymatic resolution has also been used on intermediates in the synthesis 
91,92 of carbocyclic nucleosides 
1.6.3.2: Glycosyl Transfer Reactions 
Two main classes of enzyme have been used to synthesise nucleoside 
analogues by transferring glycosyl residues from a donor nucleoside to an 
acceptor base: nucleoside phosphorylases and N-deoxyribosyltransferaseS79. 
1.6.3.2(i); Nucleoside Phosphorylases 
Nucleoside phosphorylases catalyse the reversible phosphorolysis of ribo- 
or deoxyribonucleos ides affording ribose- or deoxyribose-1 -phosphate and 
a purine or pyrimidine base. Addition of an acceptor base can lead to the 
formation of a new nucleoside with the equilibrium lying well in favour 
of nucleoside formation. Since the discovery of nucleoside phosphorylase 
and a general description of a mechanisM93 this method of nucleoside 
synthesis has been widely used. Both pyrimidine and purine nucleoside 
phosphorylases are known. They can be obtained from mammalian and 
bacterial sources and their substrate specificities can vary with the source94. 
For example, mammalian purine nucleoside phosphorylase will not 
accept adenosine as a natural substrate but will carry out the 
phosphorolysis of inosine and guanosine. However, the enzyme from 
Escherichia coli will accept all three purine nucleosides as substrates. 
Two basic strategies have generally been used (with ribose as the sugar 
moiety in Scheme 1.16). The first involves isolation of the ribose-1- 
phosphate formed from a nucleoside donor and a high concentration of 
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phosphate. This intermediate is then used as the glycosyl donor to an 
added pyrimidine or purine base. 
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Scheme 1.16 Two-stage synthesis of nucleosides using nucleoside 
phosphorylases 
The second strategy involves a one-pot exchange of one base for another 
in the presence of a catalytic amount of inorganic phosphate without the 
isolation of the intermediate ribose-1 -phosphate. 
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Scheme 1.17 One-pot synthesis of nucleosides using nucleoside 
phosphorylases 
Both methods have been used for the small scale production of a variety 
of nucleoside analogues 79. The first strategy is the most general. The 
second strategy95 has limitations such as; a) an equilibrium mixture of 
starting and product nucleosides can be formed from which the desired 
nucleoside must be separated; and b) the released base from the glycosyl 
donor may act as a competitive inhibitor of the enzyme and prevent the 
base analogue from binding. The problem of inhibition can be 
circumvented by using a pyrimidine nucleoside as the glycosyl donor and 
a purine base as the acceptor. However, both a pyrimidine nucleoside 
phosphorylase and a purine nucleoside phosphorylase are then required. 
Both methods have disadvantages as they either require the presence of 
both pyrimidine and purine nucleoside phosphorylases or the isolation of 
the intermediate ribose-1 -phosphate. These problems can be overcome 
and the yields of the coupled enzymatic reaction can be greatly increased by 
the use of an irreversible donor nucleoside96. By using the salt of 7- 
methylguanosine, as the glycosyl donor, the first stage of the 
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phosphorolysis reaction is made irreversible. The cleavage of the glycosyl 
bond produces a neutral base molecule which lacks a tautomeric proton 
on N-7: it would be highly unfavourable to form the positively charged 
nucleoside in the reverse reaction. Therefore, the 7-methylguanine does 
not function as a acceptor base in the reverse reaction and so the 
intermediate ribose-1 -phosphate formed is available exclusively for the 
formation of product nucleoside. Only one of the nucleoside 
phosphorylases, not both, is required and as the 7-methylguanine is very 
insoluble, purification of the product nucleoside is very easy. The 
effectiveness of this approach was demonstrated in the synthesis of 
ribavarin using 1,2,4-triazole-3-carboxamide (TCA) as the acceptor base 
(Scheme 1.18). 
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Scheme 1.18 Use of 7-methylguanosine as an irreversible donor in the 
synthesis of nucleoside analogues 
29 
The nucleoside phosphorylases have been found to accept a wide range of 
nucleoside analogues and base analogues as substrates. The enzymes are 
able to tolerate a high degree of modification in the base component but 
only a limited amount of modification in the sugar moiety. So far 
nucleoside analogues with D-arabinofuranosyl, 2-aminoribose, 2-deoxy-3- 
aminoribose, and 5-deoxyribose as the sugar moiety have been 
synthesised. The nucleoside analogues which have been synthesised by 
the use of nucleoside phosphorylases have been summarised79- 
Thus, nucleoside phosphorylases have provided a regio- and stereospecific 
route for the synthesis of novel nucleoside analogues with potential 
antiviral activity. Recent advances have improved yields and purification 
of products. Recently, a new route has been describe which involves the 
coupling of nucleoside phosphorylase with phosphopentomutase97. 
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Scheme 1.19 Synthesis of nucleosides using nucleoside phosphorylase and 
phosphopentomutase 
The advantage of this approach is that a pentose-5- phosphate is easier to 
prepare and more stable than the corresponding (x-pentose-I -phosphate. 
This method is limited by the substrate specificity of the mutase which, to 
date, has been shown to accept D-ribose- and D-arabinose-5-phosphate in 
addition to its natural substrate 2-deoxyribose-5-phosphate. Unfortunately, 
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2/, 3'- did e oxyrib o se -5-ph o spha te 
phosphopentomutase. 
is not a substrate for the 
1.6.3.2(ii): N-Deoxyribosyltransferases 
The other class of enzymes are the N-deoxyribosyltransferases which were 
first reported by MacNUtt98. These enzymes were shown to catalyze 
deoxyribosyl transfer from 2-deoxyribonucleo sides to free purines and 
pyrimidines without the need for phosphate ions. The reaction involves 
the direct transfer of the 2-deoxyribose group from one heterocyclic base to 
another without the formation of a 2-deoxyribose- 1 -phosphate 
intermediate. The use of 2-deoxyribose-1 -phosphate as the glycosyl donor 
did not result in the formation of any 2-deoxyribonucleo sides. Further 
experiments were performed to clarify that the reaction mechanism was 
not the hydrolysis of the glycosidic bond followed by resynthesis with the 
donor heterocyclic base to give the new nucleoside99, nor the 
transamination of 2'-deoxyinosine to produce 2'-deoxyadenosinelOO, but 
was in fact trans-N-glycosylation. 
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Thus, the mechanism of the N-deoxyribosyltransferase was confirmed to 
be: 
0 
Base, 
E0 
Base2 
HO + Base HO + 
HO H 
Base = purine or pyrimidine 
E= N-deoxyribosyltransferase 
Scheme 1.20 Reaction of N-deoxyribosyltransferase 
Base, 
An extensive screening has been undertaken to investigate the occurence 
and specificity of this enzyme'01. Nucleoside deoxyribosyltransferases are 
present in appreciable levels in some organisms, notably the family 
Lactobacillaceae, which do not contain high levels of the nucleoside 
phosphorylase enzymes and require N-deoxyribosyltransferases to produce 
2-deoxynucleosides for growth. This activity has been found in L 
helveticus"2, L. delbruecki103, L. acidophiliUS104, and L. lactis"5 but is not 
present in extracts of L. casei105, or other microbes and animals 
examined106. 
Many procedures for the purification or partial purification of the N- 
deoxyribosyltransferases from various lactobacilli have been reported103- 
108. The first preliminary investigations were performed on partially 
purified enzymes from L. helveticus 105 which were stable below 550C 
with an optimum stability near pH 6.5, and an optimum activity near pH 
5.8. However., only a few heterocyclic bases were investigated as acceptors. 
The workers also confirmed previous findings that inorganic phosphate 
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was not required for the enzymatic transfer reaction but more importantly 
they noted the effect of Tris buffer. The complete inhibition of transfer of 
the 2-deoxyribosyl group to and from pyrimidines by Tris buffer and the 
partial inhibition of the transfer to and from purines was indicative of the 
presence of at least two enzymes in the preparation. 
It was shown that one enzyme,, not inhibited by Tris, catalysed purine- 
purine transfers and the other enzyme, which was inhibited by Tris, 
catalysed pyrimidine-pyrimidine, pyrimidine-purine and possibly purine- 
purine transfers. The presence of two distinct enzymes in L. helveticus 
was confirmed by Holguin and Cardinaudl08,109 when they purified out 
both activities using affinity chromatography with two types of ligand. N- 
deoxyribosyl trans ferase I catalysed the transfer of 2-deoxyribose residues 
exclusively between purine bases, whereas N-deoxyribosyl trans ferase II 
catalysed the transfer of 2-deoxyribose residues between purine and 
pyrimidine bases. 
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dRib-Pur(l) + Pur(2) dRib-Pur(2) + Pur(l) 
N-deoxyribosyltransferase 11 
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dRib-Pur(1) + Pyr dRib-Pyr + Pur 
dRib-Pyr(1) + Pyr(2) dRib-Pyr(2) + Pyr(1) 
dRib= 2-deoxy-D-ribose 
Pur = Purine 
Pyr = Pyrimidine 
Fig. 1.21 Activities shown by the two transferase enzymes 
The two transferase types showed different physical properties and N- 
deoxyribosyltransferase H showed inhibition by Tris in agreement with the 
previous findings. Detailed kinetic studies of both transferase enzymes 
from L. helveticus were performed and the initial velocity studies 
supplied evidence that the 2-deoxyribosyl transfer reactions both proceed 
via a ping-pong bi-bi mechanisml'O. The kinetic mechanism is ping-pong 
because the first product is released before the second substrate combines 
111,112 with the enzyme and it is bi-bi because the reaction is bimolecular 
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dRib-Base(l) Base(l) Base(2) dRib-Base(2) 
Enz-dRib 
Fig. 1.22 Ping-pong-bi-bi mechanism of N-deoxyribosyl trans ferase 
The donor nucleoside combines with the enzyme and the glycosyl bond is 
cleaved. The base is released, leaving a glycosyl-enzyme intermediate. The 
acceptor base enters the active site and combines with the glycosyl-enzyme 
intermediate. Finally, the new nucleoside is released, leaving the free 
enzyme. This mechanism postulates the existence of a stable glycosyl- 
enzyme intermediate in which the 2-deoxyribosyl moiety undergoes a 
double inversion during the course of the reaction. 
A detailed study of the substrate specificities of the N- 
deoxyribosyltransferases from L. helveticus has been decribed113. A wide 
range of heterocyclic bases were accepted by the enzyme but only a very 
limited number of nucleosides with modified sugar residues were 
accepted as donors. 
Recently, two distinct N-deoxyribosyltransferase activities were purified 
from Lactobacillus leichmannii and their substrate specificities 
investigated' 14 . As with enzymes from Lactobacillus helveticus, these 
enzymes were capable of accepting a wide number of heterocyclic base 
analogues as substrates but very little tolerance was shown towards donor 
nucleosides with modified sugar residues. Once again the transfer reaction 
proceeded via a ping-pong bi-bi mechanism and kinetic and radiolabelling 
experiments provided preliminary support for the existence of a covalent 
glycosyl intermediate. Chemical modification of N-deoxyribosyltransferase 
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II with specific chemical reagents suggested that histidine and/or carboxyl 
residues may participate in binding and catalysis at the active site of the 
enzyme. A proposed mechanism was suggested which fits with the 
information ascertained so far and highlights the double- inversion of the 
2-deoxyribosyl moiety to produce P-nucleosides exclusively. 
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Scheme 1.23 Proposed mechanism of N-deoxyribosyltransferase 
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N- deoxyribosyl trans ferase has also been purified and characterised from 
Leuconostoc mesenteroides subspecies cremoris"5. A single 
multifunctional enzyme capable of carrying out the transfer of the 2- 
deoxyribosyl moiety from either pyrimidine or purine nucleosides to 
either pyrimidine or purine bases was found to be present in this strain of 
Leuconostoc. Kinetic studies carried out on the purified enzyme showed 
that the transfer reaction also proceeded via a ping-pong bi-bi mechanism. 
Further evidence for the existence of a glycosyl-enzyme intermediate was 
provided by radiolabelling studies 
Microcrystals of nucleoside deoxyribosyltransferase obtained from 
Lactobacillus helveticus have been reported102, but these were not of 
sufficient quality to be used for X-ray studies. However, crystals of 
recombinant bacterial N-deoxyribosyltransferase have been grown from 
solutions of ammonium sulphate116. Molecular weight studies performed 
on the purified protein revealed a molecular weight for the intact enzyme 
of approximately 110,000 and a subunit molecular weight of approximately 
18,000. Therefore, the enzyme is a hexamer of six identical subunits. These 
studies were only performed on one of the transferase activites but no 
indication as to which one, was given. Only a very brief paper was 
published on this work; the complete data is yet to be published. 
1.7: Function of N-Deoxyribosyltransferase Activity 
Within cells, nucleosides can be synthesised in two ways: the de novo 
synthesis; or the salvage pathway. In the de novo pathway, the purine and 
pyrimidine bases 'are constructed onto the ribose moiety in several steps 
which is an overall high energy process. A much more efficient method is 
the salvaging of bases produced by hydrolysis of nucleic acids and 
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nucleotides. The metabolic function of the N-deoxyribo sy transfer as e is 
believed to be part of nucleic acid synthesis117. The effects of varying 
vitamin B12,2'-deoxyribonucleoside, or free purine and pyrimidine bases 
have been investigated and showed that vitamin B12 participates in the 
reduction of ribonucleosides to 2" - deoxyribonucleos ides 118-120. In the 
absence of vitamin B12 a single 2'-deoxyribonucleoside is converted to the 
full complement of DNA precursors by the N-deoxyribosyltransferase 
catalysed transfer of the 2-deoxyribose residue to the exogenous free 
bases121,122. In 2'-deoxyribonucleoside- or vitamin B12-liMiting cultures, 
filamentous forms of Lactobacillus leichmannii occur as a result of 
unbalanced growth due to impaired DNA synthesis. 
Purines and pyrimidines 
De novo Preformed 
Ribonucleotides 
RNA 
T 
DNA 
Fig. 1.24 Function of N-deoxyribosyltransferase in cells 
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Thus, the N-deoxyribosyltransf erase activity serves as an alternative 
pathway for 2-deoxynucleo tide synthesis in the absence of vitamin B12. 
1.7.1: N-Deoxyribosyltransf erases in the Synthesis of Nucleoside 
Analogues 
The N-deoxyribosyltransferases offer an alternative route to nucleoside 
phosphorylases for the synthesis of nucleoside analogueS78. For the 
synthetic preparation of nucleosides with possible antiviral activity, the 
transferases from Lactobacillus helveticus and Lactobacillus leichmannii 
are usually used as crude preparations without the separation of the two 
discrete transferase activities123,124. This is a very convenient method as 
the minimum of purification of the transferase enzyme is required. As 
with the nucleoside phosphorylases, the N-deoxyribosyltransf erase 
reaction is a very regio- and stereoselective process with the glycosyl bond 
being formed at only one nitrogen within the heterocyclic base in a 
configuration125. 
The use of crude enzyme preparations can simplify the synthetic 
procedure greatly, but degradation of products and substrates by 
contaminating hydrolytic and/or deaminating activities in the crude 
enzyme preparation can occur when long reaction times are used. The 
addition of water-miscible organic solvents to the synthetic reactions 
catalysed by the crude enzyme preparations can inhibit these degradative 
side reactions. it was found that the glycosyl transfer reaction was not 
affected provided that the concentration of the organic solvent was kept 
low. However, the best results were achieved by the addition of 10% (v/v) 
ethylene glycol to the reaction which inhibited any contaminating enzyme 
while allowing the transfer reaction to proceed as normal126. 
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In the transferase reactions, thymidine or 2" -deoxycyti dine are the most 
effective glycosyl donors. The transferases will only accept 2'-deoxy-, 2', 3'- 
dideoxy-,, and 2,5'-dideoxynucleosides as the donor nucleosides: no other 
sugar modifications have yet been found which are tolerated. However, 
considerable structural variation is tolerated in the acceptor bases, as was 
shown by the synthesis of a series of 2'-deoxyadenosine derivatives127. 
Initially the transferases were used to synthesise 2'-deoxynucleoside 
analogues with therapeutic activity, such as 2-chloro-2'-deoxyadenosine 
which has antileukernic and immunosuppressive activity128,129, and 
imidazole-2'-deoxynucleosideS75- The reaction is ideal for the preparation 
of radioactively labelled compounds as the radiolabel is found exclusively 
in either the base or the sugar moiety of the product nucleoside and there 
is no contamination in other parts of the nucleoside130. This has been 
shown in the synthesis of 2-[14C]-2'-deoxyribofuranosyl-5-trifluoromethyI 
uracill3l. 
It has been found that the efficacy of the potent antiviral drugs 2', 3' 
dideoxyadenosine and 2,3'-dideoxyinosine are diminished inside cells by 
attack from adenine deaminase and mammalian PNPase respectively25. 
However, 2-halo-2', 3'-dideoxyadenosine derivatives have been found to be 
resistant to this catabolism and have been synthesised by an initial 
enzymatic transfer reaction to yield the corresponding 2-halo-2'- 
deoxyadenosine, followed by a Barton elimination of the 3'-hydroxyl 
group I to yield the required 2-halo-2', 3'-dideoxyadenosinel32. 
More recently the transferases have been used in the synthesis of 2', 3"- 
dideoxynucleosides which have been found to have antiviral activity130. A 
vast range of base modified 2', 3'-dideoxynucleosides have now been 
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synthesised by enzymatic means for screening as potential anti-HIV 
133-137 drugs 
A very interesting discovery is the production of 1,4-anhydro-2-deoxy-D- 
erythro-pent-l-enitol (D-ribal), a glycal of ribose, in the enzymatic 
reactions. In the absence of acceptor bases, the N-deoxyribosyltransferase 
catalyses the slow hydrolysis of the 2'-deoxynucleosides, to generate 
spontaneously D-ribal which only disappears later as 2'-deoxynucleoside 
hydroysis approaches completion138. 
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It has been found that in the absence of heterocyclic bases the N- 
deoxyribosyltransferase catalyses the hydration of D-ribal but when bases 
are present it catalyses the synthesis of 2'-deoxyribon ucleosi des - This 
affords a new method for the preparation of 2'-deoxynucleosides, but as yet 
only natural substrates have been reported. This reaction also circumvents 
the need to separate the product nucleoside from any substrate nucleoside 
and base that remain at the end of the reaction, by eliminating the 
substrate nucleoside from the reaction mixture. The stereochemistry of the 
nucleoside formation from D-ribal also supports previous evidence for the 
presence of a deoxyribosyl-enzyme intermediate. 
In summary, the N-deoxyribosyltransferases have practical application in 
the synthesis of a wide range of nucleoside analogues. The transferases are 
able to tolerate a minor amount of modification in the sugar moiety and a 
large amount of modification in the base moiety. The N- 
deoxyribosyltransferases have several advantages over the nucleoside 
phosphorylases which improve the enzymatic synthesis of nucleosides, 
such as the fact that, only one enzyme is required for the transfer of the 
glycosyl residue between purines and pyrimidines in the synthesis of a 
whole range of analogues, thus simplifying the procedure and giving a 
cleaner reaction. 
Further studies on the N-deoxyribosyltransferases could help to optimise 
the reaction conditions. Information about the active site and the 
mechanism of the transfer reaction would be useful in the understanding 
of the glycosyl transfer reaction for the directed chemical synthesis of 
possible substrates. The substrate specificity of the enzyme could be 
investigated to the full to try to find novel nucleoside donors with either 
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modified sugars for the synthesis of a whole range of new nucleoside 
analogues or modified bases to act as improved or irreversible donors. 
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CHAPTER 2 
ENZYMATIC SYNTHESIS OF NUCLEOSIDES 
Background 
Considerable attention has been focussed on structure-activity correlations 
of 2', 3'-dideoxynucleoside analogues as potential anti-HIV drugs139. The 
2'#, 3'-di deoxynucleosi des of purines and pyrimidines have been shown to 
be the most active anti-HIV nucleosides. Therefore, much effort has been 
invested in the synthesis of these types of compound. 
Some nucleoside analogues which, when converted to their 5'- 
triphosphates, act as chain terminators of DNA synthesis, can be effective 
inhibitors of the replication of HIV both in vitro and in vivo. Recently, 
toxicity problems have arisen in the clinical use of some nucleoside 
analogues, for example, treatment with AZT can cause bone marrow 
suppression leading to anaernia and neutropenia140. Thus, the synthesis of 
novel nucleoside analogues which have anti-HIV activity and which 
show low toxicity is of interest. 
There are numerous chemical routes to synthesise 2', 3"- 
dideoxynucleosides by either modification of an existing nucleoside or 
fusion of a sugar and base to form the nucleoside. The modification of 
existing nucleosides includes: the reduction of 3'-deoxy-3'- 
halogenonucleosidesl4l; the radical-initiated reduction of thiocarbonates to 
an olefinl42-144; the formation of a cyclonucleoside which is ring-opened to 
an olefin145,146; and the reductive deoxygenation of vicinal diols to an 
44 
olefin147. In the last three cases the olefins are then reduced to yield the 
21,3'-dideoxynucleosides. 
Chemical approaches have limitations as to the type of nucleosides that 
can be synthesised. In contrast, the convergent synthesis enables the 
synthesis of a large number of nucleoside analogues with structural 
variations in both the sugar moiety and the base along with unnatural 
configurationS65. The 2,3-dideoxyribose intermediate can be synthesised 
from a carbohydrate or non: -carbohydrate precursor. The heterocyclic base, 
synthesised as a separate entity, is then coupled to the sugar to yield the 
2', 3'-dideoxynucleoside. 
Both these synthetic procedures are not without difficulties. Therefore, 
much interest has been shown in the development of enzymatic methods 
for the synthesis of nucleoside analogues where precise stereo- and 
regiochernical control is possible without the use of protecting groups on 
reactive residues. N-Deoxyribosyltransferases are specific and glycosylate 
only one nitrogen in a heterocyclic base to give a nucleoside with a P- 
configuration. Several enzymatic synthesise of nucleoside analogues have 
been described 75,125,127,133, 134 using a crude nucleoside N- 
deoxyribosyltransferase from Lactobacillus leichmannii. This route is 
complementary to one involving a combination of purine and pyrimidine 
phosphorylases148. The availability of enzymatic synthetic methods means 
that a range of novel nucleosides is now accessible. 
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2.1.1: N-Deoxyribosyltransferases from Lactobacillus leichmannii 
Lactobacillus leichmannii is a member of the subdivision of obligately 
hornofermentative lactobacilli which ferment glucose almost entirely to 
lactic acid. These lactic acid bacteria occur as regular, non-sporing, gram- 
positive rods with rounded ends (0-5-0.8 x 2-94m). The cells of 
Lactobacillus leichmannii occur singly, in pairs and in short chains, and 
can be isolated from milk, cheese, compressed yeast and grain mash. They 
require not only carbohydrates as energy and carbon sources but also 
nucleotides, amino acids and vitamins are essential growth factor 
requirements149. Both N-deoxyribosyltransf erase I and N- 
deoxyribosyltransferase II have been purified from Lactobacillus 
leichmannii'14, but for the synthetic reactions a crude preparation of the 
enzyme is employed. The crude preparation contains both transferase 
activities as well as many other enzymes, such as hydrolases and 
deaminases. The other enzyme activities are inhibited by the addition of 
10% ethylene glycol to the reaction mixture126. The addition of the organic 
solvent protects the products of the reaction from degradation by other 
enzymes present in the crude preparation. This improves the yields of 
products and removes the necessity of purifying the N- 
deoxyribosyltransferases, thus greatly simplifying the procedure. 
It has been shown that a wide range of bases act as competent acceptors 
with N-deoxyribosyltransferases but only very minor modifications on the 
sugar moiety are tolerated114. Analogues that lack a hydroxyl group in the 
3 f- 109,134,150 or 5'-position are accepted by the enzyme as glycosyl donors 
However, the rate of transfer of the 2,3-dideoxyribosyl moeity occurs at a 
much slower rate than the natural 2-deoxyribosyl substrate 130 - 
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Fig. 2.1 Sugar moeities accepted as glycosyl donors by N- 
deoxyribosyltransferase 
With this in mind it was decided to use N-deoxyribosyltransferase to 
investigate new synthetic routes to 2", 3'- did eoxynucleosides and to 
synthesise 2', 3'-dideoxynucleosides with modified bases as possible anti- 
HIV compounds. 
2.2: RESULTS AND DISCUSSION 
2.2.1: Chemical Synthesis of Nucleosides and Bases 
Synthesis of Glycosyl Donors 
For the synthesis of 2'-deoxy- and 2', 3'-dideoxynucleosides, suitable 
glycosyl donors are required which give high levels of transfer with a large 
number of acceptor bases. From substrate specificity studies performed it 
has been shown that 2'-deoxycytidine is a better 2-deoxyribosyl donor than 
thymidine or 2"-deoxyuridinelO5 and this is also true of the corresponding 
2', 3'-dideoxyribosyl donors. These glycosyl donors can all be purchased 
from Sigma: 2-deoxycyti dine (E17.60 per 1g), thymidine (E6.20 per Ig), 2', 3'- 
dideoxycytidine (E320.20 per 1g), and 3'-deoxythymidine (E1757.00 per 1g). 
However, due to'the expense it was necessary initially to chemically 
synthesise the 2', 3'-did eoxynucleos ides which were to be used as the 2,3- 
dideoxyribosyl donors. 
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2.2.1.1: Synthesis of 3'-deoxythymidine (6) 
There have been many papers published on the synthesis of 1-(2,, 3- 
dideoxy-p-D-glycero-pento-2-enofuranosyl)thymine (5) and the various 
intermediates which can be combined to form a useful synthesis of 3'- 
deoxythymidine (6)146,151. Two different routes were employed, via 
cyclonucleosides, to synthesise 1-(2,3-dideoxy-p-D-glycero-pento-2- 
enofuranosyl)thymine (5) which after hydrogenation gave 3'- 
deoxythymidine (6). 
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In order to synthesise the 2,3', -anhydro thymi dine (4) intermediate it was 
necessary to synthesise diphenyl sulphite from phenol and thionyl 
chloride152. 
O-OH 
"ýýCllss=o 
cl 
llýý I 
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0 ool 
pyridine 
+ 
(cl 
ether I 
H 
cl 
- HCI 
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HCI 0 1111% S=O 
ci / 
Chlorosulphite ester 
Scheme 2.3 Synthesis of diphenyl sulphite 
When thymidine (1) was heated with a four-fold excess of diphenyl 
sulphite at 1560C in dime thylace tami de solution, in the presence of a 
catalytic quantity of 1-methylimidazole, and the products were then 
subjected to a mildly alkaline hydrolytic work-up, 2,3'-anhydrothymidine 
(4) was obtained as a nearly pure white solid in 57% yield. 
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Scheme 2.4 Synthesis of 2,3'-anhydrothymidine (4) 
The reaction is assumed to proceed via an intermediate cyclic sulphite. 
This converts the hydroxyl groups of the nucleoside into better leaving 
groups which are then displaced by intramolecular nucleophilic attack of 
0-2 on the 0-face of the sugar. The 1-methylimidazole acts as a proton 
acceptor and catalyses the cyclisation step which yields the required 2,3'- 
anhydrothymidine (4). 
The reaction of thymidine with 2.5 equivalents of methanesulphonyl 
chloride gave the corresponding 3', 5'-di-0-mesyl derivative in nearly 
quantitative yield. This was converted to the 3,5-oxetane (3) derivative on 
treatment with aqueous sodium hydroxide. 
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The reaction involves the intermediate formation of the 2,3"- 
anhydrothyrni dine, which on continued exposure to the basic reaction 
conditions results in the formation of the 3', 5'-oxetane (3) in 75% yield. 
On treatment with potassium t-butoxide in dimethyl sulphoxide at 
ambient temperatures both the 2,3'-anhydrothymidine (4) and 3", 5'- 
oxetanothymidine (3) underwent ring opening of the ether moiety to yield 
the 2', 3' -unsaturated thymidine (5). 
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Scheme 2.6 Synthesis of 1-(2', 3'-dideoxy- P- D- glycero- pen to-2'- 
enofuranosyl)thymine (5) 
Due to problems of removal of DMSO the yields of this step varied but it 
appeared that overall the two-step synthesis involving the 2,3- 
anhydrothymi dine intermediate gave the best yields. Catalytic 
hydrogenation as the final step yielded the required 3'-deoxythymidine (6) 
in 67% yield. The overall yields were 27%, via 2.3"-anhydrothymidine, and 
21 %, via 3', 5'-cyclothymidine. 
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2.2.1.2: Synthesis of 2",, 3"-dideoxycytidine (11) 
To date, the most favoured method for the synthesis of 2,3'- 
di deoxynucleos ides is from 2'-deoxynucleosides by Barton-type 
deoxygenation reactions144,153 or from intact nucleosides by routes 
involving deoxygenation reactions to yield 2",, 31 -unsaturated 
dideoxynucleosides, which are then hydrogenated. The conversion of 
cytidine to 2", 3-dideoxycyti dine by protection of the T-hydroxyl function, 
thioacylation, radical-induced reductive cleavage, deprotection and 
hydrogenation combines many of the literature methodS142,143 to provide 
an efficient five-step synthesis. 
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Scheme 2.7 Total synthesis of 2', 3'-dideoxycytidine (11) 
The initial protection of the F-hydroxyl group with ter t-butyl dime th yls ilyl 
chloride proceeded in high yield. The imidazole acted as a proton acceptor 
and activated the F-hydroxyl group to nucleophilically attack the tert- 
butyldimethylsilyl chloride and displace the chloride ion. 
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Free radical reduction of 2'- and T-hydroxy groups was used for several 
142. 
reasons . 
othe nucleophilic SN2 displacement at the C-2' functional group of 
nucleosides is inhibited by steric and electronic factors; 
egeneration of a cation, by an SN1 reaction, at C-2' is precluded by 
bonding to the adjacent electron- deficient anomeric carbon. 
*generation of an anion at C-2' would result in cleavage of the 
glycosidic bond. 
Thus, homolytic cleavage of the C-2'-0-2' bond is the only feasible 
method. The phenyl chlorothionocarbonate was the favoured reagent as it 
can be introduced into the nucleoside by a simple acylation reaction in 
good yield142. Pyridine can be used to catalyse the acylation of relatively 
unhindered alcohols, but for the rapid and high yielding conversion of 
nucleosides to their corresponding 0-phenoxythiocarbonyl derivatives, 4- 
(dime thylamino)pyridine (DMAP) is required. This base is superior to 
pyridine as a catalyst for 0-acylations of alcohols, particularly for tertiary 
and sterically hindered alcohols. The enhanced activity over pyridine is 
not a result of increased basicity (DMAP, pKa=9.70; Pyridine, pKa=5.29), but 
is due partly to the formation of high concentrations of N-acylpyridinium 
salts, which are very effective acylating reagentS154. Thus, the N- 
thioacylpyridinium salt formed was open to nucleophilic attack by the 2/- 
and Y-hydroxyl groups to give the thiocarbonate in 88% yield. 
The reductive cleavage of the 5-'-O-(tert-bu tyl dime thylsilyl) -2', 3" -bis-0- 
(phenoxythiocarbonylcytidine) (8) occured readily in the presence of tri-n- 
butyltin hydride in toluene under reflux with addition of oc, (x'- 
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azobis(isobutyronitrile) as the radical initiator to give 2,3'-didehydro-2', 3'- 
dideoxycytidine (9). 
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Scheme 2.8 Reductive cleavage of the thiocarbonate 
The vicinal diols were converted in high yield into an olefin by the 
reaction of tri-n-butyltin hydride with the bisdithiocarbonates. Previous 
studies have shown that the reaction proceeds by a stepwise radical 
fragmentation144,153. Therefore, substitution in the P-position of the 
intermediate radical by a leaving group, which could leave as a stable 
radical, permitted the synthesis of the required alkene in 72% yield. 
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As catalytic hydrogenation is sensitive to steric hindrance, the unsaturated 
nucleoside was desilylated before the olefin was reduced. Deprotection was 
effected in nearly quantitative yield to give the 2', 3'-didehydro-2', 3'- 
dideoxycytidine (10) which was then reduced to afford an 88% yield. The 
overall yield of 2', 3'- di deoxy cyti dine (11) was 41% compared to the 27% 
overall yield of 3'-deoxythymidine. 
Synthesis of Base Acceptors 
2.2.1.3: Synthesis of N6-methoxyadenine (12) 
0-Methylhydroxylamine and hydroxylamine are highly efficient 
mutagens in many biological systemS155,156. Therefore, it was of interest to 
synthesise the N6-methoxyadenine 2'. 3'-dideoxynucleoside to investigate 
its anti-HIV properties. Initial attempts to synthesise N6-methoxyadenine 
155 (12) by the method of Budowsky et al. , where the 0 
methylhydroxylamine directly substitutes the amino group in the 
adenine, proved to be low yielding. The method of Robins157' was applied 
to our system where 6-chloropurine was heated with methoxyamine 
hydrochloride in ethanol to displace nucleop hil ic ally the chlorine atom 
and yield N6-methoxyadenine (12) in 62% yield. 
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Scheme 2.9 Methoxyamination of 6-chloropurine 
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The method of Saneyoshi et al-158 was applied to both adenine and 2/- 
deoxyadenosine. Reaction of the 1-oxide (13) with methyl iodide followed 
by alkaline treatment resulted in a rearrangement to give the required N6- 
methoxy derivative (15). 
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Scheme 2.10 Methoxyarnination of adenine and 2'-de oxya deno sine 
The initial oxidation step with m-chloroperbenzoic acid in aqueous 
dioxane gave the 1-oxide in high yield. This was then reacted with methyl 
iodide in dimethy1formamide to give the 1-methoxy derivative (14) which 
was not isolated. Heating at 600C under basic conditions facilitated a 
Dimroth rearrangement to yield the N6-methoxy derivative (15). 
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Scheme 2.11 Dimroth rearrangement of 1-methoxyadenine (14) to N6- 
methoxyadenine (15) 
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In the Dimroth rearrangement the first step is the rapid addition of the 
base across the most electrophilic C=N bond (in this case, the 2- and 3- 
positions), resulting in a ring carbon atom having three electron- 
withdrawing substituents. This situation leads to hydrolytic ring fission (at 
the N1, C2-bond) to expose an amidine group. The final step is the slow 
ring closure, after rotation of the amidine group, and the expulsion of the 
facilitating base. 
Initially this method was used on 2'-deoxya deno sine and then the glycosyl 
bond was hydrolysed, by the use of solid phase acid in the form of Dowex 
H+, to liberate the free N6-methoxyadenine from the 2-deoxyribose. It was 
subsequently found that the method could be applied to adenine to give 
the free N6-methoxyadenine straight away, for use in the enzyme transfer 
reactions. 
2.2.1.4: Synthesis of N4-methoxy-5-methylcytidine (17) 
For the same reasons, N4-methoxy-5-methylcytosine (18) was synthesised 
also for use in the enzymatic synthesis of the N4-methoxy-5- 
methylcytosine 2', 3-dideoxynucleoside, to be investigated for possible anti- 
HIV properties. 
The method of XU159 was adapted for the synthesis of N4-methoxy-5- 
methylcytidine (17) in 81% overall yield. The 3'- and F-hydroxyl groups of 
thymidine were first protected with the ter t-bu tyldime thylsilyl groups in 
high yield, before the substitution of the C-4 carbonyl group for the 
methoxyamino group. The silyl protecting groups were removed during 
the work-up and purification steps therefore, there was no need to use 
tetra- n -butylammonium fluoride in a deprotection step. 
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Scheme 2.12 Synthesis of N4-me thoxy-5-methylcyti dine (17) 
The same method was also used on thymine to yield the required N4- 
me thoxy-5-methylcyto sine (18),, thus avoiding the need to hydrolyse the 
thymidine derivative to liberate the free base. 
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Scheme 2.13 Synthesis of N4-me thoxy-5-me thylcyto sine (18) 
The substitution step involved the initial formation of the phosphorus 
intermediate by nucleophilic attack of the excess methoxylamine on the 
phosphorus oxychloride. After 0.5 hours, the thymine was added to react 
with the phosphorus intermediate and thus transform the C-4 carbonyl 
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group into a good leaving group, for the subsequent nucleophilic attack of 
the methoxylamine base to give the product in 72% yield. 
2.2.2: Enzymatic Synthesis of Nucleoside Analogues 
2.2.2.1: Purification of nucleoside N-deoxyribosyltransferases (E. C. 2.4.2.6) 
from Lactobacillus leichmannii 
Bacteria are one of the. most favoured sources of enzymes and the 
purification of a crude preparation of N-deoxyribosyltransferases from 
lactic acid bacteria was fairly simple. Lactobacillus leichmannii was grown 
for 24 hours at 370C. The cells were then harvested by centrifugation 
during their stationary phase, when the highest levels of N- 
deoxyribosyltransferases are present. The cells were broken open by the use 
of a French pressure cell, which forces the cell suspension through a 
restricted orifice at high pressure. After cell breakage, the cell debris was 
removed by centrifugation. The resulting yellow liquid was dialysed to 
remove salts and thus yielded the crude preparation of enzyme. However, 
this preparation contained a multitude of different enzymes which could 
interfere with the transfer reactions. To remove the need for any further 
purification steps a technique, whereby the other enzymes in the crude 
preparation are inhibited by the addition of 10% ethylene glycol, has been 
developed126. This crude enzyme preparation was then assayed for its 
protein concentration using the dye-binding BioRad protein assay, and 
assayed to determine the number of units present. 
The basic enzymatic transfer reaction involves the exchange of the base 
moiety in the nucleoside with a free base molecule to yield a new 
nucleoside. 
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Scheme 2.14 Standard enzymatic transfer reaction 
The standard assay system used to calculate the number of units present is 
as shown above: 2'-deoxycytidine (dQ is the glycosyl donor while adenine 
(A) acts as the glycosyl acceptor. The rate at which the new nucleoside, 2'- 
deoxyadenosine WA), was produced was followed by reverse-phase HPLC, 
detected by UV at 254nm. It is important to remember that the units and 
specific activity of a sample of enzyme will vary with the assay system 
used. Therefore, a unit of enzyme must be defined for the particular assay 
system used, as can be found in the Experimental section. An example of 
the different substrate specificities and rates of reaction is clearly seen 
when several nucleosides and bases are investigated as donors and 
130 acceptors for the transfer reaction 
2.2.2.2: Comparison of glycosyl donors 
The transfer reaction is an equilibrium and therefore, if it is to have any 
use as a synthetic tool it must be displaced as fully as possible in the 
direction of the products. The adaptations which are generally used to 
push the equilibrium to the right-hand-side are: 
NH2 
NN NH2 </ 
HO'^ 0NN + ýk... Oo 0N 
H 
H 
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*a ratio of 3: 1 donor nucleoside to acceptor base; 
*a donor nucleoside which has a high affinity for the enzyme; 
*a donor nucleoside whose base is a good leaving group. 
For the synthesis of 2'-deoxy- and 2,3'-di deoxynucleos ides, a glycosyl 
donor is required which will give high levels of transfer with a large 
number of acceptor bases. From substrate specificity studies performed it 
has been shown that 2'-deoxycyti dine is a better 2-deoxyribosyl donor than 
thymidine, 2'-deoxyuridine or any of the other naturally occuring 
nucleosides105. A brief investigation and comparison of the glycosyl donor 
abilities of 2-deoxycytidine, thymidine, 2", 3'-dideoxycytidine (11), and 3'- 
deoxythymidine (6) confirmed the findings for 2-deoxyribosyl donor: 
*the transfer with 2'- deoxycyti dine and adenine was five times 
faster than the corresponding reaction with thymidine as the 
glycosyl donor and adenine as the glycosyl acceptor; 
ethe transfer with 2'-deoxycyti dine and 2-aminopurine was four 
times faster than the corresponding reaction with thymidine as the 
glycosyl donor and 2-aminopurine as the glycosyl acceptor. 
It was also discovered that the 2', 3'-dideoxynucleosi des follow the same 
pattern, in that 2', 3'-di deoxycyti dine (11) is a better 2,3-dideoxyribosyl 
donor than 3-deoxythymi dine (6). A study by Carson and Wasson130 
indicated that 2', 3--dideoxycytidine and 3-deoxythymi dine were 
approximately equivalent as glycosyl donors, and were superior to the 
purine 2', 3'-dideoxynucleosides. However, 2', 3'-dideoxycytidine (11) was 
the best glycosyl donor when adenine was the acceptor base, as in our 
studies. Therefore, for the transfer reactions employing N- 
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deoxyribosytransf erases, normally 2'-d eoxycyti dine 
dideoxycytidine were used as the glycosyl donors. 
an 2', 
2.2.2.3: Synthesis of N6-methoxy-2'-deoxyadenosine (15) and N6-methoxy- 
2', 3'-dideoxyadenosine (19) 
As discussed previously, these compounds are of interest as possible anti- 
HIV drugs because of the mutagenic properties of methoxylamine. Using a 
crude preparation of N- deoxyribos yl trans f erases from Lactobacillus 
leichmannii the transfer of 2-deoxyribose from 2-deoxycyti dine to N6- 
methoxyadenine (12) in the presence of ethylene glycol occured in good 
yield. The ethylene glycol inhibits the degradative enzymes present in the 
crude N-deoxyribosyltransferase preparation. Only one compound was 
detected by HIPLC. N6-Methoxy-2'-deoxyadenosine (15) was synthesised in 
72% yield after purification by flash chromatography on silica gel. 
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Scheme 2.15 Enzymatic synthesis of N6-methoxyamino-2'-deoxy- (15) and - 
2/, 3'-dideoxyadenosine (19) 
The structure of the N6-methoxy-2'-deoxyadenosine (15) was confirmed by 
the use of nuclear Overhauser enhancement experiments, whereby a 
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signals in the spectrum are observed. This method confirmed that the new 
nucleoside not only had a P-glycosyl linkage of the sugar moiety to the 
heterocyclic base but also that the glycosyl bond had been formed to the 
correct nitrogen in the heterocyclic base,, which in this instance was the N- 
9. 
HO 
meo, 
N *H 
N oolý 
HO 
meo 
N 
HO H 
Irradiation at H1, Irradiation at H8 
Fig. 2.16 Sites of nuclear Overhauser enhancements in the 1H NMR 
spectrum of N6-methoxy-2-deoxyadenosine (15) 
Saturation of the signal due to H1, caused enhancement of the signal due 
to H8,, on the heterocyclic base as well as the signals due to H4, and H2'b on 
the underside of the 2-deoxyribose ring. No enhancements were observed 
for signals on the topside of the 2-deoxyribose ring. When the signal due 
to H8 was saturated, the signals due to H1, as well as those due to H3'a and 
H2'a on the topside of the 2-deoxyribose ring were enhanced. This 
confirmed that the nucleoside has a P-glycosyl bond and indicated that the 
N6-methoxyadenine lay at an angle to the sugar moiety. 
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Irradiation at H1, (6.29ppm) 
1 % Enhancement 
at 
Compound H-8 H-2b(down) 1 H-4' 
1 
15 i 4.9 6.1 1.8 
Irradiation at H8 (8.15ppm) 
1 % Enhancement 
at 
Compound H-l' H-2a(up) H-3'a(up) 
15 3.8 
1 
1.2 1.1 
Table 2.1 Nuclear Overhauser enhancements M caused by irradiating 
signals in the 1H NMR spectrum of N6-methoxy-2'-deoxyadenosine (15) 
Confirmation of the position of attachment of the 2-deoxyribosyl residue 
at the N-9 in a P-configuration was also made by comparison of the 1H 
NMR spectrum of this compound with the 1H NMR spectrum of the 
chemically synthesised nucleoside. 
However, the equilibrium of the transfer of the 2,3-dideoxyribosyl moiety 
to N6-methoxyadenine was unfavourable and there was no significant 
amount of the 2', 3-dideoxynucleoside formed. 
2.2.2.4: Synthesis of N4-methoxy-5-methylcytidine (17) 
The N4-methoxy-5-me thylcyto sine (18) was synthesised to compare with 
N6-methoxyadenine as a 2-deoxy- and 2,3-dideoxyribose acceptor and to 
investigate any anti-HIV activity. Unfortunately no transfer was observed 
for either reaction. 
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Scheme 2.17 Possible reaction of N4-methoxy-5-methylcytosine (18) at the 
active site of an enzyme 
The possible inhibitory effects of N4-methoxy-5-methylcyto sine (18) were 
investigated by incubation of the compound with the crude N- 
deoxyribosyltransferase and then assaying the enzyme for activity after 
certain intervals of time. No loss in activity was observed so inhibition did 
not appear to be a factor for the lack of transfer. 
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Fig. 2.18 Structure of N4-methoxy-5-methylcytosine (18) 
The reason for the lack of transfer in the reaction for the formation of N4- 
methoxy-5-methylcytidine is thus postulated to be due to the low 
nucleophilicity of the acceptor base in the reaction. The pyrimidine base 
now has two electron withdrawing groups, the C-2 carbonyl and the C-4 
methoxyamine, which reduce the nucleophilicity of N-1 dramatically and 
render it as a very poor substrate. 
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2.2.2.5: Synthesis of 2-deoxy- (20) and 2'. 3-dideoxyguanosine (21) 
Guanine, guanosine and their derivatives are very insoluble in aqueous 
and alcoholic solution which can cause many problems in any synthesis 
involving these compounds. Therefore, it was felt that a procedure 
involving a masked guanosine derivative with good solubility properties, 
which could be converted to the guanosine derivative as the final step, 
would provided an excellent pathway to synthesise a whole selection of 
different derivatives in good yields. There have been several chemical 
methods published which involve the initial chemical synthesis of a 
masked nucleoside derivative which is then treated with adenosine 
dearninase as the final step to yield the required nucleoside derivative87, 
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Scheme 2.19 Synthesis of guanosine derivatives (20) and (21) by a coupled- 
enzyme system 
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A crude preparation of N-deoxyribosyltransferases from Lactobacillus 
leichmannii was employed in the transfer of 2-deoxyribose from 21- 
deoxycytidine to 2,6-diaminopurine in the presence of ethylene glycol. 
When the reaction had reached -100% transfer in the production of the 
2,6-di aminop urine 2'-deoxynucleoside, the pH was adjusted to 7.4 and 
adenosine dearninase was added. This yielded the required 21- 
deoxyguanosine (20) in 93% yield, after purification by ion exchange 
chromatography. Only one final product was detected by HPLC. 
The structure of the 2-deoxyguanosine (20) was confirmed by the use of 
nuclear Overhauser enhancement experiments as described previously. 
The 1H NMR spectrum was also compared to the spectrum of an authentic 
sample. 
Irradiation at HI, (6.22ppm) 
1 % Enhancement 
at 
Compound H-8 H-2'b(down) 1 H-41 
20 1 2.5 5.1 1.1 1 
Irradiation at Hý (7-83ppm) 
% Enhancement 
at 
Compound H-Y H-2a(up) H-Ta(up) 
20 4.9 3.9 2.8 
Table 2.2 Nuclear Overhauser enhancements (%) caused by irradiating 
signals in the 1H NMR spectrum of 2-deoxyguanosine (20) 
Unfortunately, the transfer of 2,3-dideoxyribose from 2', 3-dideoxycytidine 
to 2,6-diami nopurine using a crude preparation of N- 
deoxyribosyltransferase from Lactobacillus leichmannii was unsuccessful. 
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It was therefore felt that further investigations into this procedure with 
the transfer reaction as the first step were not worthwhile. 
It is interesting to note the many conflicting results presented to date 
regarding the ability of 2,6-diaminop urine to act as a glycosyl acceptor in 
these deoxyribose transfer reactions. 2,6-Di aminop urine has been reported 
to give negative results with extracts of Lactobacillus helveticus", 
Thermobacter acidophilus104, and L. leichmanniil6l . However, it has been 
also be found to act as a competent substrate with extracts of L. 
delbrueckil6l, L. helveticus113 and L. leichmanniill4. 
2.2.2.6: Synthesis of 9-p-D-2'-deoxy- (22), and 9-p-D-2',, 3"- 
dideoxyribofuranosyl 2-aminopurine (23) 
A crude preparation of N-deoxyribosyltransferase from Lactobacillus 
leichmannii was used to transfer the 2-deoxyribosyl and 2,3-dideoxyribosyl 
residues from 2'-deoxycytidine and 2', 3'-dideoxycytidine, respectively, to 2- 
aminopurine. Ethylene glycol was added to the reaction mixture to inhibit 
hydrolase and deaminase activities in the crude enzyme preparation. After 
purification by flash chromatography on silica gel the 2'-deoxy- (22) and 
21,3'-di deoxyribonucleo sides (23) of 2-aminopurine were prepared in 57% 
and 80% yield respectively. 
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Scheme 2.20 Synthesis of the 2--deoxy- (22) and 2', 3- 
did eoxyribonucleosides (23) of 2-aminopurine 
2-Aminopurine contains five nitrogen atoms and a mixture of products 
may be expected to result from these experiments. Only one product was 
formed in each of the synthetic reactions. The structures of these 
nucleosides were confirmed by high field NMR spectroscopy, in particular 
by using nuclear Overhauser enhancement experiments to demonstrate 
the P-configuration at the glycosidic centre and the attachment of the 
glycosyl residue to N-9. Thus, irradiation of the signal due to H1, in the 1H 
NMR spectra of nucleosides (22) and (23) enhanced inter alia the signals 
due to H2b and H4'. Therefore, Hj,, H2'b and H4, must be on the underside 
of the glycosyl ring which confirms the presence of the P-glycosidic link. 
Irradiation of the signal due to H8 enhanced the signals due to H2a and 
H3'a which are on the topside of the glycosyl ring. The signal due to H1, 
was also enhanced and the magnitude of the enhancements observed 
suggests a syn-conformation for the nucleosides. Irradiation of the signal 
due to H6 in both nucleosides caused no enhancement of any of the 
signals due to sugar protons. This confirmed that the position of 
attachment of the glycosyl rings was at N-9, as attachment at N-7 might be 
expected to give rise to nOe enhancements of signals due to sugar protons 
when the signal due to H6 was irradiated. 
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Irradiation at Hl, 
% Enhancement 
at 
Compound H-8 H-2'b(down) H-4' 
22 3.6 6.1 0.7 
23 1.2 6.1 0.9 
Irradiation at H8 
% Enhancement 
at 
Compound H-l' H-2a(up) H-3a( 
22 4.7 1.7 0.6 
23 . 2.1 0.8 0.4 
Table 2.3 Nuclear Overhauser enhancements M caused by irradiating 
signals in the 1H NMR spectrum of the 2'-deoxy- (22) and 2', 3- 
dideoxyribonucleos ides (23) of 2-aminopurine 
9- P-D-2', 3'-Dideoxyribof uranosyl-2- aminop urine (23) was assayed to 
investigate any anti-HIV or anti-SIV activities or toxicities162. It was found 
to selectively inhibit the replication of HIV-1, HIV-2, and SIV which were 
measured by examining syncytia formation, total cell viability and gp120 
production. The EC50 values, based on reduction in gp120 synthesis, were 
in the region of 8-40ýtM depending on the virus strain and cell type. The 
antiviral activity of (23) was shown to be similar, though somewhat less 
than that of ddA particularly in JM cells where its activity was reduced like 
that of AZT. 9- P-D-2-, 3 -- Dideoxyribofuranosyl-2- aminop urine (23) lacked 
the toxicity of ddC as its TC50 values were >1000ýiM in both cell lines. 
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Virus compow-d C8166 Cells /ýM JM Cells /ýtM F 
EC50 TC50 EC50 TC50 
HI -V-1 111B 23 40 >1000 8 >1000 
ddA 4 >1000 1.6 >1000 
ddC 0.05 >1000 0.05 0.5 
AZT 0.016 >1000 100 >1000 
HIV-2ROD 23 100 >1000 
ddA 4 >1000 
ddC 0.05 >1000 
AZT 0.016 >1000 
SIVMac 23 80 >1000 
ddA 4 >1000 
ddC 0.05 >1000 
AZT 0.016 >1000 
EC50 represents the concentration of compound that decreases gpl20 
antigen production in infected cells to 50% of control. The values in the 
table are the mean of three determinations. The cytotoxicity (TC50) values 
for compound (23) were >10OOgM, we were unable to test at higher 
concentrations than 1000ýM 
Table 2.4 Median effective (EC50) doses of 9-p-D-2', 3-dideoxyribofuranosyl- 
2-aminopurine (23) for inhibition of HIV and SIV 
This investigation indicated that 9-p-D-2', 3'-dideoxyribofuranosyl-2- 
aminopurine (23) had appreciable anti-HIV-1 activity together with some 
anti-HIV-2 and anti-SIV activity even though it lacks an oxygen, 
nitrogen, or chlorine substituent at the 6-position in the purine ring and 
appeared from spectroscopic studies to have the syn -conformation. There 
has been little published on the effect of syn- and anti-conformations of 
bases in anti-HIV nucleosides. However, the influence on the anti-HIV 
activity of the shapes of the sugar rings of such nucleosides, as determined 
in the solid state by X-ray crystallography, has been discussed163. These 
results suggest that an anti-conformation for the nucleoside in solution is 
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not essential. While crystallographic data gives information about 
nucleosides in solid state, it is important to remember that in solution the 
nucleoside does not possess a unique rigid structure but is in a dynamic 
equilibrium between many rapidly interconverting conformations. More 
information and discussion about nucleoside conformation will be 
presented in Chapter 4. 
The published data on the anti-HIV activity of the only other 2',, 3'- 
dideoxynucleo side examined which lacks a substituent in the 6-position of 
the purine ring system, 9-p-D-2,3'-dideoxyribofuranosyI purine, is 
conflicting. One report suggests that it is active as an inhibitor of HIV 
replication148, while another report indicates that it is inactive (Chu et al., 
personal communication). This discrepancy probably lies in the difference 
in cell lines used to study the activities of the compounds, as the assay for 
9-0-D-2', 3'-dideoxyribofuranosyl-2-aminopurine (23) indicated a noticeable 
difference in activity of the compound in the two cell lines which were 
used. 
2.2.2.7: Synthesis of 2-Thio-2'-deoxyuridine (24) 
2-Thio-2'-deoxyuridine (24) was required for synthesising base modified 
sections of DNA, so a large scale synthesis was required. Therefore, the 
synthesis was investigated on a small scale using a soluble extract of N- 
deoxyribosyltransferase from Lactobacillus leichmannii prior to a large 
scale synthesis using a poly(acrylamide-co-N-acryloxysuccinimide) (PAN) 
immobilised extract of the enzyme (as described in Chapter 3). After 
purification by flash chromatography on silica gel to give 2-thio-2'- 
deoxyuridine in 47% yield, the structure was assigned using NMR and 
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nuclear Overhauser enhancement experiments by the methods discussed 
previously. 
2.2.3: Conclusion 
The successful synthesis of 2", 3'- did eoxycytidine (11) and 3/- 
deoxythymidine (6) as glycosyl donors and the N6-methoxyadenine (12) 
and N4-methoxy-5-methylcytosine (18) as glycosyl acceptors was 
demonstrated. From these studies it can be seen that the enzyme does 
have a high degree of selectivity for both modified sugars and bases. The 
transfer of the 2,3-dideoxyribosyl moiety is always much slower than the 
corresponding transfer of the 2-deoxyribosyl moiety and if the acceptor 
base contains any unusual features tlýis can often create an unfavourable 
equilibrium and slow down or even stop the transfer reaction. The 
synthesis of N4- me thoxy-5-me thyl cyti dine (17) was unsuccessful due to 
the low nucleophilicity of the acceptor base, N4-methoxy-5-methylcytosine 
(18), and not because of irreversible inhibition at the active site of the 
enzyme. 
The problem of unfavourable equilibrium was encountered in the 
synthesis of 2', 3'-di de oxyguano sine (21). As a result of the difficulty in 
synthesising nucleoside analogues with 2- and 6-substituted purine base 
an investigation into the transfer rates of 2,6-disubstitued purines was 
undertaken and the results are tabulated in Appendix 1. 
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The results were in agreement with other workersI14' in that the 2,6- 
disubstituted purines were found to act as acceptors with the N- 
deoxyribosyltransferase enzyme but their respective velocities, when 
compared to the natural C-6 mono-substituted purines, were considerably 
lower. Of all the purines investigated, 2,6-diaminop urine was found to 
have the slowest rate of transfer with both 2'-deoxycyti dine and 2', 3'- 
dideoxycytidine and although it was found to transfer on an analytical 
scale, only a minor amount of product is seen in preparative scale 
reactions. The positions 1,2,3 and 6 are not essential for binding although 
large substituents on the 6-position will reduce the rate of reaction, 
possibly because of steric hindrance. 
N 
2N -ý\ N 
HZH N 
IHN 
H2C., jk 
I 
H H 
H 
Fig. 2.22 Syn -conformation in 9-p-D-2,3'-dideoxyribofuranosyl-2- 
aminopurine (23). 
The successful synthesis of the 2-deoxy-(22) and 2', 3'-dideoxynucleoside 
(23) of 2-aminopurine was demonstrated and the 9-p-D-2', 3'- 
dideoxyribofuranosyl- 2- aminop urine (23) was shown to have anti-HIV 
and anti-SIV activity. The 2', 3'-dideoxynucleoside was unusual in that it 
lacks an oxygen, nitrogen or chlorine substituent at C-6 in the purine ring 
and appeared from spectroscopic studies to have the syn-conformation, 
perhaps caused by hydrogen bonding between the exocyclic CF-OH on the 
sugar and the C2-NH2 on the purine base. 
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2.3: GENERAL MATERIALS AND METHODS 
2.3.1: Materials 
Chemicals and starting materials were either commercially available or 
synthesised as described in the text. Chemicals were either purified using 
literature methods164, or purchased as the highest available grade. All 
solvents were dried and distilled before use. 
2.3.2: Methods 
1H NMR spectra were recorded at 220MHz on a Perkin-Elmer R34 
spectrometer, at 250MHZ on a Bruker ACF250 spectrometer, or at 40OMHZ 
on a Bruker WH400 spectrometer. Chemical shifts are given in ppm 
relative to either tetramethylsilane (TMS) (0.00ppm) or sodium 3- 
(trimethylsilyl)-l -propane sulphonate (TSS) as internal standards. 
Multiplicities of 1H NMR signals, where applicable, are abbreviated as 
follows: s (singlet), d (doublet), t (triplet), q (quartet), dd (doublet of 
doublets), ddd (doublet of doublet of doublets), dt (doublet of triplets), dq 
(doublet of quartets), and m (mutliplet). 
13C NMR spectra were recorded at 100.62MHz on a Bruker WH400 
spectrometer or at 62.89MHz on a Bruker ACF250 spectrometer with 
CHC13 and CH30D as internal standards. 
19F NMR spectra were recorded at 235.192MHz on a Bruker ACF250 
spectrometer with CFC13 as an internal standard. 
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Long range 13CAH shift correlation was carried out by a heteronuclear 
COSY-type experiment, with the use of a composite 1800 carbon pulse, and 
refocussing delays of 3.7ms and 1.85ms. 
Nuclear Overhauser enhancement spectra were measured on a solution 
that had not been deoxygenated and were acquired with an irradiation 
time of 2 seconds. 
Mass spectra were recorded using a Kratos MS80 instrument. Electron 
impact (EI) spectra were recorded at 70eV and for chemical ionisation (CD 
spectra ammonia was used as the carrier gas. 
High-Performance Liquid Chromatography (HPLC) analysis was 
performed on a Waters or Gilson machine. The concentration of 
nucleosides and bases present in the reaction mixture were determined 
using reverse phase HPLC on a Techsphere 5C8 column (25cm x 4.6 mm 
and a precolumn, 5cm x 4.6mm; HPLC Technology Ltd, Macclesfield, 
Cheshire, UK). The samples were eluted from the column using a mobile 
phase of acetonitrile and double distilled water at a flow rate of 1.2 ml/min 
and detected by UV at 254nm. 
Unless otherwise stated t. l. c. analyses were run on aluminium plates 
coated with silica gel (Merck 60F 254,, 0.20mm) and eluted in the solvent 
systems given in the text. Visualisation was achieved by UV or by spraying 
the plate with 10% H2SO4 in ethanol followed by heating to observe the 
sugars. Compounds were usually purified by flash chromatography on 
silica gel. 
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2.3.3. - Microorganisms and Media 
Lactobacillus leichmannii was obtained from the American Type Culture 
Collection (ATCC, Rochville, Maryland, USA). Adenosine deaminase 
E. C. 3.5.4.4, Type VI from calf intestinal mucosa, was purchased from 
Sigma, Poole, Dorset, UK The growth media MRS Broth165was purchased 
from Oxoid, Basingstoke, Hampshire, UK, and was used as instructed on 
the bottle. The BioRad protein assay was purchased from BioRad, Watford, 
Hertfordshire, UK 
2.4: EXPERIMENTAL 
2.4.1: Chemical Synthesis of Nucleosides and Bases 
2.4.1.1: Synthesis of 3', deoxythymidine (6) 
Synthesis of diphenyl sulphite152 
Thionyl chloride (32.70 ml, 0.17 mol) in dry ether (30 ml) was added 
dropwise, from a pressure equalised funnel under nitrogen, to phenol 
(32.44 g, 0.34 mol) in dry ether (150 ml) and dry pyridine (26.30 ml, 0.34 
mol) at -50C with vigorous stirring. The precipitated pyridine 
hydrochloride (37 g) was filtered off through a sinter funnel and the 
filtrate was collected and reduced in vacuo. The remaining solution was 
distilled (b. p. 1350C/2mm Hg) to give 34.02 g (86% yield): Rf=0.65 (diethyl 
ether/petroleum ether (40-60), 1/4); MS (EI) m/z (%) 77 (100), 94 (48), 141 
(97), 169 (5), 234' (43, M+-), 
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Synthesis of 2,3-anhydrothymidine (4)151 
Thymidine (5-0 g, 20.6 mmol), diphenyl sulphite (19.34 g, 82.6 mmol), 1- 
methylimidazole (0.34 ml, 4.27 mmol) and N,, N-dimethylacetamide (50 
ml) were stirred at 1560C for 1 h. The reaction was then cooled to OOC and 
poured, with stirring, into a mixture of triethylamine (50 ml) and water 
(90 ml) at OOC. The solution warmed to, room temperature after 40 min 
and was then washed with chloroform (4 x 50 ml). The remaining aqueous 
layer was concentrated under reduced pressure and the viscous oil 
obtained was dissolved in absolute ethanol (2 x 30 ml), and the solution 
was re-evaporated. The residue was triturated with ether (3 x 50 ml) and 
finally CH2CI2 (50 ml) was added and left overnight to crystallise the 
product. The colourless precipitate was collected by filtration, washed with 
CH2CI2 (2 x 10 ml) and lyophilised to give 2.62 g (56.6% yield): Rf=0.13 
(MeOH/CH2CI2,5/95); 1H NMR (CD30D) 5 1.95 OH, d, J=l. llHz, Me), 2.55- 
2.72 (2H, m, H2'a and b), 3.73 (2H, d, J=6.33Hz, H5a and b), 4.36 (1H, ddd, 
J=2.23,2 x 6.35Hz, H4, ), 5.36 (1 H, d, J=2.22Hz, HT), 5.93 (1 H, d, J=2.97]Hz, Hl, ), 
7.62 OH, d, J=l. llHz, HA 13C NMR (CD30D) 8 13.96 (C5-Me), 34.52 (C2'), 
61.44 (CT), 79.25 (CY), 87.26 (Cl, ), 89.29 (C4), 118.66 (C5), 139.07 (CO, 153.17 
(C2)., 167.12 (C4); MS (EI) m/z M 55 (54), 69 (78), 81 (100), 98 (53), 110 (30), 
126 (53), 149 (25), 206 (9), 224 (21, M+-); (CI) m/z (%) 127 (14), 225 [10, 
(M+H)+]. 
Synthesis of 1-(2', 3'-dideoxy-o-D-glycero-pento-2'-enofuranosyl)thymine 
(5)145 
To a solution of t-BuOK (0.90 g, 8.0 mmol) in DMSO (20 ml) was added 
2,3' -anhydrothymi dine 
(1.68 g, 7.5 mmol). The reaction mixture was 
stirred under nitrogen at room temperature for 1h and then warmed to 
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600C for a further 1 h. Water (10 ml) was added and the mixture was 
neutralised from PH 10 to PH 7 with dilute acetic acid (- 3 ml) to produce a 
gelatinous precipitate which was filtered, washed with water (2 x 10 ml) 
and Iyophilised. The solid was Purified by flash chromatography on silica 
gel(MeOH/CH2Cl2., 1/9) to remove DMSO and unreacted starting material 
to give 1.21 g (72% yield): Rf=0.44 (MeOH/CH2Cl2,, 1/9); 1H NMR (CD30D) 
8 1.88 (3H, d, J=1.13Hz, Me), 3.76 (1H, dd, J=3.10,12.5Hz, H5a), 3.83 UH, dd, 
J=3.03,12.5Hz, HTO, 4.88 (1H, brs, ff4, ), 5.95 (1H, dq, J=1.88,5.96EIz, H2'), 6.44 
OH, dt, J=1.67,5.95Hz, KT), 6.99 (1H, q, J=1.86,3.35Hz, Hy), 7.79 OH, d, 
J=1.12HzI HO; 13C NMR (CD30D) 8 12-40 (C5-Me), 63.81 (C5, ), 88.98 (C4'), 
91.06 (Cl, ), 111.21 (C5), 127-32 (C2'), 135-96 (CY), 138-92 (C6)/ 152.90 (C2), 166-59 
(C4); MS (CD m/z M 99 (20), 127 (100), 155 (13), 193 (8), 207 (15), 225 [20, 
(M+H)+]. 
Synthesis of 3', 5'-dimethanesulphonylthymidine (2) 
Thymidine (5.0 g, 20. Ommol) and DMAP (4 mg) were dissolved in dry 
pyridine (60 ml). Methanesulphonyl chloride (6.0 ml, 50-Ommol) was 
added to the cooled solution at OOC under nitrogen. The reaction mixture 
was stirred overnight at room temperature and then poured onto ice- 
water (500 ml), with vigorous stirring. The precipitate was collected by 
filtration through a glass sinter funnel, and washed with water (10 ml). 
The white precipitate was dissolved in acetone, filtered and reduced in 
vacuo before being Iyophilised to give 7.6 g (92% yield): Rf=0.54 
(MeOH/CH2CI2., 15/85); 1H NMR (CD30D) 8 1.93 OH, d, J=1.08Hz, Me), 2.51 
(1 H, ddd, J=2 x 6.92,14-8FIZ, H2'b), 2.64 (1 H, ddd, J=2.28,6.06,14.6Hz, H2'a), 
3.16 OH, S, S02Me), 3.19 OH, S, S02Me), 4.48 (1H, ddd appears as quintet, 
J=2.97,3.87,6.84Hz, H4, ), 4.56 (2H, m, H5'a and b). 5.37 (1H, ddd, J=2 x 2.82, 
6.8OHz, HY), 6.32 (1 H, dd, J=6.09,8.07Hz, Hl, ), 7.47 (1H, d, J=1.17Hz, H6); MS 
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(EI) m/zM 55 (100), 70 (80), 96 (63), 126 (55, thymine+ . ); (CI) m/zM 127 
[67, (thymine+H)+1,144 (4), 207 (6), 303 (8), 399 [2, (M+H)+1. 
Synthesis of 1-(2'-deoxy-3', 5'-epoxy-o-D-threo-pentofuranosyl)thymine 
(3)146 
A solution of 3', 5'-dimesylthymidine (7-5 g, 0.02 mol) in water (300 ml) 
containing sodium hydroxide (56 ml, 1.0 N) was refluxed for 4h under 
nitrogen. The reaction mixture was cooled to room temperature and 
neutralised with HCI (19 ml, 1.0 N) before being concentrated in vacuo. 
The white crystals were dissoved in chloroform (30 ml) and the impurities 
were removed by filtration. The solution was concentrated in vacuo before 
being Iyophilised to give 3.2 g (75% yield): Rf=0.41 (MeOH/CH2Cl2,1/9); 1H 
NMR (CD30D) 8 1.92 (3H, d, J=1.12Hz, Me), 2.53-2.62 (2H, m, J= 3.00,5.4lHz, 
H2'a and b), 4.16 (1H, dd, J=1.73,8.16Hz, H4, ), 4.82 (IH, dd, J=3.97,8.2OHz, 
H5'a), 4.97 (1H, m, J=1.88,4. OlHz, H5'b), 5.58 (IH, ddd appears as q, J=3.65, 
6.25Hz, H3'), 6.64 (1H, dd appears as t, J=2 x 5.34Hz, Hl, ), 8.16 (1H, d, 
J=1.18Hz, HO; 13C NMR (CD30D) 8 13-05 (C5-Me), 38-90 (C2'), 77.19 (CO, 
82.21 (CY), 89.05 (C4'), 90.40 (Cl, ), 112.33 (C5), 138.58 (C6), 153-29 (C2), 166.34 
(C4); MS (EI) m /z (%) 55 (40), 69 (90), 81 (1), 99 (100), 110 (16), 126 (75), 224 
(23, M+. ); (CI) m/z (%) 55 (1), 64 (2), 81 (4), 99 (4), 127 (18), 144 (2), 225 [100, 
(M+H)+]. 
Synthesis of 1-(2'., 3'-dideoxy-o-D-glycero-pento-2'-enofuranosyl)thymine 
(5)146 
To a solution of t-BuOK (3-0 g, 27.0 mmol) in DMSO (15 ml) was added 
3,5'-cyclothymidine (3.0 g, 13.0 mmol). The reaction mixture was stirred 
under nitrogen at room temperature for 3 h. The mixture was neutralised 
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from pH 10 to pH 7 with dilute acetic acid (- 9 ml) to produce a gelatinous 
precipitate which was filtered, washed with water (2 x 10 ml) and 
Iyophilised. The residue was triturated with hot acetone (5 x 20 ml) and 
the salts were filtered off. The filtrate was concentrated in vacuo to 
produce a brown residue which was dissolve in absolute ethanol (10 ml) 
and benzene (25 ml) and concentrated on a hot plate to 5 ml. This 
procedure was continued until a slight turbidity was evident (4 times) and 
then the solution was left at 40C until the product crystallised. The product 
was collected by filtration and recrystallised from ethanol and benzene to 
give 1.42 g (47% yield): Rf=0.38 (MeOH/CH2CI2.1/9); 1H NMR (CD30D) 8 
1.88 OH, d, J=1.13Hz, Me), 3.76 (1H, dd, J=3.10,12.5Hz, H5'a), 3.83 OH, dd, 
J=3.03, l2.5Hz, H5'b), 4.88 (1H, brs, 1-14, ), 5.95 (1H, dq, J=1.88,5.96HZ, H2'), 6.44 
(1 H, dt, J= 1 . 67,5.95fiz, HY), 6.99 (1 H, quintet, J= 1 . 86,3.35Hz, Hl, 
), 7.79 (1 H, 
d, J=1.12Hz, HO; 13C NMR (CD30D) 8 12.40 (C5-Me), 63-81 (CO, 88-98 (C4'), 
91.06 (Cy), 111.21 (C5), 127.32 (C2'), 135-96 (CY), 138.92 (C6), 152.90 (C2), 166.59 
(C4); MS (EI) m/z M 55 (60), 69 (100), 99 (46), 126 (11), 150 (5), 193 (15); (CI) 
m/z (%) 99 (20), 127 (100), 155 (13), 193 (8), 207 (15), 225 [20, (M+H)+]. 
SynthesiS of 3'-deoxythymidine (6)146 
A solution of 1-(2,3-dideoxy-p-D-glycero-pento-2-enofuranosyl)thymine 
(1.20 g, 5.36 mmol) in absolute ethanol (100 ml) containing 10% 
pall adium-charcoal catalyst (0.2 g) was stirred under 1 atm of hydrogen at 
room temperature for 3 h. The solution was filtered through a celite pad 
and the filtrate was evaporated to dryness in vacuo to give 0.81g (67% 
yield) of a white solid: Rf=0.61 (MeOH/CH2CI,, 1/4); 1H NMR (CD30D) 8 
1.78 OH, d, J=1.04Hz, Me), 1.74-2.36 (4H, m, H2'a and b& H3'a and b), 3.58 (1H, 
dd, J=3.72,12.2HZ, H5'a), 3.78 (1 H, dd, J=2.96,12.2Hz, H5'b), 4.03 (1 H, dddd 
appears as septet, J=2 x 3.41,2 x 7.17Hz, H4, ), 5.95 (1 H, dd, J=3.12,6.51Hz, 
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Hl, ), 8.07 (IH, d, J=1.14Hz, H6); 13C NMR (CD30D) 5 12-53 (C5-Me), 25-91 
(C2'), 33-37 (CY), 63.71 (CO, 83.22 (C4'), 87.32 (Cl, ), 110-86 (C5),, 138-45 (C6), 
152.40 (C2), 166-58 (C4); HRMS (EI) calc (ClOH14N204) 226-0953, found 
226.0953. 
2.4.1.2: Synthesis of 2", 3-dideoxycytidine (11) 
Synthesis of 5'-O-(tert-butyldimethylsilyl)-cytidine (7) 
Cytidine (5.0g, 20mmol) and imidazole (0.26g, 48mmol) in dry pyridine 
(30ml) was cooled in an ice-water bath followed by the addition of tert- 
butyldimethylsilyl chloride (3.62g, 24mmol). The mixture was stirred 
under nitrogen overnight at room temperature and then poured into 
water and extracted with CH202 (2 x 50ml). The organic layer was washed 
with water (2 x 30ml) and aqueous sodium chloride (30ml), dried over 
MgS04, filtered and concentrated in vacuo. The residue was purified by 
flash chromatography on silica gel (MeOH/CH2CI2,2/98) to give 5.71g 
(80% yield) of a white solid: 1H NMR (CDC13) 8 0.09 (6H, s, Me2SO, 0.09 (9H, 
s, Me3CSO, 3.75-4.08 (5H, m, HT, HY, H4,, H5'a and b), 5.07 (IH, brs, OH), 5.59 
(IH, d, J=4.7Hz, OH), 5.69 (1H, d, J=7.6Hz, H5), 5.76 (1H, dd appears as t, 
J=6.12Hz, Hl, ), 7.12 (2H, s, NH2), 8.31 (1 H, d, J=7.6F[Z, H6). 
Synthesis of 5"-O-(tert-butyl dime thylsilyl)-2", 3'-b is-0-phenoxythiocarb onyl 
cytidine (8) 
A solution of phenyl chlorothionoformate (7.3g, 42.0mmol) in dry CH202 
(20ml) was added dropwise to a stirred solution of the silyl protected 
cytidine (5-0g, 14. Ommol) and 4- (dimethyl amino) pyri dine (6.83g, 
56.0mmol) in dry CH3CN (100ml) at -200C. The solution was stirred at 
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room temperature for 6h and then the solvent was evaporated and the 
residue was purified by flash chromatography on silica gel (CH2CI2/EtOAcIF 
10/1) to give 7.75g (88% yield) of a pale yellow solid: IH NMR (CDC13) 8 
0.04 (6H, s, Me2SO, 0.85 (9H, s, Me3CSO, 3.83 (1H, dd, J=4.01,12.3Hz, H5'a), 
3,92 (1H, dd, J=3.02,12.31-Iz, H5'b), 4.56 OH, ddd appears as q, J=3 x 5.6FIZ, 
H4'), 5.72 (1H, d, J=7.6HZ, HO, 6.14-6.42 OH, m, Hl,, HT, H3'), 7.14 (2-H, s, 
NH2), 7.20-7-55 (1 OH, m, 2x Ph), 8.13 (1 H, d, J=7.6Hz, F16). 
Synthesis of 5'-O-(tert-butyldimethylsilyl)-2,3'-didehydro-2".. 3'-dideoxy 
cytidine (9) 
A refluxing solution of (8) (7.0g, 11-Ommol) and azobis(isobutyronitrile) 
(0-83g, 5-6mmol) in dry toluene (100ml) was treated with a solution of tri- 
n-butyltin hydride (9.77g, 33.3mmol) in dry toluene. The solution was 
stirred under nitrogen at reflux for 3h before the solvent was removed in 
vacuo. The residue was purified by flash chromatography on silica gel 
(MeOH/CH2CI2,2/98) to give 2.56g (72% yield) of a white solid: 1H NMR 
(CDC13) 5 0.04 (6H. s, Me2SO, 0.83 (9H, s, Me3CSO, 3.71 (1H, dd, J=4-07, 
12.2Hz/ H5'a), 3.89 (1H, dd, J=2.97,12.2Hz, H5b), 4.89 (IH, ddd, J=l . 95,3.01, 
3.991-Iz, H4, ), 5.21 (1 H, d, J=7.4Hz, H5), 6.03 (1 H, dd, J=2.12,6.15Hz, HT), 6.38 
OH, dd, J=1.97,6.15Hz, HY), 6.78 (1H, d, J=2.08Hz, Hl, ), 7.16 (2H, s, NH2). 
8.12 OH, d, J=7.3FIz, M). 
Synthesis of 2', 3-didehydro-2', 3'-dideoxycytidine (10) 
The silylated 2', 3-didehydro-2', 3'-dideoxycytidine (9) (2.50g, 7.7mmol) in 
dry THF (30ml) was cooled in an ice-water bath before the addition of a 
LOM solution of tetra- n -butylammoni um fluoride in THF (15ml, 
15mmol). The mixture was stirred at room temperature for 1h before the 
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solvent was removed itz vacuo. The resulting pale yellow syrup was 
purified by flash chromatography on silica gel (MeOH/CH2CI2,5/95) to 
give 1.48g (92% yield) of a pale yellow solid: 1H NMR (DMSO-d6) 8 3.42 
(1H, m, HTA 3.60 (1H, m, H5'b), 4.74 (IH, ddd, J=1.12,2.81,3.94Hz, H4, ), 4.87 
(1H, t, J=5.48Hz, OH), 5.67 (1H, d, J=7.3Hz, HO, 5.83 OH, dd, J=1 . 17,5.92Hz, 
H2'), 6.35 (1H, dd, J=1.09,5.94Hz, HY), 6.90 (1H, d, J=1.2lHz, Hl, ), 7.11 (2H, s, 
NH2), 7.71 (1 H, d, J=7.3Hz, HJ 
Synthesis of 2', 3'-dideoxycytidine (11) 
2', 3'-Didehydro-2', 3'-dideoxycytidine (1-40g, 6.7mmol) in ethanol (100ml) 
was hydrogenated at 30psi in the presence of 10% Pd/C (200mg) for 2 h. 
The reaction mixture was filtered through a celite pad and the filtrate was 
concentrated bi vacuo. The crude product was purified by flash 
chromatography on silica gel (MeOH/CH2CI2,5/95) to give 1.24g (88% 
yield) of a white solid: IH NMR (CD30D) 8 1.86-2.50 (4H, 4x dddd appears 
as dddd and m, J=6.87,6.72,7.81,10.04Hz, H2'a and b, 
H3'a and b), 3.73 (1 H, dd, 
J=4.06,12.2Hz, H5'a), 3.91 (1H, dd, J=2.28,12.2Hz, H5'b), 4.19 UH, dddd, 
J=3.21,4.10,6.33,6.7OHz, H4'), 5.91 (1H, d, J=8. lOHz, H5), 6.06 (IH, dd, J=3.36, 
6.67Hz, Hl, ), 8.15 (1H, d, J=8. lOHz, HO; 13C NMR (CD30D) 6 25.91 (C2'), 
33.53 (CY), 63-73 (CO, 83.53 (C4'), 87.73 (CI), 102.02 (C5), 142.73 (CO, 152.32 
(C2), 166.53 (C4); HRMS (EI) calc (CqH13N303) 211.0957, found 211.0954. 
2.4.1.3: Synthesis of N6-methoxyadenine (12) 
a) 6-Chloropurine (1.0g, 7.4mmol), methoxyamine hydrochloride (6.2g, 
74mmol) and calcium carbonate (14.83g, 148mmol) in absolute ethanol 
(100ml) were stirred at reflux for 4h under nitrogen. The solvent was 
removed itz vacuo and the residue was purified by ion-exchange 
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chromatography on Dowex 50 H+. The product was eluted with increasing 
molarities of ammonium hydroxide solution from OAM to 0-5M to give 
760mg (62 % yield) of a pale yellow solid: UV kmax=201nm (41300), 270nm 
(12500); 1H NMR (D20) 8 3.79 (3H, s, OCHA 7.77 (1 H, brs, H2), 7.92 (1 H, brs, 
H8); 13C NMR (D20) 6 70.13 (OCH3),, 120.93 (C5), 142-41 (C8)., 148-75 (C4)f 
158-00 (C2),, 158-50 (CO; MS (EI) m/z(%) 120 (44), 135 (100), 150 (14), 165 (44, 
M+. ); (CD m/z M 136 (100, adenine+), 166 [45, (M+ H)+]. 
b) To a solution of adenine (0.5g, 3.7mmol) in distilled water (10ml) was 
added a solution of m-chloroperbenzoic acid (1.92g, 11-Immol) in dioxane 
(20ml). The mixture was stirred at room temperature for 3h before the 
solvent was removed in vacuo and the residue was washed with acetone. 
The white precipitate was collected by filtration from the yellow filtrate. 
The crude adenine 1-oxide was recrystallised from ethanol to give 0-54g 
(96% yield) of white crystals. The adenine 1-oxide (0.47g, 3.1mmol) was 
dissolved in dry DMF (10ml) and methyl iodide (1.99g, 0.87ml, 14. Ommol) 
was added. The mixture was stirred under nitrogen at room temperature 
for 3h but there was still some solid material so the mixture was heated at 
600C for a further 2 h. To the resulting yellow solution was added ether 
(30ml) and the precipitate was filtered off. The crude 1-methoxyadenine 
hydroiodide was dissolved in water (20ml) and the pH was adjusted to 8 by 
the addition of triethylamine before being heated at 600C for 8 h. The 
solvent was removed in vacuo and the residue was crystallised from hot 
water to give 180mg (35% yield) of pale pink crystals: data as above. 
0 Hydrolysis of N6-methoxy-2'-deoxyadenosine 
The N6-methoxy-2'-deoxyadenosine (180mg, 0.64mmol) was dissolved in 
distilled water (10ml) and Dowex 50 H+ (5g) was added. The mixture was 
stirred for 2h before the Dowex was filtered off and washed with water (2 x 
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20ml). The 2-deoxyribose was in the aqueous layer while the required N6- 
methoxyadenine was bound to the Dowex. The base was eluted from the 
Dowex with 0-5N ammonium hydroxide solution (20ml) and the solution 
was evaporated in vacuo to give 75mg (71 % yield) of the base: data as 
above. 
2.4.1.4: Synthesis of N6-methoxy-2-deoxyadenosine (15)156 
Synthesis of 2'-deoxyadenosine 1-oxide (13) 
To a solution of 2'-deoxyadenosine (1-0g, 4. Ommol) in distilled water 
(20ml) was added a solution of m-chloroperbenzoic acid (2.8g, 16mmol) in 
dioxane (30ml). The mixture was stirred at room temperature for 3 h. The 
solvent was removed in vacuo and the residue was washed with acetone. 
The resulting precipitate was collected by filtration and the crude product 
was recrystallised from ethanol (-15ml) to give 0.82g (77% yield) of a white 
solid: 1H NMR (DMSO-d6) 8 2.30 (1 H, ddd, J=3.69,6.33,13.3Hz, H2'a), 2.70 
(1H, ddd appears as quintet, J=2x6.05,13.2Hz, H2'b), 3.50 (1H, dd, J= 4.49, 
11.6Hz, H5'a), 3.59 (1H, dd, J=4.65,11.7Hz, H5'b), 3.85 (1H, ddd appears as q, 
J=3x4.57Hz, H4, ), 4.40 (1 H, ddd appears as q, J=2x3.31,6.02Hz, HY), 4.98 (1 H, 
brs, NH), 5.36 (IH, brs, NH), 6.32 (1H, dd appears as t, J=2x6.73Hz, Hl, ), 8.51 
(1 H, s, H2), 8.63 (1 H, s, HA 13C NMR (DMSO-d6) 8 39.4 (C2'), 61.6 (CO, 70.6 
(CY), 83.6 (Cl, ), 88.0 (C4'), 128.0 (CO, 141.6 (CO, 142.4 (C4), 143.3 (Q), 148.4 
(C6). 
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Synthesis of 1-methoxy-2'-deoxyadenosine hydroiodide (14) 
2'-Deoxyadenosine 1-oxide (0-70g, 2.6mmol) was dissolved in dry DMF 
(10ml) and methyl iodide was added (1-67g, 0.73ml, 11.7mmol). The 
mixture was stirred under nitrogen at room temperature overnight. The 
required product was precipitated by the addition of ether (50ml). The 
crude 1-methoxy-2'-deoxyadenosine hydroiodide was filtered off to give 
550mg (75% yield) of a white crystalline precipitate: 1H NMR (D20) 8 2.67 
(1H, m, H2'a), 2.85 (IH, m, H2, b), 3.82 (2H, 2x dd, H5'a and b), 4.17 (IH, q, H4, ), 
4.34 (3H, s, OCH3), 4.68 OH, m, HY), 6.54 (1H, t, Hl, ), 8.62 (1H, s, H2), 9.03 
(IH, s, H8)- 
Synthesis of N6-methoxy-2-deoxyadenosine (15) 
The crude 1-methoxy-2'-deoxyadenosine hydroiodide (500mg, 1.87mmol) 
was dissolved in water (15ml) and the pH was adjusted to 8 by the addition 
of triethylamine before being heated at 600C for 6 h. The solvent was 
removed in vacuo and the residue was purified by flash chromatography 
on silica gel (MeOH/CH2CI2,5/95), to give 370mg (74% yield) of pale pink 
crystals: 1H NMR (C D30D) 6 2.43 (1 H, ddd, J=2.92,6.09,13-5FIZ, H2'a), 2.76 
(1 H, ddd, J=5.89,7.83,13-6Hz, H2'b), 3.75 (1 H, dd, J=3.65,12.2HZ, H5a), 3.85 
(1 H, dd, J=3.25,12.2Hz, H5'b), 3.89 (3H, s, OCH3), 4.07 (1 H, ddd, J=30-3711z, 
H4'), 4.58 (1H, ddd, J=2x2.77,5.69Hz, HT), 6.39 (1H, dd, J=6.08Hz, H1, ), 7.82 
(1H, brs, H2), 8.15 (1H, s, HA 13C NMR (CD30D) 8 41.8 (C2), 62.5 (OCH3), 
63.5 (CO, 72.9 (CY), 86.7 (C 1, ), 89.7 (C4'), 93.1 (C5), 95.1 (C8),, 120.2 (C4), 139.5 
(C2), 147.1 (CO; MS (EI) m/z (%) 281 (1.3, M+), 250 (1.2, M+ - -OCH3), 236 (1.1, 
M+. -NOCH3), 221 (1.7), 205 (0.8), 
192 (10-3), 165 (27.8, N6- 
methoxyadenine+. ), 135 (100, adenine+. ); (CI) = 282 [6.2, (M+H+)], 252 
(54.9)" 
166 (6-9), 136 (47.2). 
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2.4.1.5: Synthesis of N4-methoxy-5-methylcytidine (17)159 
Synthesis of 3', 5-di-tert-butylmethylsilylthymidine (16) 
Thymidine (2.42g, 10mmol) and imidazole (2.02g, 30mmol) were dissolved 
in DMF (20ml) and tert-butyldimethylsilyl chloride (4-5g, 30mmol) was 
added. The mixture was stirred at room temperature for 3h before the 
volume was reduced to 5ml in vacuo. The solution was dissolved in 
diethyl ether (40ml), washed with saturated aqueous sodium chloride Qx 
40ml), dried over anhydrous MgS04 and filtered. The filtrate was 
concentrated in vacuo to give 4.15g (88% yield) of the crude product as a 
white solid: Rf = 0.67 (MeOH/CH2CI2., 1/9); 1H NMR (CD30D) 8 0.05 (6H, d/ 
J=2.79Hz, Me2Si)., 0-09 (6H, d, J=1.06Hz, Me2Si),, 0.87 (9H, s, Me3Si). ' 0.90 
(9H, 
s. Me3SO., 1.98 (1H, ddd, J=6.06,7.91,13. lFlz, H2'b), 2.22 (1H, ddd, J=2.63,5.81, 
13. lHz, H2'a), 3.73 (1H, dd, J=2.42,11.37Hz, H5'a), 3.84 (1H, dd, J=2.58, 
11.38Hz, H5'b), 3.91 (1H, ddd appears as q, J=3 x 2.49, H4), 4.38 (1H, ddd 
appears as quintet, J=2 x 2.56,5.99Hz, HY), 6.32 (1H, dd, J=5.83,7.9OHz, Hl, ), 
7.45 (1H, d, J=1.22Hz, HO, 9.25 (1H, brs, NH); 13C NMR (CD30D) 8 -5-60, 
-5.52, -4.99, -4.78 (2 x Me2SO, 12.40 (C5-Me), 17.86,18.26,25.60,25.70 
(2 x 
Me3Si), 41.24 (C2"), 62.82 (CO, 72.08 (CY), 84.67 (Cl), 87-66 (C4")., 110.70 (C5), 
135-33 (C6)., 150.26 (C2)., 163.85 (C4)- 
Synthesis of N4-methoxy-5-methylcytidine (17) 
Methoxylamine hydrochloride (0.70g, 8.4mmol) was suspended in dry 
CH3CN (10ml) at OOC. POC13 (0.2ml) and triethylamine (1.7ml) were added 
slowly and the mixture was stirred for 1h. 3,5"-Di-tert- 
butylm ethyl silylthymidine (0.27g, 5.7mmol) dissolved in CH3CN (3ml) 
was added over 15 min and the resulting solution was stirred at room 
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temperature overnight. The solution was filtered, diluted with ethyl 
acetate (20ml), washed with saturated aqueous NaHC03 (20ml) and 
saturated aqueous NaCl (2 x 20ml). The organic layer was dried over 
MgS04 and filtered. The filtrated was evaporated in vacuo to give the 
crude product. The pale yellow solid was purified by flash chromatography 
on silica gel (MeOH/CH2CI2,5/95) to give 1.41g (91% yield) of the de- 
silylated product: Rf = 0.32 (MeOH/CH2CI2,, 1/9); 1H NMR (CD30D) 5 1.79 
(1H, d, J=1.1 1Hz, Me), 2.17 (1H, ddd, J=3.46,6.48,13.7Hz, H2'b), 2.33 OH, m. 
J=7.10,14. OHz, H2'a), 3.75 (1H, dd, J=3.47,11.92Hz, H5'a), 3.82 (1H, dd, J=3.25, 
11.94Hz, H5'b), 3.83 (3H, s, OMe), 3.91 (1H, ddd appears as q, J=3 x 3.46Hz, 
H4'), 4.48 (1H, ddd appears as quintet, J=2 x 3.40,6.72Hz, HY), 6.09 (1H, dd 
appears as t, J=7.05Hz, Hl, ), 6.60 (1H, d, J=1.23Hz, HO, 8.23 (1H, brs, NH); 13C 
NMR (CD30D) 5 12.60 (C5-Me), 38.97 (C2'), 61.67 (OMe), 62.42 (CO' 71.47 
(C3), 85.93 (Cl, ), 86.32 (C4'), 107.19 (C5), 127.71 (CA 144.38 (Q), 149.35 (C4); 
MS (EI) m/z (%) 124 (29), 155 (100), 271 (6, M+); (CI) m/z (%) 81 (1.9), 98 
(2.7), 116 (3.0), 126 (6.6), 156 (4.3), 182 (1.3), 217 (0.4), 242 (1.1), 272 [3, 
(M+H)+]; HRMS (EI) calcd (C11H17N305) 271.1169, found 271.1185. 
2.4.1.6: Synthesis of N4-methoxy-5-methylcytosine (18)159 
Methoxylamine hydrochloride (1-40g, 16.8mmol) was suspended in dry 
CH3CN (20ml) at OOC. POC13 (0.4ml) and triethylamine (4.4ml) were added 
to the suspension slowly and the mixture was stirred for 0.5 h before 
thymine (0.142g, 1.13mmol) in CH3CN (20ml) was added over a period of 
10 min. The solution was stirred at room temperature overnight and then 
heated for 5h at 600C. The solvent was removed in vacuo and the residue 
was purified by flash chromatography on silica gel (MeOH/CH2CI2,3/97) 
to give 126mg (72% yield) of a white solid: Rf = 0.61 (MeOH/CH2CI2,1/9); 
1H NMR (CD30D) 5 1.79 (3H, d, J=1.33Hz, Me), 3.86 (3H, s, OMe), 6.57 (1H, 
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d, J=1.33Hz, H6); 13C NMR (CD30D) 5 12.63 (C5-Me), 61.82 (OMO, 107.90 
(C5), 129.83 (C6), 145.20 (C2)i 150.70 (C4); MS (EI) rn /zM 58 (27.3), 86 (100), 
101 (22.4), 155 (4-5, M+); (CI) M/Z M 86 (10), 102 (62), 156 (19, (M+H)+); 
HRMS (EI) calcd (C6H9N302) 155.0695, found 155.0699. 
2.4.2: Enzymatic Synthesis of Nucleoside Analogues 
2.4.2.1: Purification of nucleoside N-deoxyribosyltransferases (E. C. 2.4.2.6. ) 
from Lactobacillus leichmannii 
Lactobacillus leichmannii ATCC 4797 was grown in a MRS (DeMan- 
Rogosa-Sharpe) medium (52gl-1) previously sterilised by autoclaving at 
1200C. The medium was inoculated with a 24 h starter culture (1%) grown 
in the same medium and incubated at 370C without aeration or agitation. 
The bacterial suspension was harvested by centrifugation (10 000g) for 15 
min at 40C. The pellet produced was washed twice with 0-02M PIPES buffer 
(pH 6.5) containing 0.02% (w/v) sodium azide, and the cell paste stored at - 
200C. Thawed cells were disrupted by three passes through a French 
pressure cell (20 000 psi) keeping the temperature below 100C, and the cell 
debris was removed by centrifugation (20 000g) for 30min at 40C. Cell-free 
extracts were dialysed overnight against 100 volumes of 0.02M PIPES 
buffer (pH 6.5) containing 0.02% (w/v) sodium azide. The final 
preparation could be stored at -200C for up to 3 months without significant 
loss of activity. 
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2.4.2.2: Protein Determination 
The concentration of protein was estimated using the dye-binding BioRad 
protein assay according to the method of Bradford166. The colorimetric 
property of Coomassie blue G-250 was employed, where the absorbance 
maximum of the dye changes from 465nm to 595nm when binding to 
protein occurs. Bovine serum albumin was used as the standard. 
2.4.2.3: Definition of Unit and Specific Activity 
One unit of enzyme activity was defined as the amount of enzyme 
catalysing the formation of 1.0 ýtmol of product (2-deoxyadenosine) 
formed in 1 min in the assay conditions from 2"-deoxycytidine and 
adenine. Specific acitivity was defined as units per milligram of protein. 
2.4.2.4: Standard Assay of N-deoxyribosyltransferase 
The standard reaction assay mixture contained 2'-deoxycyti dine (1 .5 mM), 
as the donor nucleoside, and adenine (0.5 mM), as the acceptor base, in 
citrate buffer (50 mM, pH 6.0). The reactions were initiated by the addition 
of a volume of the crude enzyme preparation equivalent to 50ýtg/ml of 
protein. The final volume of the reaction mixture was 0.5 ml and it was 
incubated at 400C with no shaking. At intervals of 0,5,10,15,20, and 30 
min a 20 ýLl aliquot was removed from the reaction mixture and applied to 
an HPLC column. The rate of deoxyribosyl transfer from the pyrimidine 
nucleoside to the purine base was measured by following the formation of 
2'-deoxyadenosine. The concentration of nucleosides and bases present in 
the reaction mixture were determined using reverse phase HPLC on a 
Techsphere 5C8 column (25cm x 4.6 mm and a precolumn, 5cm x 4.6mm). 
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The samples were eluted from the column using a mobile phase of 
acetonitrile and double distilled water (5/95) at a flow rate of 1.2 ml/min 
and detected by UV at 254nm. 
2.4.2.5: Comparison of Glycosyl Donors 
Four standard assay reactions were set up (as described before): 
a) 2'-deoxycytidine as the donor nucleoside and adenine as the acceptor 
base; 
b) thymidine as the donor nucleoside and adenine as the acceptor base; 
c) 2'-deoxycyti dine as the donor nucleoside and 2-aminopurine as the 
acceptor base; 
d) thymidine as the donor nucleoside and 2-aminopurine as the acceptor 
base. 
The rate of each reaction was followed as described in the standard assay 
method by reverse phase HPLC. The same set of reactions were also 
investigated using 2', 3"-dideoxycytidine and 2', 3'-dideoxythymidine as the 
donor nucleosides. 
2.4.2.6: Synthesis of N6-methoxy-2'-deoxyadenosine (15) 
N6-Methoxyadenine (30mg, 0.18mmol) and 2'- d eoxycyti dine (144mg, 
0.55mmol) were dissolved in citrate buffer (15ml, 10mM, pH 6.0 
containing 0.05% sodium azide) and ethylene glycol (1-5ml, 10%). The 
crude N-deoxyribosyltransferase extract (1ml, 15.8mg ml-1 protein, 7U) was 
added and the mixture was incubated for 10 days at 400C. The progress of 
the reaction was followed by reverse phase HPLC analysis (Techsphere 5C8 
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column, 25cm x 4.6mm,, elution with 6% CH3CN/1OmM NH40Ac). When 
the reaction had reached equilibrium, the mixture was Iyophilised and the 
residue was purified by flash chromatography on silica gel (MeOH/CH2CI2, 
5/95) to give 37mg (72% yield) of white crystals: Rf = 0.18 (MeOH/CH2CI2, 
1/9); 1H NMR (CD30D) 8 2.43 (1H, ddd, J=2.92,6.09,13.5Hz, H2'b), 2.76 OH, 
ddd, J=5.89,7.83,13.6Hz, H2'a), 3.75 (1H, dd, J=3.65,12.2FIZ, H5'a), 3.85 (1 H, 
dd, J=3.25,12.2FIz, H5'b), 3.89 OH, s, OCH3), 4.07 (1H, ddd, J=3 x 3.37Hz, H4, ), 
4.58 (1 H, ddd, J=2 x 2.77,5.69Hz, HY), 6.39 (1 H, dd, J=6.08Hz, Hy), 7.82 (1 H, 
brs, H2), 8.15 (1H, s, H8); 13C NMR (CD30D) 8 41.8 (C2'), 62.5 (OCH3), 63.5 
(CO, 72.9 (CY), 86.7 (C 1), 89.7 (C4'), 93.1 (C5), 95.1 (CO, 120.2 (C4), 139.5 (C2), 
147.1 (CO; MS (EI) m/z M 135 (100, adenine+-), 165 (27.8, N6_ 
methoxyadenine+. ), 192 (10-3), 205 (0.8), 221 (1.7), 236 (1.1, M+. -NOCH3), 
250 (1.2, M+. -OCH3), 281 (1.3, M+. ); (CI) m/z M 136 (47.2), 166 (6-9), 252 
(54.9), 282 [6.2, (M+H)+]. 
Nuclear Overhauser enhancement experiments: irradiation of the signal 
at 6.4ppm (Hl, ) caused enhancement of signals due to H8,1-4', and H2'b. 
Irradiation of the signal at 8.15ppm (HO caused enhancement of signals 
due to Hl,, H3'a, and H2'a- 
2.4.2.7: Synthesis of N6-methoxy-2', 3-dideoxyadenosine (19) 
N6-Methoxyadenine (20mg, 0.12mmol) and 2', 3'-dideoxycyti dine (77mg, 
0-36mmol) were dissolved in citrate buffer (10ml, 10mM, pH 6.0 
containing 0.05% sodium azide) and ethylene glycol O. Oml, 10%). The 
crude N-deoxyribosyltransferase extract (1ml, 15-8mg ml-1 protein, 7U) was 
added and the mixture was incubated for 4 weeks at 400C. A further 
addition of enzyme was made every week but only minimal reaction was 
observed (<3% transfer). The progress of the reaction was followed by 
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reverse phase HPLC analysis (Techsphere 5C8 column, 25cm x 4.6mm, 
elution with 6% CH3CN/1OmM NH40Ac). Due to the low transfer no new 
nucleoside was purified. 
2.4.2.8: Synthesis of N4-methoxy-5-methylcytidine (17) 
04-Methoxyaminothymine (30mg, 0.19mmol) and 2'-d eoxycy ti dine 
(132mg, 0.58mmol) were dissolved in citrate buffer (20ml, 10mM, pH 6.0 
containing 0.05% sodium azide) and ethylene glycol (2. Oml, 10%). The 
crude N-deoxyribosyltransferase extract (1ml, 16.3mg ml-1 protein, 8U) was 
added and the mixture was incubated for 2 weeks at 400C. A further 
addition of enzyme was made after one week but no reaction was 
observed. The progress of the reaction was followed by reverse phase 
HPLC analysis (Techsphere 5C8 column, 25cm x 4.6mm, elution with 3% 
CH3CN/lOmM NH40Ac). 
2.4.2.9: Inhibition Studies of N4-methoxy-5-methylcytosine (18) 
N 4-methoxy-5-methylcytosine (LOMMOO and crude N- 
deoxyribosyltransferase extract (0.1ml, 16.3mg ml-1 protein, -1U) were 
dissolved in citrate buffer (0.3ml, 10mM, pH 6.0 containing 0.05% sodium 
azide) and ethylene glycol (0.1ml, 10%). The mixture was incubated at 400C 
and at intervals of 1,3, and 6h an aliquot (0.6ml) of the reaction mixture 
was removed and assayed for activity by the addition of 2'-deoxycytidine 
(3-Ommol) and adenine (1.0mmol) to a total volume of 1.0ml. The 
progress of the reaction was followed by reverse phase HPLC analysis 
(Techsphere 5C8 column, 25cm x 4.6mm, elution with 3% CH3CN/1OmM 
NH40AO. 
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2.4.2.10: Synthesis of 2'-deoxyguanosine (20) 
2,6-Diaminopurine (20mg, 0.1mmol) and 2'- deoxycyti dine (74mg, 
0.3mmol) were dissolved in phosphate buffer (10ml, 1-OmM, pH 6.0). The 
crude N-deoxyribosyltransferase extract (200gl,, 16.3mg ml-1 protein, 2U) 
was added and the mixture was incubated for 24 h at 400C. The progress of 
the reaction was followed by reverse phase HPLC analysis (Techsphere 5C8 
column, 25cm x 4.6mm, elution with 6% CH3CN/1OmM NH40Ac). The 
reaction had reached >95% transfer to produce the 2,6-d iaminop urine 2'- 
deoxynucleoside. Without purification the pH was adjusted to 7.4 by the 
addition of LOM NaOH and adenosine deaminase (10gl, 9.2mg ml-I 
protein, 18U) was added to the mixture, which was incubated for 30 min at 
250C. The progress of the reaction was followed by reverse phase HPLC 
analysis (Techsphere 5C8 column, 25cm x 4.6mm, elution with 6% 
CH3CN/1OmM NH4OAc). When the reaction had reached equilibrium the 
mixture was Iyophilised. The residue was redissolved in distilled water 
(10ml, pH 5.0) and purified by ion exchange chromatography on Dowex 50 
NH4+ (200-400 mesh). The required 2"-deoxyguanosine was eluted with 
distilled water (pH 5.0) to give 25mg (93% yield) of white crystals: UV 
(H20., pH 7.0) kmax = 253.6nm; 1H NMR (D20/NaOD) 5 2.33 (1H, ddd, 
J=4.45,6.38.13-6Hz, H2'b), 2.62 (1 H, ddd, J=2 x 6.70,13.6HZ, H2'a), 3.65 (1 H, 
dd, J=-1,5.03,12AHz, H5a), 3.78 (1H, dd, J=-1,3.31,12.4Hz, H5b), 3.97 (1H, 
unresolved ddd, J=4.6lHz, H4'), 4.46 (1H, ddd, J=2x4.29,5.5Hz, HY), 6.22 
OH, dd appears as t, J=6.6lHz, Hl, ), 7.83 (1H, d, J=0.99Hz, H8); 13C NMR 
(D20/NaOD) 8 40.6 (C2'), 61.3 (CO, 72.1 (CY), 84.4 (Cl, ), 89.1 (C4'), 118.5 (C5), 
136.6 (C8), 151.52 (C4), 161.66 (C2),, 168.81 (CO; MS (FAB) m/z 267 (M+. ). 
Nuclear Overhauser enhancement experiments: irradiation of the signal 
at 6.22ppm (Hl, ) caused enhancement of signals due to H8,1-14,, and H2'b- 
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Irradiation of the signal at 7.83ppm (HO caused enhancement of signals 
due to Hl,, HY, and H2'a- 
2.4.2.11: Synthesis of 2', 3-dideoxyguanosine (21) 
2,6-Diaminopurine (10mg, 0.05mmol) and 2', 3'-dideoxycytidine (32mg, 
0.15mmol) were dissolved in phosphate buffer (10ml, 1-OmM, pH 6-0). The 
crude N-deoxyribosyltransferase extract (1ml, 16.3mg ml-1 protein, 8U) was 
added and the mixture was incubated for 4 weeks at 400C. A further 
addition of enzyme was made every week but only minimal reaction was 
observed (<5% transfer). The progress of the reaction was followed by 
reverse phase HPLC analysis (Techsphere 5C8 column, 25cm x 4.6mm, 
elution with 6% CH3CN/1OmM NH40AO. Due to the low transfer no new 
nucleoside was purified. 
2.4.2.12: Synthesis of 9-p-D-2-deoxyribofuranosyl 2-aminopurine (22) 
2-aminopurine (20mg, 0.15mmol) and 2'-deoxycytidine (101mg" 0.45mmol) 
were dissolved in citrate buffer (Joml,, 10mM, pH 6.0 containing 0.05% 
sodium azide) and ethylene glycol (1.0ml, 10%). The crude N- 
deoxyribosyltransferase extract (0.5ml, 16.3mg ml-1 protein, 9U) was added 
and the mixture was incubated for 2 days at 400C. The progress of the 
reaction was followed by reverse phase HPLC analysis (Techsphere 5C8 
column,, 25cm x 4.6mm, elution with 6% CH3CN/1OmM NH40Ac). When 
the reaction had reached equilibrium,, the mixture was Iyophilised and the 
residue was purified by flash chromatography on silica gel (MeOH/CH2CI2,, 
1/9) to give 30mg (80% yield) of white crystals: 1H NMR (CD30D) 
5 2.43 
(lH,, ddd, J=3-11,, 6.20,13.5Hz,, H2b), 2.84 OH, ddd,, J=5-97,7.67,13-6Hz,, H2'a), 
3.78 (lH,, dd, J=3.87,12. lHz,, H5'a),, 3.86 (IH, dd, J=3.44,12. lHz,, H5b), 4.07 
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(1H, ddd, J=3 x 3.55liz, H4, ), 4-62 OH, ddd, J=2 x 2.98,5-93HZ, HT), 6.42 OH, 
dd, J=6.18,7.62Hz, Hl, ), 8.33 (1H, s, H8), 8.60 (1H, s, H6); 13C NMR (CD30D) 8 
40.98 (C2'), 63-44 (CO, 72.85 (CT), 85-99 (Cl, ), 89-45 (C4), 128-68 (C5), 148.40 
(C8), 150-19 (C6), 153.92 (C4), 161.70 (C2); HRMS (CI) m/z calcd (ClOH12N503 
+ H+) 252.1094, found 252.1096. 
Nuclear Overhauser enhancement experiments: irradiation of the signal 
at 6.42ppm (Hl, ) caused enhancement of signals due to H8, H4,, and H2'b. 
Irradiation of the signal at 8.33ppm (HO caused enhancement of signals 
due to Hl,, H3, and H2'a. Irradiation of the signal at 8.60ppm (HO caused 
no enhancements of any signals. 
2.4.2.13: Synthesis of 9-p-D-2', 3'-dideoxyribofuranosyI 2-aminopurine (23) 
2-Aminopurine (20mg, 0.15mmol) and 2', 3'-dideoxycytidine (94mg, 
0.45mmol) were dissolved in citrate buffer (50ml, 10mM, pH 6.0 
containing 0.05% sodium azide) and ethylene glycol (5-5ml, 10%). The 
crude N- deoxyribos yl trans fera se extract (0.5ml, 16.3mg ml-1 protein, 9U) 
was added and the mixture was incubated for 12 days at 400C. The progress 
of the reaction was followed by reverse phase HPLC analysis (Techsphere 
5C8 column, 25cm x 4.6mm, elution with 6% CH3CN/IOmM NH40Ac). 
When the reaction had reached equilibrium, the mixture was lyophilised 
and the residue was purified by flash chromatography on silica gel 
(MeOH/CH2CI2,3/97) to give 20mg (57% yield) of white crystals: 1H NMR 
(CD30D) 5 2.20 (2H. m, H3'a and b), 2.55 (2H, m, J=5.97,7.67,13-6Hz, H2'a and 
b), 3.70 (1 H, dd, J=4.30,12.1 Hz, H5'a), 3.87 (1 H, dd, J=3.23,12.1 FIZ, H5'b), 4.28 
OH, dddd appears as septet, J=2 x 3.79,2 x 7.41FIz, H4, ), 6.28 UH, dd appears 
as t, J=2 x 5.22Hz, Hl, ), 8.40 (1H, s, H8), 8.59 (1H, s, H6); 13C NMR (CD30D) 8 
26.62 (CY), 33.20 (C2'), 64.30 (CO, 64.50 (C4, ), 83-48 (Cl, ), 128.60 (C5), 143.22 
99 
(C8),, 149-88 (C6), 153-85 (C4),, 161.78 (C2); HRMS (CI) m/z calcd (ClOH12N502 
H+) 236-1145, found 236-1147. 
Nuclear Overhauser enhancement experiments: irradiation of the signal 
at 6.28ppm (Hl, ) caused enhancement of signals due to H8, ff4,, H3'b, and 
H2'b. Irradiation of the signal at 8-40ppm (HO caused enhancement of 
signals due to Hy, H3'a, and H2a- Irradiation of the signal at 8-60ppm (H, 6) 
caused no enhancements of any signals. 
2.4.2.14: Synthesis of 2-Thio-2"-deoxyuridine (24) 
2-Thiouracil(15mg, 0.11mmol) and thymidine (80mg, 0.35mmol) were 
dissolved in citrate buffer (10ml, 1-OmM, pH 6.0 containing 0.05% sodium 
azide) and ethylene glycol (1.0ml, 10%). The crude N- 
deoxyribos yl trans ferase extract O. Oml, 16.3mg ml-1 protein, 18U) was 
added and the mixture was incubated for 1 day at 400C. The progress of the 
reaction was followed by reverse phase HPLC analysis (Techsphere 5C8 
column, 25cm x 4.6mm, elution with 2% CH3CN/1OmM NH40Ac). When 
the reaction had reached equilibrium, the mixture was Iyophilised and the 
residue was purified by flash chromatography on silica gel (MeOH/CH2CI2, 
1/18) to give 14mg (47% yield) of a white crystalline solid: Rf = 0.17 
(CH2Cl2/MeOH, 9/1): 1H NMR (CD30D) 8 2.20 (1H, ddd appears as sextet, 
J=12.8,9,03,6.14Hz, H2a), 2.57 (IH, ddd appears as dt, J=6.03,5.08Hz, HAL 
3.68 (1H, dd, J=4.42,12.6Hz, H5"b), 3.79 OH, dd, J=3.07,12.8Hz, H5"a), 4.02 
OH, ddd appears as q, J=3 x 3.91Hz, H4% 4.29 (IH, ddd appears as q, J=3 x 
4.54Hz, HD, 6.35 (1 H, dd, J=6.02,8.99Hz, Hl'), 6.66 (1 H, d, J=7.6FIZ, H5), 8.16 
(1H, d, J=7.6FIz, HO; MS (CI) m/z 128 (76), 243 [9, (M+H+)]. 
Nuclear Overhauser enhancement experiments: irradiation of the signal 
at 6.35ppm (HO caused enhancement of signals due to H8,1-14,, and H2'b- 
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Irradiation of the signal at 8.16ppm (H6) caused enhancement of signals 
due to Hl,, HY, and H2'a- 
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CHAPTER 3 
IMMOBILISED ENZYMES 
Background 
Chemists have been aware for a long time of the advantages that the use 
of enzymes as catalysts have over purely chemical means. Enzymes 
demand attention chiefly because of the efficiency and selectivity with 
which they catalyse reactions and the mildness of their reaction conditions 
but their use has been restricted because their stability is often limited. 
This problem can usually be overcome by immobilising the enzyme on a 
solid support and thus enhancing its thermal, mechanical and chemical 
stability to produce a recoverable catalyst. The ease of separation of the 
immobilised enzyme from the reaction mixture,, its extended life-span and 
the possibility of reuse all offer considerable operational advantages over 
the corresponding free enzyme. The physical and physicochemical 
properties of immobilised enzymes have been shown, in some cases, to 
differ from those of their counterparts in free solution, such as pH-activity, 
kinetic parameters, substrate specificity and stability. These immobilised 
enzymes have found many uses in industrial, analytical and medical 
82,167-172 procedures 
An immobilised enzyme molecule is prevented from diffusing freely 
through the reaction medium by being attached physically and/or 
chemically to a support material. Chemical methods are usually 
irreversible whereas physical techniques, such as hydrophobic 
interactions, should, in theory, be completely reversible. The reaction 
system thus consists of two phases: the bulk solution, and the immobilised 
102 
enzyme with its support environment. The support materials are usually 
insoluble in water and are often high molecular weight, hydrophilic 
polymers. There are four general methods for immobilising enzymeS82: 
covalent binding, 2) adsorption, 3) entrapment and 4) encapsulation. 
3.1.1: Covalent Binding 
Immobilisation by covalent bonding of an enzyme to an activated polymer 
is probably the most extensively used method. The outer surface of the 
enzyme contains many different amino acid functional groups which are 
suitable for participation in the covalent bond formation. As the support 
matrix is more robust than the enzyme, this is activated before addition of 
the enzyme. The activated functional groups on the support then react 
with the ones present on the enzyme surface, under much milder 
conditions. A number of amino acid functional groups which are most 
often involved in the covalent binding are: the amino group (NH2) Of 
lysine or arginine; the carboxyl group (C02H) of aspartic acid or glutamic 
acid; the hydroxyl group (OH) of serine or threonine; and the sulphydryl 
group (SH) of cysteine. 
Fig. 3.1 Immobilisation by covalent binding 
103 
There are many support materials available for covalent binding and the 
advantages and disadvantages of each must be considered for each 
required application. Hydrophilicity is the most important factor for 
maintaining enzyme activity in a matrix environment. Therefore, 
biological polysaccharide polymers, which are very hydrophilic, such as 
cellulose, dextran (Sephadex), starch and agarose (Sepharose) are widely 
used for enzyme immobilisations. Sepharose and Sephadex are the two 
most commonly used supports; they are spherical bead forms of the 
polymeric natural products and possess superior mechanical strength 
compared with the fibrous polysaccharide, are of defined physical 
dimensions and have known pore sizes. The hydroxyl groups on the sugar 
residues in these polymers are ideal for covalent bonding and can also 
hydrogen bond with water to form micro-cavities and small channels. 
These beads are very strong and durable but are less hydrophilic than the 
polysaccharide materials, such as cellulose. Organic supports such as 
polystyrene and polyacrylamide can also covalently bond to the enzyme 
and form cross-linked networks of fibres which form a hydrophilic 
environment. 
There are many reactions for joining an enzyme to the immobilisation 
matrix by a covalent bond such as: 
oformation of an isourea linkage; 
*formation of a diazo linkage; 
*formation of a peptide bond; 
*an alkylation reaction. 
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The favoured method is chosen so as not to react with any groups which 
may be important in the catalytic action of the active site of the enzyme. 
The residues at the active site of the enzyme must be avoided when 
coupling takes place, and their protection can be achieved by the use of 
substrate or reversible inhibitors. Similarly, coupling should not take place 
through residues involved in allosteric control or subunit-subunit 
interactions. 
The functional groups on the support material are activated first by a 
specific reagent to make, them strongly electrophilic. The enzyme is then 
added and the amino acid functional groups nucleop hili call y attack the 
activated groups to form the covalent bond. 
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Scheme 3.2 Cyanogen bromide activation 
Cyanogen bromide is used to activate the hydroxyl groups of 
polysaccharide support materials. 
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Scheme 3.3 Carbodiimide activation 
Carbodiimide activation involves the bonding of the carboxyl group and 
the enzyme via a peptide bond. 
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Scheme 3.4 Nitrous acid activation 
Aromatic amine groups on the support can be diazotised using nitrous 
acid. The bond is formed between the reactive diazo group of para- 
aminobenzoyl on the support and the ring structure of an aromatic amino 
acid such as tyrosine. 
However, hydroxyl ions from the aqueous solvent can also react with the 
activated support therefore, activation levels must be high to allow for 
loss by hydrolysis. Activated materials must be carefully stored and it is 
preferably to use them as quickly as possible. 
Normal functional groups on a support can be chemically modified to 
produce a range of derivatives containing different functional groups. For 
example, the hydroxyl group in cellulose can be modified to produce CM- 
cellulose (carboxymethyl), and DEAE-cellulose (diethylaminoethyl). 
Derivatization can also modify the charges on the surface of a support to 
improve the binding of the immobilised enzyme. Chemical 
immobilisation is more likely to alter the characteristics of the enzyme 
because covalent links may alter electrostatic, hydrogen and/or 
hydrophobic bonds keeping the enzyme in its active form. This will 
therefore affect the catalytic ability, stability and activity of the immobilised 
enzyme. Loss of activity may arise in a multi-unit enzyme if dissociation 
of the subunits occurs to leave only one of the subunits covalently 
attached to the support. 
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3.1.2: Adsorption 
The simplest method of immobilisation is adsorption of an enzyme onto 
the support material. However, the ease with which binding is achieved is 
reflected in the ease with which the enzyme may also be removed. No pre- 
activation steps are required to alter the functional groups on the support 
as the method relies on the adhesion of the enzyme to the support 
material by non-covalent interactions, such as ionic interactions, van der 
Waal's forces, hydrophobic effects and hydrogen bonding. 
The outer surface of the enzyme may have regions which are 
hydrophobic, hydrophilic, charged or neutral and these properties will 
vary in distribution and dominance with the surrounding conditions of 
pH, molarity, hydrophilicity and temperature. Support materials with 
complementary features will adsorb the biocatalyst with a strength and 
specificity related to the extent of the complementarity. The strength of 
these interactions can be increased by the introduction of strong, charged 
groups, as in ion exchange resins; or by the incorporation of an ion which 
forms strong complexes with proteins, such as titanium (IV) ions; or by 
the use of a specific affinity ligand such as an antibody to the biocatalyst. 
There are many support materials available, such as alumina, activated 
carbon, kaolinite, bentonite, porous glass, anion-exchange resins (e. g. 
DEAE-Sephadex) and cation-exchange resins (e. g. CM-cellulose). 
Fig. 3.5 Immobilisation by adsorption 
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The enzyme is bound to the support by mixing the aqueous solution of 
both for a period of time, after which any excess enzyme is washed away. 
Problems with adsorption of other ions and unwanted proteins which 
compete for the adsorption sites are common place. The pH and ionic 
strength must be carefully monitored as any fluctuations can alter the 
charges on both the enzyme and the support, resulting in the release of the 
enzyme from the support. Although leakage of the enzyme occurs due to 
the weak non-covalent bonds, this method is cheap, simple and the 
support can be regenerated with fresh enzyme. As with covalent 
immobilisation, the properties of the enzyme can also be altered by 
adsorption, due to the great influence of ionic or steric repulsion of the 
support material on enzyme activity. 
3.1.3: Entrapment and Encapsulation 
The immobilisation of enzymes by entrapment or encapsulation differs 
from the other methods discussed, in that the enzyme molecules are free 
in solution, but restricted in movement by the three-dimentional lattice of 
a gel or by a semi-permeable membrane. There is minimum effect on the 
enzyme since the enzyme is still in solution but within a defined physical 
volume. 
Sý 
6(3 
Fig. 3.6 Immobilisation by entrapment and encapsulation 
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The porosity of the gel lattice or semi-permeable membrane is controlled 
to ensure that the structure is tight enough to prevent leakage of the 
enzyme but at the same time allow free diffusion of substrate and product 
molecules. 
3.1.3.1: Entrapment 
Entrapment can be achieved by mixing the enzyme with a fluid precursor 
of the gel and subsequently inducing gelation, either by polymerisation or 
precipitation. For example, polymerisation of acrylamide monomers to 
form polyacrylamide or methyl acrylate to form polymethacrylate. Cross- 
linking agents can also be added during polymerization to create a three- 
dimentional lattice. The relative amounts of monomer and cross-linking 
agent can be varied to determine the pore size and mechanical properties 
of the gel. 
Alginic acid cross-linked with calcium ions has proved useful for cell 
entrapment but often the gel is too open to retain enzymes and calcium 
chelation can eventually lead to loss of gel structure. Some gelling 
materials, such as carrageenan, are sold in grades specifically for 
immobilisation work. 
3.1.3.2: k-Carrageenan 
Carrageenans are sulphated derivatives of polysaccharides obtained from 
some seaweeds, and are often used as a food additive. There are three 
principal types of natural carrageenan K, t, and X. Carrageenans are mainly 
composed of D-galactose,, 3., 6-anhydro-(x-D-galactose and about 20-30% of 
sulphate groups to produce a molecular weight of 100,000 to 800,000167. The 
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characteristics of K-carrageenan, compared to the other types., make it the 
173,174 
more suitable for immobilisation purposes 
OS()3- 
CH20H 
0 0 
OH 
OH 
D- glactase-4-sulphate 3,6-anhydro-D-galactose 
Fig. 3.7 Limiting structure of K-carrageenan 
The bonding of the carbohydrate rings leads to the formation of a double 
helix. ic-Carrageenan is easily induced to gel by contact with metal ions, e. g. 
K+, Rb+, and Cs+ ions, amines, e. g. hexamethylenediamine, amino-acid 
derivatives, e. g. DL-histidine hydrazine, water-miscible organic solvents 
and cooling below 100C. Inclusion of cells or enzyme in the fluid prior to 
gelling results in a mild and efficient immobilisation method. The 
preparations can be formed into cubes, beads or membranes and used in 
various forms of continuous or batch reactors. 
3.1.3.3: Encapsulation 
Encapsulation of enzymes can be achieved by enveloping the molecules 
within various forms of semi-permeable membranes. Once again, the 
enzyme is prevented from passing out of the immobilisation medium but 
small substrate and product molecules can pass freely across the 
membrane. Microcapsules varying from 10gl to 1000[il diameter have been 
made from many materials such as nylon and cellulose nitrite. Biological 
cells, such as erythrocytes can be used and liposomes can be formed from 
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lipids to produce two-layered structures similar to that found in cell 
membranes. 
Both these methods have the disadvantage that leakage of enzyme can be 
high and often only low yields of immobilisation are achieved. These 
methods have a more limited use than the other techniques. However, by 
combining entrapment with covalent bonding a very useful technique has 
been developed175,176. 
Fig. 3.8 Immobilisation by combined covalent bonding and matrix 
entrapment 
The procedure involves the simultaneous reaction of three components 
in neutral buffered aqueous solution at room temperature: a copolymer of 
acrylamide and N-acryloxysuccinimide, a low molecular weight am- 
diamine, and the enzyme. The copolymer, poly(acrylamide-co-N- 
acryloxysuccinimide) (PAN) is prepared by the azobis(isobutyronitrile) 
(AIBN) catalysed reaction of acrylamide and N-acryloxysuccinimide. The 
water-soluble copolymer is then cross-linked by reaction of the (x, CO- 
diamines with the active ester groups of the PAN to form an insoluble gel 
connected through amide groups. The addition of enzymes to the reaction, 
as cross-linking takes place, results in reaction of the lysine E-amino 
functions of the enzyme to the gel through additional amide linkages. In 
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the presence of saturating concentrations of reagents which bind at the 
active site, the enzyme is maintained in its active conformation during 
the covalent bond formation and the active site residues are protected 
from the covalent bonding. 
3.1.4: Applications of Immobilised Enzymes 
Due to the vast array of techniques and immobilisation supports available, 
it is necessary to choose a particular method to meet the specific 
requirements of any investigation. In this project the use of immobilised 
N-deoxyribosyltransf erase from Lactobacillus leichmannii was 
investigated for the batch production of nucleoside analogues. In the large 
scale production, enzyme immobilised on a suitable support can be rapidly 
removed from reaction mixtures and have the advantage of being 
reusable. In order to be able to select a suitable immobilisation method, 
several supports must be investigated to evaluate their usefulness in 
retaining and stabilising the enzyme for repeated use. 
3.2: RESULTS AND DISCUSSION 
3.2.1: Standard Assay 
Deoxyribosyltransferase 
of Immobilised Nucleoside 
Three distinctly different methods of enzyme immobilisation were 
investigated to find which method and matrix support would give the 
most stable enzyme preparation for use in a batch reactor. Each method 
was assay by the standard glycosyl transfer reaction: 
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Scheme 3.9 Standard assay for immobilised enzyme activity 
As all the nucleosides in this reaction absorb in the UV, the reaction was 
followed by reverse-phase HPLC using a UV detector at X=254nm (as 
described in Chapter 2). The assay method for each immobilisation 
support is described in the Experimental section. 
3.2.2: Immobilisation on Hydrophobic Supports 
The hydrophobic nature of the proteins and enzymes in the crude 
preparation were investigated by trying to immobilise the crude enzyme 
preparation by adsorption. Three different columns were prepared 
containing agarose with different groups covalently attached (phenyl, 
trityl, and octyl). An equal amount of enzyme was applied to each column 
and allowed to equilibrate at room temperature. Each column was washed 
with buffer and the eluate collected for analysis of the unbound activity. 
These initial washings showed a small amount of enzyme activity but 
most was retained on the column. The immobilised enzyme was assayed 
every hour to measure the retention of activity on the column. 
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Fig. 3.10 Retention of N-deoxyribosyltransferase on hydrophobic 
Sepharose 
3.2.2.1: Octyl Sepharose 
As can be seen on the graph, the most promising results were found with 
octyl Sepharose. When the enzyme was immobilised on the octyl 
Sepharose as described in the Experimental, considerable activity was 
retained on the column. The initial eluate was collected for analysis and 
negligible activity was found. The immobilised enzyme was subjected to 
numerous assay cycles and it was found that good levels of activity (59%) 
remained after ten cycles. After this the levels of activity started to decrease 
0 Octyl Sepharose 
Phenyl Sepharose 
Trityl Agarose 
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slowly. The levels of retained activity could have been affected by several 
factors: initially losses in activity might have be due to the elution of the 
active enzyme from the octyl Sepharose; later on after the percentage of 
retained activity had levelled out, any losses in activity may have been 
due to deactivation of the N-deoxyribosyltransferase retained on the 
column. After the first few washings there was no enzyme activity 
measured in the eluates so therefore, it was assumed that the losses in 
activity were due to deactivation. This deactivation may be caused by the 
116 dissociation of the subunits of this hexameric enzyme 
3.2.2.2: Immobilised Enzyme Stability at 40C 
A sample of the octyl Sepharose immobilised N-d eoxyribos yl trans ferase 
was stored at 40C and assayed every day to ascertain the levels of retained 
activity. Similar levels of activity to the continuous assay described above 
were obtained. However, after seven cycles the levels activity started to 
decrease due to deactivation of the immobilised enzyme. It was decided 
that the simplicity of immobilisation on octyl Sepharose was conducive to 
the preparation of the immobilised enzyme when it was required and 
there was no need to prepare and store the enzyme in this form. 
3.2.2.3: Phenyl and Trityl Sepharose 
The adsorption of N-deoxyribosyltransf erase onto phenyl and trityl 
Sepharose was performed as described for octyl Sepharose. However, 
unlike octyl Sepharose, the retention of activity on the column was very 
poor. The initial washings of both columns showed a small amount of 
enzyme activity but most was retained on the column. After only a few 
assay cycles the levels of activity on both columns was very low and when 
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the eluted fractions were assayed, by a Bio-Rad assay (as described in 
Chapter 2), they showed the presence of enzyme. The loss in activity in 
this case was due to elution of the enzyme and not due to any 
deactivation. 
As a result of these findings, further investigation into immobilisation on 
phenyl or trityl Sepharose was abandoned. The retained activity found on 
the octyl Sepharose column have a reasonable life-span but before any 
conclusions as to the preferred method of immobilisation were made, 
other methods were investigated. 
3.2.3: Immobilisation by Entrapment using K-Carrageenan 
K-Carrageenan was chosen as the support matrix to investigate for the 
entrapment of N-deoxyribosyltransferase. The solid cubes of the 
immobilised enzyme were prepared as described in the Experimental and 
placed in a filtration unit to make a batch reactor. The cubes were washed 
with citrate buffer and the eluate collected for analysis of the unbound 
activity. These initial washings showed a small amount of enzyme activity 
but most was retained in the ic-carrageenan cubes. The immobilised 
enzyme was assayed every two hours to measure the retention of activity 
in the cubes. 
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Fig. 3.11 Retention of N-deoxyribosyl trans ferase by entrapment in 
K-carrageenan 
Considerable activity appeared to be retained in the K-carrageenan. The 
immobilised enzyme was subjected to numerous assay cycles but it was 
found that the levels of activity fell after each assay cycle due to leakage of 
the enzyme from theK-carrageenan. The presence of enzyme in the eluted 
assay mixtures was confirmed by a Bio-Rad protein assay (as described in 
Chapter 2). 
To try to prevent enzyme leakage from the ic-carrageenan cubes, different 
concentrations of KCI solution were investigated in the hardening of the 
gel but this was found to have very little effect. During the assay cycles the 
K-carrageenan gel remained reasonably intact in the cubic form in which it 
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had been moulded so it was felt that enzyme leakage was partly due to the 
collapse of the gel structure, but was more likely to be related to the size of 
the pores in the gel structure which were obviously too large to retain the 
enzyme. The pores not only allowed diffusion of the substrate molecules 
in and out of the gel matrix but also diffusion of the enzyme was possible. 
As an obvious continuation from these results the use of a combined 
method of entrapment and covalent binding was investigated. 
3.2.4: Covalent Binding and Entrapment 
Due to the problems encountered in the adsorption and entrapment of the 
enzyme, a combination of covalent binding and entrapment was 
investigated. The method of Pollak et al. 175 was used to synthesise the 
polymer and to immobilise the enzyme as described in the Experimental. 
This method was reported to be applicable to small quantities of enzyme, 
to give high yields of immobilised activity and to incorporate a link 
between the enzyme and the immobilising matrix which is hydrolytically 
stable. The enzyme is incorporated into a hydrophilic medium and the 
matrix produced has a high permeability towards low molecular weight 
substrates. 
3.2.4.1: Preparation and Characterisation of PAN 
PAN (27) was prepared by the free-radical polymerisation of acrylamide 
(25) and N-acryloxysuccinimide (26) in THF solution, using thermal 
initiation with azobis(isobutyronitrile) (AIBN). 
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Scheme 3.12 The thermal decomposition of the radical initiator AIBN 
This method produced low molecular weight polymers as a white solid. 
The polymer was very stable at room temperature in a desiccator under 
dry air but the active ester groups hydrolyzed very quickly in the presence 
of moisture. 
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3.2.4.2: Assay for the Active Ester Content of PAN 
The polymer was assayed for active ester groups by allowing it to react 
with aqueous propylamine solution and measuring the absorbance due to 
the anion of N-hydroxysuccinimide. The rate of appearance of N- 
hydroxysuccinimide was followed spectrophotometrically at X=259nm at 
room temperature. After the reaction was completed (-60 min) the active 
ester concentration was calculated. The absorbance due to the anion of N- 
hydroxysuccinimide is equal to the final absorbance minus the initial 
absorbance (F_=860OM-1cm-1). Therefore, using Beer-Lambert law, the 
concentration of active ester groups was found to be 573ýimol per gram in 
this sample. The composition of the polymer was specified in the paper in 
terms of the content (in ýtequiv/g) of active ester groups: thus, PAN-550 is 
a polymer which releases 550 (±25) 4mol of N-hydroxysuccinimide per 
gram of dry polymer on treatment with excess aqueous propylamine 
solution. To avoid confusion resulting from unnecessary precision, these 
descriptive numbers of active ester groups are rounded to the nearest 50; 
thus a polymer assayed to contain 5734equiv/g of active ester groups is 
called PAN-550. 
3.2.4.3: Determination of the Gel Time 
The rate of gel formation can be altered by changing the temperature or pH 
of the coupling reaction. Before performing an immobilisation using PAN 
it was necessary to investigate the time the gel would take to form and to 
adjust this as necessary, as gels taking longer than 5 min to form are soft 
because of the hydrolysis of the active ester groups. To increase the rate of 
the coupling reaction the temperature can be raised or the pH can be made 
more basic; by reversing these conditions the gel time can be lengthened. 
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To produce a gel which has the correct mechanical properties for enzyme 
immobilisation requires the following composition: the reaction of a 20% 
solution of PAN (O-3M Hepes buffer, pH 7.5) having 450-1550 ýtequiv of 
active ester groups/g with a quantity of TET providing 0.85 equiv of 
primary amine groups/equiv of active ester. This stoichiometry leaves 
-15% of the active ester groups unreacted and available for reaction with 
the nucleophilic groups on the enzyme. Therefore, addition of the N- 
deoxyribosyltransferase to the reacting solution of PAN and TET before 
gelling is complete will result in its covalent incorporation into the cross- 
linked polymer network. 
The corresponding quantities of each reagent, as outlined above, were 
mixed together without the addition of the enzyme to ascertain the gel 
time. After 2 min the mixture had set to a transparent,, mechanically 
resilient gel. Therefore, this method seemed to be suitable for the 
immobilisation of the enzyme. 
3.2.4.4: Immobilisation of N-Deoxyribosyltransferase on PAN-550 
In the standard procedure, a quantity of PAN sufficient to give a 20% w/w 
solution was weighed rapidly in air and dissolved in O-3M Hepes buffer 
containing components intented to protect enzymatic activity. In the case 
of N-deoxyribosytransferase, a nucleoside or base was added to occupy the 
active site. The substrate should bind to the active site of the enzyme and 
prevent modification of nucleophiles close to or at the active site by 
acylation with PAN during the immobilisation. 1,4-Dithiothreitol (DTT), a 
reducing thiol, was also added during the immobilisation to inhibit 
protein autoxidation for enzymes containing essential catalytic or 
structural thiol groups. As the structure of N-deoxyribosyl trans ferase 
has 
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not been published it was assumed that the enzyme might contain some 
stucturally important disulphide bridges,, although it is known that there 
are no essential catalytic thiol groups in the active site114 - The cross-linking 
agent, TET was added at the same time as DTT and the gelling process 
started. About 30 sec after the addition of TET, the enzyme solution 
(10mg/g of PAN) was added to the reaction mixture. After preliminary 
investigations it was found that the highest yields of immobilised activity 
were obtained using quantities of enzyme not greater than 10mg/g of 
PAN. For high yields of immobilised activity, the enzyme must be added 
after about one-third of the gel time so that there is enough time for 
thorough mixing of the components but only a limited amount of time 
for the enzyme to be exposed to PAN before gel formation. 
0104N 0 
1 
u- -, -0 
N. J 
PAN (27) 
NH2 
1) TET, DTT 
2) Enz-N-H2 
Adenine 
HEPES buffer pH 7.5 
60mins, room temp 
0 
NH 
0., 11,1 1 Enz 
Ki 
v 
TET = triethylenetetramine 
DTT = dithiothreitol 
Enz = Lactobacillus leichmannii (crude extract) 
NH2 
Scheme 3.14 Immobilisation of N-deoxyribosyltransferase on PAN 
The enzyme-containing gel was allowed to stand for 60 min to complete 
the coupling reaction before being ground into particles and washed with 
aqueous buffer containing ammonium sulphate to convert residual active 
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ester groups to amides. Finally, the immobilised enzyme activity was 
assayed. To maximise the ease of separation of the reaction mixtures from 
the gel, the gel particles were kept in the centrifuge tubes for the assays and 
reactions. The initial washings with buffer were collected for analysis of 
the unbound activity. These initial washings showed a negligible amount 
of enzyme activity but most was retained in the gel. The immobilised 
enzyme was assayed every day to measure the retention of activity in the 
gel. 
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Considerable activity appeared to be retained in the PAN gel. The 
immobilised enzyme was subjected to numerous assay cycles; it was found 
that initially the levels of activity were very high for the first 7 days 
(ý! 80%), after this the activity slowly decreased to 50% and then there was a 
much more rapid loss of activity. A sample of PAN immobilised enzyme 
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was also stored at 40C and fractions were removed periodically to assay the 
activity. As can be seen on the graph the losses in activity showed a similar 
pattern to that produced by the continuous assay except that the decrease 
in activity was more rapid. The levels of retained activity could have been 
I/ 
affected by several factors: losses in activity might have been due to the 
elution of the active enzyme from the PAN gel, but this was only a minor 
contributing factor as negligible amounts of protein were found in the 
initial washings or the eluted reaction mixtures; any losses in activity were 
more likely to have been caused by deactivation of the N- 
deoxyribosyltransferase retained in the gel. As was postulated for the loss 
in activity seen for the octyl Sepharose, this deactivation may be caused by 
the dissociation of the subunits of this hexameric enzyme. 
3.2.4.5: Synthesis of 2-Thio-2-deoxyuridine (24) using PAN Immobilised 
Enzyme 
A large scale immobilisation of N-deoxyribosyltransferase on PAN-550 
was performed as described in the Experimental section and this was used 
in the synthesis of the nucleoside analogue, 2-thio-2'-deoxyuridine (24). 
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Thymidine, the glycosyl donor, and 2-thiouracil, the acceptor base, were 
thermostated in citrate buffer (pH 6.0) at 400C. The reaction was followed 
by reverse-phase HPLC and had reached equilibrium after 10 h. The 
purified white crystals were identified by 1H NMR and MS (CI) and were 
compared with the sample prepared using the soluble enzyme. The yield 
(35%) was comparable with that obtained using soluble enzyme but the 
use of immobilised enzymes enabled the reaction to be repeated several 
times, with the same batch of enzyme, to synthesise a large amount of 2- 
thio-2'-deoxyuridine (24). 
3.2.5: Conclusion 
Immobilisation of N-deoxyribosyltransferase on octyl Sepharose and 
PAN-550 gel were both successful methods however, the PAN method 
gave higher and more sustained levels of activity, was easier to handle 
and incubate, and provided a general batch reactor method for the 
synthesis of nucleosides. Once the starting PAN is prepared, it is just as 
convenient to immobilise the enzyme on the gel as it is to absorb it to the 
Sepharose. From the investigations it was concluded that, because of the 
ease of preparation of the immobilised enzymes, synthesis of the 
immobilised enzymes when required, rather than synthesising large 
batches to store, was the preferred method. 
3.3: MATERIALS 
Phenyl and octyl Sepharose CL-4B were purchased from Pharmacia. Trityl 
agarose was purcased from Miles-Yeda Ltd. The filters for the K- 
carrageenan filtration unit were purchased from Millipore. K-Carrageenan, 
Type III from Eucheuma cottonii (containing 0.7% Na, 3.6% K, 2.9% Ca), 
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was purchased from Sigma. N-Deoxyribosyltransferase (EC 2.4.2-6) was 
prepared from Lactobacillus leichmannii as described in Chapter 2. The 
reverse phase HPLC was performed on a Techsphere 5C8 column (25cm x 
4.6 mm and a precolumn, 5cm x 4.6mm) form HPLC Technology Ltd, 
Macclesfield, Cheshire, UK. 
3.4: EXPERIMENTAL 
3.4.1: Standard Assay 
Deoxyribosyltransferase 
of Immobilised Nucleoside 
The standard reaction assay mixture containing 2'-deoxycytidine and 
adenine is described for each immobilisation method. After the described 
time the reaction mixture was separated from the immobilised enzyme 
and a 20gl aliquot of the assay mixture was applied to an HPLC column. 
The rate of deoxyribosyl transfer was measured by reverse phase HPLC (as 
described in Chapter 2). The samples were eluted from the column using a 
mobile phase of acetonitrile : double distilled water (5: 95) at a flow rate of 
1.2 ml/min and detected by UV at 254nm. 
3.4.2: Immobilisation on Hydrophobic Sepharoses 
Phenyl, trityl, and octyl Sepharose were used to immobilise a crude 
preparation of N-deoxyribosyltransferase. Each gel was poured into a small 
disposable column (4.5cm x 0.8cm). Each column was washed several 
times with 10 bed volumes (ý! 35 ml) of citrate buffer (0-05M, pH 6.0) to 
remove any organic storage solvents. The enzyme (200ýd, 2.4mg protein, 
2U) was pipetted onto each respective column, allowed to flow onto the 
Sepharose. The column was then stoppered and left to stand at room 
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temperature for 10 min. The columns were washed with 2-3 bed volumes 
of citrate buffer (10ml) before the reaction mixture for the enzyme assay 
was loaded onto them. This assay mixture contained 2'-deoxycytidine 
(3. OmM) and adenine (1. OmM), in citrate buffer (10-OmM., pH 6.0). The final 
volume of the reaction mixture was 1.0ml and it was incubated at 400C. 
After 30 min at room temperature the reaction mixture was eluted from 
the column and the reaction analysed by reverse-phase HPLC immediately 
and after three hours of being removed from the column. The columns 
were washed with buffer (10ml) before another sample of the reaction 
mixture was loaded. These washings were also assayed for enzyme 
activity. These steps were repeated until no activity was shown to be 
remaining. 
3.4.2.1: Immobilised Enzyme StabRity at 40C 
Octyl Sepharose showed good retention of activity and so a sample was 
stored at 40C and removed periodically to assay. 
3.4.3: Entrapment using ic-Carrageenan 
An aqueous solution of x-carrageenan (4.4%, w/v) was prepared by 
heating the mixture of powder and distilled water to 600C to dissolve the 
polysaccharide. The solution was maintained at 400C and the enzyme 
solution (200gl, 2.4mg protein, 2U) was added, and mixed thoroughly. The 
warm ic-carrageenan and enzyme solution was hardened by the addition 
of KCI solution (0.3M, 30ml). The mixture was left to harden in the KCI 
solution for one hour. The resulting solid sheet was cut into small cubes 
which were placed in a protein filtration unit to produce a batch reactor. 
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Fig. 3.16 Batch reactor containing K-carrageenan 
The cubes were then assayed for their enzyme activity. The assay reaction 
mixture, containing 2-deoxycytidine (30-OmM) and adenine (10. OmM), in 
citrate buffer (10. OmM, pH 6.0), final volume 10.0ml, was added to the 
reactor. After 30 min at room temperature the reaction mixture was eluted 
from the reactor and the assay mixture analysised by reverse-phase HPLC 
immediately and after three hours of being eluted from the reactor. The K- 
carrageenan cubes were washed with buffer (10ml, 1-OmM. pH 6.0) before 
the next reaction mixture was added to the reactor. The KCI solution and 
the washings were also assayed for enzyme activity. These steps were 
repeated until no activity was shown to be remaining. 
3.4.4: Poly(acrylamide-co-N-acryloxysuccinimide) (PAN) (27) 
The PAN was synthesised as described by Pollak et al. 175. 
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3.4-4-1: Synthesis of N-acryloxysuccinimide (25) 
This was carried out by the method of Pollak et a1175 to give 61.5g (73% 
yield): 1H NMR (400 MHz, CDC13) 5 2.80 (4H, s, 2x CH2), 6.11 (IH, dd, J= 0.9, 
10.7HZ, Htrans), 6.26 (1H, dd, J=10.7,17.3Hz, Hgem), 6.63 UH, dd, J=0.9, 
17.3Hz, Hcis); 13C NMR (40OMHz, CDC13) 5 25.44,122.76,136.10,160-91, 
168-95; IR (Nujol, cm-1) 870,995,1260,1735,1775,1800. 
3.4.4.2: Synthesis of Poly(acryamide-co-N-acryloxysuccinimide) (PAN) (27) 
This was carried out by the method of Pollak et al 175 to give 31.5g (100% 
yield): IR (Nujol, cm-1) 1070,1210,1660,1730,3200,3340. 
3.4.4.3: Assay for the Active Ester Content of PAN 
PAN (-50mg, -50ýtmol of active ester groups, dried under vacuum 
(0.2mm Hg) at 450C for 24 h) was dissolved and made up to volume in 
distilled water in a 5ml volumetric flask. A 50gl aliquot of this solution 
was added into a 5ml quartz cuvette containing Hepes buffer (3000ýd O-1M, 
pH 7.5), propylarnine (50gl LOM), and mercaptoethanol (10gl, LOM). The 
rate of appearance of N-hydroxysuccinimide was followed 
spectrophotometrically at 259nm at room temperature. After the reaction 
was completed (-60 min) and the increase of the absorbance leveled off, 
the active ester concentration was calculated. The concentration of active 
ester groups was calculated to be 573ýLmol gm-1. 
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3.4.4.4: Determination of the Gel Time 
PAN-550 (100mg) and Hepes buffer (500gl, 0.3M, pH 7.5) were added to a 
beaker, and the polymer was brought into solution within 1 min. A 
solution of TET (42ýfl, 0-5M) was added to the stirred solution and the time 
taken for the polymer to form a gel was measured. The polymer rapidly 
became viscous and after 2 min the magnetic stirring bar had stopped 
turning. 
3.4.4.5: Immobilisation of N-Deoxyribosyltransferase 
PAN-550 (1.0g, 5704mol of active ester groups), and Hepes buffer (4ml, 
0.3M, pH 7.5 containing 50mM adenine) were placed in a 50ml beaker 
containing a small stirring bar. The polymer was dissolved within 1 min 
and to the magnetically stirred solution was added DT"T (50ýil, 0.5M), TET 
(0.7ml, 0.5M). After 15 sec the crude preparation of N- 
deoxyribosyltransferase (1.0ml, 10mg protein, 7U) was added to the 
mixture and the mixture set to a transparent, mechanically resilient gel 
after 3 min. The gel was allowed to stand for 1h at room temperature to 
complete the coupling of the enzyme to the polymer. The pale yellow gel 
was transferred to a small mortar and ground with a pestle for 2 min. 
Hepes buffer (25ml, 50mM, pH 7.5 containing 50mM (NH4)2SO4) was 
added and the grinding continued for an additional 2 min. This produced 
small particles which were diluted by another addition of the Hepes 
buffer/ammonium sulphate solution (25ml). The mixture was transferred 
to a centrifuge tube and the gel suspension was stirred magnetically for 15 
min to destroy any unreacted esters. The gel suspension was separated 
from the buffer solution by gentle centrifugation (-30OOrpm). The 
supernatant buffer was assayed for the nonimmobilised N- 
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deoxyribosyltransferase activity. The assay mixture, containing 2'- 
deoxycytidine (3. OmM) and adenine O. OmM) in citrate buffer (10-OmM, pH 
6.0), final volume 1.0ml, was added to some of the supernatant buffer 
(10. Oml, adjusted to pH 6.0). The reaction mixture was incubated at 400C 
for 30 min, after which time it was analysed by reverse-phase HPLC. The 
gel particles were washed with citrate buffer (2x5Oml, 10mM, pH 6.0) and 
then assayed for enzyme activity. The assay reaction mixture, containing 
2"-deoxycytidine (30. OmM) and adenine (10. OmM) in citrate buffer 
(IO. OmM, pH 6.0), final volume 50. Oml, was added to the gel particles in 
the centrifuge tube. After 30 min at 400C the reaction mixture was 
separated from the gel particles by gentle centrifugation and the reaction 
analysed by reverse-phase HPLC immediately and after three hours. The 
gel particles were then washed with citrate buffer (2 x 50ml, 10mM, pH 6-0) 
before the next assay mixture was added. The washings were also assayed 
for enzyme activity. The assays were continued for several days to follow 
the level of retained activity. 
3.4.4.6: Immobilised Enzyme Stability at 40C 
A sample of immobilised enzyme as prepared above was stored at 40C - 
Fractions were removed periodically to analyse for enzymatic activity. 
3.4.4.7: Large Scale Immobilisation of N-Deoxyribosyltransf erase on PAN- 
550 
A suspension of PAN-550 (3.0g,, 1710ýimol of active ester groups) in Hepes 
buffer (10ml, 0.3M, pH 7.5 containing 50mM thymidine) was dissolved 
within 1 min. A magnetic stirrer was added to the polymer solution which 
was stirred for 30 sec before solution of DDT (150ýfl, 0.5M) and TET (2. Oml, 
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0.5M) was added with vigorous stirring, immediately followed by the 
addition of the crude preparation of N-deoxyribosyltransferase (3. Oml,, 
36mg protein, 25U). The mixture set to a transparent, resilient gel in 2 min 
and was allowed to stand for 1h at room temperature. The gel was 
transferred to a mortar and ground with a pestle for 5 min. Hepes buffer 
(100ml, 50mM, pH 7.5 containing 50mM (NH4)2SO4)) was added and the 
grinding continued for an additional 5 min. This produced small particles 
which were diluted by another addition of the Hepes buffer/ammonium 
sulphate solution (100ml).. The mixture was transferred to centrifuge tubes 
and the gel suspension was stirred magnetically for 15 min. The gel 
suspension was separated from the buffer solution by gentle centrifugation 
(~3000rpm). The gel particles were washed with citrate buffer (3x1OOml, 
10mM, pH 6.0) and then a small sample was assayed once for enzyme 
activity (as described for the small scale immobilisation). This preparation 
of immobilised enzyme was used for the large scale preparation of some 
nucleosides. 
3.4.4.8: Synthesis of 2-Thio-2'-deoxyuridine (24) using PAN Immobilised 
Enzyme 
Thymidine (805mg, 3.54mmol) and 2-thiouracil(150mg, 1.18mmol) were 
added to citrate buffer (100ml, l. OmM, pH 6.0) in a centrifuge tube. The 
mixture was thermostatted at 400C before the addition of the PAN-550 
immobilised N-deoxyribosyltransferase (10ml, 90mg protein -8U). The 
centrifuge tube was placed in a pre-warmed stirrer bath at 400C and the 
reaction followed by reverse-phase HPLC. The reaction had reached 
equilibrium after 10 h, therefore the gel suspension was separated from 
the reaction mixture by gentle centrifugation (-30OOrpm). The remaining 
gel suspension was washed with citrate buffer (3x1OOml) to remove all of 
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the reaction mixture. The above reaction was repeated using the same 
sample of immobilised enzyme. The volume of the supernatant from the 
first reaction was reduced in vacuo and then Iyophilised before being 
purified by silica flash chromatography (eluted with CH2CI2/MeOH, 18/1) 
to give 100mg (35% yield) of a white crystalline solid: Rf = 0.17 
(CH2Cl2/MeOH, 9/1); 1H NMR (CD30D) 8 2.20 OH, ddd appears as sextet, 
J=12.8,9,03,6-14Hz, Hid, 2.57 (1H, ddd appears as dt, J=6.03,5.08HZ, HAL 
3.68 (1H, dd, J=4.42,12.6Hz, H5b), 3.79 (1 H, dd, J=3.07,12-8Hz, H5'a), 4.02 
(1H, ddd appears as q, J=3 x 3-91Hz, H4% 4.29 (1H, ddd appears as q, J=3 x 
4.54Hz, HY), 6.35 (1H, dd, J=6.02,, 8.991-lz, Hl'), 6.66 (1H, d, J=7.6FIZ, H5), 8.16 
(1H, d, J=7.6FIz, HO; MS (CI) m/z 128 (75), 243 [8, (M+H)+]. 
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CHAPTER 4 
CONFORMATIONAL STUDIES 
Background 
4.1.1: Fluorinated Nucleosides 
The introduction of fluorine into naturally occuring compounds involved 
in biochemical processes can produce analogues having significant 
biological activity and therapeutic value. For example, the replacement of 
hydrogen or hydroxyl by fluorine can alter the biological properties of 
nucleosides dramatically and many fluorinated nucleosides have antiviral 
177,178 or anticancer activities 
The main reasons for the effect of fluorine on the properties of organic 
compounds are: 
*fluorine and hydrogen have similar van der Waals radii (H = 
1.20A, F= 1-35A), but differ dramatically in the polarization of their 
bonds to carbon. Even greater comparison can be made between 
fluoro- and hydroxyl- groups. The C-F and C-OH bonds are more 
similar physiochernically (for instance, in their bond length, C-F = 
1-39A, C-0 = 1-43A, and polarizations) than C-F and C-H bonds (C- 
H=1.08-1.11A). The C-F bond is the strongest single bond (C-F = 
108kcal/mol, C-H = 98.7kcal/mol, C-0 = 85.5kcal/mol). These 
factors rnean that the substitution of F for H in a molecule should 
not dramatically alter the steric bulk of the molecule, or impose any 
gross conformational changes; 
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*the electronegativity of fluorine (F = 4.0,0 = 3.5, H=2.1) can have 
pronounced effects on the electron distribution in the molecule; 
affecting both the acidity and basicity of neighbouring groups, dipole 
moments within the molecule, and overall reactivity and stability. 
Fluorine has a pronounced electron withdrawing effect, but can 
have a repulsive interaction also by electron donation. The fluoro- 
and hydroxyl- groups have different hydrogen bonding capabilities: 
the hydroxyl group can be both a donor and an acceptor; whereas 
the fluoro group can act only as an acceptor. Fluorine is a 
moderately good leaving group and can sometimes be displaced by 
nucleophiles at or near the active sites of enzymes, with resultant 
covalent attachment of an organic moiety to the enzyme; 
*the C-F bond improves lipophilicity of the molecule and hence its 
distribution within an organism. The CF3 is one of the most 
lipophilic group known. 
Methods of Fluorination 
Due to the interest in fluoro-organic compounds, there are numerous 
methods for the insertion of fluorine into organic moleculeS179' 180, but 
only the reagents most commonly used for fluorine insertion into 
nucleosides will be mentioned here: 
Fluorine 
Elemental fluorine is a dangerous oxidizing agent and the gas is usually 
diluted with nitrogen or argon in the selective fluorination of alkenes in 
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the presence of other functional groups. The synthesis of 5-fluorouracil is 
a good example. 
00 
HF 
HN F HN A HN 2F 
0, 
HOAc OAc -HOAc 
co N Oj. ". - N 4001, 
HHH 
60 - 90% yield 
Scheme 4.1 Synthesis of 5-fluorouracil 
It was originally proposed that the reaction involved syn addition of 
fluorine, with subsequent solvent-assisted elimination of fluoride, though 
more recent work suggests the involvement of acetyl hypofluorite (AcOF). 
4.1.2.2: Sulphur Tetrafluoride 
Sulphur tetrafluoride (SF4) was first introduced as a fluorinating agent in 
1960 and its main uses are: 
SF4, <200C RCOF 
RC02H 
SF4, A A 
RCF3 
RX 
SF4 
»- RF X= OH, Cl, Br 
R, SF4 R, F 
R 
ýýF 
Scheme 4.2 Fluorination with sulphur tetrafluoride 
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When used in conjunction with Lewis acids or liquid hydrogen fluoride 
reaction temperatures and times may often be reduced, and these 
species usually act catalytically. Reactions of carbonyls with SF4 almost 
invariably require more forcing conditions. The major drawbacks of SF4 
are its volatility (b. p. = -380C) and its toxicity (comparable to phosgene), and 
reactions often require the use of sealed, stainless steel vessels. The yields 
of reactions with simple alcohols are usually low and for this reason the 
modified reagent die thylamino sulphur trifluoride (DAST) is now 
preferred. 
4.1.2.3: Diethylaminosulphur Trifluoride (DAST) 
DAST and related reagents were prepared by Middleton74 by the 
substitution of one of the fluorine atoms in sulphur tetrafluoride with 
dialkylarnino groups by treating with a dialkylaminotrimethylsilane. 
R2NSiMe3 + SF4 Imm- R2NSF3 + FSiMe3 
In DAST, R= Et 
Scheme 4.3 Synthesis of DAST 
DAST is relatively easy to handle (b. p. = 46-470C at 10mmHg) and can be 
stored in plastic bottles at room temperature or below. The reaction for 
displacing hydroxyl groups with fluorine, under very mild conditions, is: 
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F 
Et2N- Slý-F + HO--CH2R 
cI 
F 
F 
I 
Et2N-býO RCH2F 
F 
1+ 
k-t2N-b-O-CH2R 
il 
C 
HHI r-*ý 
F 
1-12N-b-O-CH2R 
1 
F 
F 
Scheme 4.4 Fluorination of alcohols with DAST 
Primary, secondary and tertiary alcohols all react, with high yields of the 
unrearranged fluoride usually resulting. DAST can also be used for 
replacing carbonyl oxygens with two fluorine atoms: 
F 
EtP 
C IF 
D=CHR 
Et2N RCF2H 
F 
1 +-. gý 
ý--t2N -b -0=CHR 
F 
F 
1 0--ý 
ý--t2N-b-O-CHRF 
CFI 
Scheme 4.5 Fluorination of carbonyl oxygens with DAST 
This reagent is particularly useful for fluorinating acid sensitive 
compounds. The reactions proceed in good yields using solvents like 
dichloromethane, and in nucleoside chemistry the reactions usually occur 
with inversion Of stereochemistry. 
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CH3 0 CH3 
HN HN oej' 
YI 
O'ýýk N DAST 0N 
TrO"o" 
0 CH2C12 0 
OH TrO""*ý 
0 
F 
Scheme 4.6 Fluorination of a nucleoside with DAST 
Another fluorosulphur reagent is tris(dimethylamino)sulphonium 
difluorotrimethylsilicate, (Me2N)3S+Me3SiF2-, (TASF). This reagent is a 
hygroscopic solid that is freely soluble in the common organic solvents. Its 
main use so far has been as a source of fluoride in the displacement of 
triflates. 
4.1-2-4: Hydrogen Fluoride 
Anhydrous hydrogen fluoride is one of the classical fluorinating agents, 
but though cheap and readily available its volatility (b. p. = 19-60C) and 
corrosiveness provide obstacles to its utility. Its reactions generally require 
superatmospheric pressure due to its low boiling point. Due to this, the 
less volative complexes of HF with various n-donor bases have been 
studied: the introduction of pyridinium poly(hydrogen fluoride), (HF)"py, 
a stable liquid of approximate composition 30% pyridine and 70% HF, 
provided a useful synthetic tooll8l. 
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Alkenes show a typical Markovnikov type addition: 
R, 
C=C 
R3 
R2 R4 
HIF/py 
mom 
-IF 
FH 
II 
RI-C-C-R3 
II 
R2 R4 
Scheme 4.7 Fluorination of alkenes with HF/py 
Reactive tertiary and secondary alcohols are readily fluorinated: 
R, >< H IIF/py R, H 
R2 OH R2>< F 
Scheme 4.8 Fluorination of alcohols with HF/py 
Primary alcohols react only in the presence of added fluoride ions, which 
indicates that the monomeric fluoride ion is a strong nucleophile, 
whereas polymeric F(HF)x- is a very weak one. 
There are also various modified forms of HF/pyridine with improved 
properties and reactivity in certain reactions. 
4.1.2.5: Fluoride 
The nucleophilic displacement of an halide ion by a fluoride ion is 
amongst the cheapest and most widely used methods for the introduction 
of fluorine. Nowadays,, the most common reagents are potassium fluoride, 
cesium fluoride, potassium fluoride-hydrogen fluoride, and 
tetralkyl ammonium fluorides, such as tetrabutyl ammonium fluoride. 
The reactions often involve the displacement of good leaving groups such 
as tosylates, mesylates and triflates. To attain an adequate concentration of 
dissolved fluoride, anhydrous (water reduces the nucleophilicity of 
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fluoride), polar solvents (CH3CN, DMF, glycols) are required, though the 
tetraalkylammonium fluorides can be used in THF and other less polar 
solvents, as they are more dissociated than other fluoride reagents in 
organic solvents. Recently, crown ethers with KF in benzene/CH3CN and 
po lymer- supported fluoride have been used successfully in these SN2 
displacement reactions. 
RO'00' oTofl OMe 
xs BU4NF 
THF 
Tfl = S02CF3, triflate 
RO*'ý 
0 
OMe 
F 
Scheme 4.9 Fluorination of alcohols with tetrabu tyl ammonium fluoride 
In addition to the displacement of halides and sulphonates, fluoride 
reagents can react with epoxides to produce the corresponding 
fluorohydrins. 
RO*"' 
KHF2 
- 
0c 
ethylene glycol 
CH2Ph 1400C 
RO'OON 
0F 
c OCH2Ph 
HO 
RO 0F 
C OCH2Ph 
OH 
Scheme 4.10 Fluorination of epoxides with KF-HF 
A number of other reagents are available but all have seen limited use, 
for 
example; tetrafluoroboric acid, silver tetrafluoroborate, perchloryl 
fluoride, 
hypofluorites, caesium fluoroxysulphate and xenon difluoride. 
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Synthesis of Fluorinated Nucleosides 
Numerous 5-fluorouracil derivatives have been prepared as potential 
anticancer agents. However, more recently nucleosides containing fluoro 
sugars have come under scrutiny due to their anticancer and antiviral 
activitieS177,178. A large number of fluorinated nucleosides have been 
evaluated for inhibitory activity against HIV-1 and 3'-fluoro-3'- 
deoxythymidine has emerged as having the highest antiretroviral 
potency48,182. Studies were then instigated to see if the cytotoxic effects of 
3'-fluoro-3'-deoxythymi dine could be reduced by modifying the base 
moiety of the nucleoside. 5-Chloro-2', 3'-dideoxy-3'-fluorouridine and 4- 
thio-3'-fluoro-3'-deoxythymidine were found to have improved 
cytotoxicity44. 
The synthesis of deoxyribonucleosides has been performed enzymatically 
using N-deoxyribosyltransferases from lactobacilli to catalyse the transfer 
of a deoxyribosyl residue or an analogue from a donor nucleoside to an 
acceptor base (as described in Chapter 2). For this reaction 2'-deoxy-, 2', 3'- 
dideoxy-, and 2', 5'-dideoxynucleosides are efficient glycosyl donors. 3'- 
Subs ti tuted-2', 3'- di deoxynu cleos ides were studied as possible glycosyl 
donors for the synthesis of base modified 3'-substituted-2', 3'- 
dideoxynucleos ides - Unfortunately, 3'- subs titu ted-2', 3'-dideoxynucleosi 
des 
did not act as glycosyl. donors in the transfer reaction and so the structures 
of these nucleosides were investigated to rationalise these results. 
Recently, several nucleosides, modified at the CT-position by a 
heteroatorn such as 2,3'-dideoxy-3'-thiacytidine ((±)-BCH-189)183, and W-1- 
(2p, 4p)-2-(hydroxymethyl)-4-dioxolanyl)thymine (dioxolane-T)184 have 
been reported which show excellent anti-HIV activity in vitro. 
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Dioxolane-T was synthesised in order to investigate the substrate ability of 
CY-heteroatom modified sugars in our enzyme system. 
4.1.4: Structure-Activity Investigations 
The crystal structures of many of the nucleosides and their analogues have 
been determined and the relationship between their crystal structures and 
their efficacies as anti-HIV agents has been discussed 163 - However, crystal 
structures give information on molecular conformations in the solid state 
and little information can be gained concerning the flexibilities of the 
molecules and their shapes in solution or in an active site of an enzyme. 
4.1.4.1: Structure of Nucleosides 
The structure of a nucleoside can be defined by185: 
9 the conformation of the sugar group; 
*the conformation at the glycosidic linkage, i. e. the position of the 
base relative to the sugar group; 
*atomic bonding distances and angles within a molecule; 
einter- and intramolecular interactions, especially hydrogen 
bonding. 
The conformations are described using dihedral (torsion) angles. In the 
atomic group A-B-C-D these angles denote the angle between the bonds 
A-B and C-D looking along the B-C bond. The dihedral angle is zero 
when A-B and C-D are cis-planar to each other, and is regarded as 
positive when C-D is twisted clockwise relative to A-B. A dihedral angle 
is designated cis or trans when the angle is approximately 0 or 1800 
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respectively and as (+)gauche and Hgauche when the angle is about +60 or 
-600 respectively. 
4.1.4.2: Geometry of the Sugar Group 
The five-membered sugar ring adopts a puckered conformation because of 
eclipsing effects. All the bonds are positioned so there will always be 
unwanted transannular interactions (i. e. interactions between the 
substituents on C-1 and C-3 or C-1 and C-4). These occur because the 
internal space is not large enough for all the quasi-axial hydrogen atoms to 
fit without coming into conflict. The transannular strain can be reduced if 
the molecule adopts a conformation where some of the C-C bonds are 
eclipsed or partically eclipsed but this results in Pitzer strain. Therefore, 
each ring adopts conformations that minimise both sorts of strain as much 
as possible. For the sugar ring the conformation is either in an envelope, 
E, or in a half-chair, T, form. Substitution effects lead to preference for 
those conformations in which the atoms C(2') and C(Y) are displaced by 
~0.5A from the plane through the other atoms C(4")-0(4")-C(1'). Atoms 
lying on the same side of this plane as C(5) are designated endo and those 
on the other side exo. 
It has been shown by X-ray data and NMR studies that the sugar ring can 
adopt a plethera of conformations. The whole feasible range of sugar 
conformations has been described by a pseudorotation cycle where the 
barrier to planarity has been reported to be 5.2kcal/mol. However, the 
introduction of the N and S type notation by Altona and 
Sundaralingam186 has clarified the classification and has shown that two 
relatively narrow pseudorotational ranges are preferred by the sugar rings. 
Type N conformers comprise all conformations that occupy the northern 
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half of the pseudorotational cycle and type S conformers occupy the 
southern half of the cycle. 
HOH2 
R3 
3' Base 
2' R, 
H 
R2 
Type N 
C(2')-exo, C(3')-endo 
3 T2 
HOF 
H 
Base 
R4 
Type S 
C(2')-endo, C(3')-exo 
2 T3 
Fig. 4.11 Conformation of the sugar ring 
4.1.4.3: Orientation about C(4')-C(S') 
The C(4-)-C(5') can rotate relative to the sugar ring, assuming three 
possible conformations, designated gauche, gauche, gauche, trans, or 
trans, gauche depending upon the angles. 
05', 
5I 
HO OH 
gauche, gauche 
-60'9 +600 
gauche, trans 
+60', 180' 
C 
Fig. 4.12 Orientation about C(4)-C(5') 
trans, gauche 
180', -60' 
In most ribonucleosides and deoxyribonucleosides the preferred 
orientation is gauche, gauche due to the formation of intramolecular 0(5)- 
--H-C hydrogen bonding between the sugar and the 
heterocyclic base. 
However, in some nucleoside analogues the change in sugar puckering 
Rl 
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HO - OH HO OH 
and the presence of substituents on the sugar or base can cause various 
effects on the orientation of the C(4')--C(5') bond. 
4.1.4.4: Orientation about the Glycosidic Bond 
Rotation of the base around the glycosidic bond relative to the sugar group 
is not free but subject to steric hindrance, primarily by the endo proton at 
C(2'). Thus the nucleosides can exist in two conformations, designated syn 
and anti depending upon whether 0(2) in pyrimidine nucleosides or N(3) 
in purine nucleosides lies above the plane of the sugar group or points 
away from it. 
H r-- N0 
HOH2 N 
>'ý4 
IH NZ: v 
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H HO 
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HOH2C N. 
H HO H H 
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HýHO H0 
H 
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HOH2 
H 0' 
N 
CH3 
c 
>'ý4 
H HO IH SYN 
OH 
H 
Fig. 4.13 Orientation about the glycosidic bond 
The preferred orientation of the heterocyclic base is anti but some 
nucleosides with substituted bases, such as 8-bromoadenosine, do adopt 
the syn conformation. 
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4.1.4.5: Conformational Analysis by 1H NMR Spectroscopy 
The conformation and configuration of a nucleoside are vital 
determinants of its properties in a biological system. Most of the available 
structural data has been derived from X-ray crystallographic studies which 
have been very useful in determining the conformations of nucleosides as 
described previously. However, the inherent flexibility of nucleosides has 
stimulated investigations of the structural and conformational behaviour 
of nucleosides in solution. The most widely used method for structural 
studies in solution is high-resolution NMR spectroscopy, which can give 
information on intermolecular interactions, conformational properties 
186-188 and the dynamic behaviour of nucleosides 
The conformationally significant bonds in a nucleoside are those which 
exhibit some torsional freedom about the covalent bond linking two 
atoms. This freedom may be constrained within the limits of a cyclic ring 
or they may take the form of unhindered rotation about a bond. A typical 
nucleoside can be viewed as consisting of three components: 
*rotation about the glycosidic C-N bond joining the base and sugar 
rings; 
*rotation about the exocyclic groups, especially about the C-4'--C-5' 
bond; 
, opseudorotation of the sugar ring, where the atoms adopt a variety 
of ring pucker modes. 
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This conformational information can be obtain from three NMR 
parameters: 
echemical shifts (8), which give information about hydrogen 
bonding and base-stacking interactions; 
ospin-spin coupling constants (J/H17z), which are the most important 
source of conformational data, due to the dependence of vicinal 
coupling constant magnitudes on the dihedral angle; 
espin-lattice relaxation times (Ti) and nuclear Overhauser 
enhancement (nOe) measurements, which are used to resolve 
conformational features of nucleosides by studying the proximity of 
certain groups and atoms. 
These methods can be used in the determination of the conformational 
features of nucleosides as outlined previously. Several empirical and 
semi-empirical methods have been proposed for the evaluation of pentose 
ring conformational properties from coupling data and of these, the 
pseudorotation approach of Altona and SundaralingaM186 is conceptually 
the most sophisticated. In this approach, the pentose ring is described in 
terms of two pseudorotation parameters,, P,, the angle of pseudorotation, 
and r, the degree of pucker. From this method, coupled with 
crystallographic data, it is possible to calculate pseudorotational parameters 
for all the major conformations of nucleosides. This method also gives a 
quick way to calculate the conformer populations and related equilibrium 
constants. 
While crystallographic data gives information about the nucleosides in 
the solid state, it is important to remember that in solution the pentose 
ring does not possess a unique rigid structure but it is in a dvnamical 
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equilibrium between at least two or more rapidly interconverting 
puckered conformations which have been termed type N conformers 
0± 900),, and type S conformers (P = 180 ± 900). 
5' 
HOH2C, 
R3 
3' Base 
2' 
Rl 
H 
R2 
Rl 
Type N 
C(2')-exo, C(3')-endo 
3 T2 
5' J2ý 
HOH2C. R5, 
-Base 
I 
H 1% R3Y3' H 
R4 
Type S 
C(2')-endo, C(3')-exo 
2 T3 
Fig. 4.14 Conformation of N and S sugars 
Analysis of the NMR data can lead to information about the conformer 
populations and the equilibrium constants for the equilibrium N-"'"-W- S. 
Studying the variable temperature NMR spectra of nucleosides leads to 
information about the free energy, enthalpy and entropy of the system. 
The temperature dependance of the coupling constants can yield 
quantitative information with regard to the position of the dynamic 
equilibrium between the principal conformers of the sugar ring. 
As the synthesis of Y-subs tituted-2'., 3'-dideoxynucleo sides was not possible 
by the enzymatic transfer method (as described in Chapter 2), an 
investigation into the conformations adopted by the nucleosides, which 
were and were not glycosyl donor nucleosides in the transfer reaction, was 
undertaken. Little is known about the active sites of the N- 
deoxyribosyltransferases from lactobacilli, but major factors accounting for 
this lack of reactivity may be steric hindrance or dipolar effects that inhibit 
the binding of a substrate to the transferase. Another factor which may be 
important is the conformation and "flexibility"' of the deoxyribose ring, as 
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outlined above, because a substrate which adopts a "rigid", unfavourable 
shape may bind incorrectly, or not bind at all, to the active site of the 
transferase and may be inactive as a substrate. A number of NMR studies 
of nucleoside conformation have been reported at constant temperature186, 
188. Altona and Sundaralingam, and Davies and Danyluk have described 
methods for calculating, from coupling constants in 1H NMR spectra, the 
amount of N- and S-character in the favoured conformations of 
nucleosides in solution. However, little work has been published on the 
change in conformation of the sugar residues with change in temperature. 
Slessor and Tracey 189 investigated the conformation of the 2-deoxyribosyl 
moiety in the naturally occuring nucleosides and found a preference for 
them to adopt an S-conformation. Information from variable 
temperature 1H NMR studies can be used to determine the "'flexibility" of 
sugar rings in nucleosides. Therefore, variable temperature NMR 
spectroscopy was used to investigate the conformations and "flexibility"' of 
the deoxyribose ring in a number of deoxyribonu cleos ides, with and 
without substituents on the ring. 
4.2: RESULTS AND DISCUSSION 
4.2.1: Synthesis of 1-(2-deoxy-p-D-erythro-pentofuranosyl)thymidine 
(31)73 and 3"-fluoro-3"-deoxythymidine (32) 
The 5'-hydroxyl monomethoxytritylation of thymidine followed by the 
Y-hydroxyl mesylation in the presence of DMAP (as discussed in Chapter 
2) gave the required starting material for both syntheses in 69% yield. 
The 
monomethoxytrityl protecting group was used rather than trityl as the 
conditions for its removal are less severe than those 
for trityl and 
therefore higher yields of product are obtained. Refluxing 3'- 
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methanesulphonyl-5'-me thoxytritylthyrni dine (29) with excess of alkali 
afforded the 5'-methoxytrityl derivative of 2-deoxylyxosylthymine (30) via 
the 2,3'-anhydronucle o side. 
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pyridine Ap- MMTrO 
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HN 
0; 
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0 
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(32) 
Scheme 4.15 Synthesis of 1-(2'-deoxy-p-D-erythro- 
pen tofuranosyl) thymidine (31) and 3-fluoro-3'-deoxythymidine (32) 
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This compound could be either demethoxytritylated with acetic acid to 
afford the 1-(2'-deoxy-p-D-erythro-pentofuranosyl)thymidine (31) in 57% 
overall yield, or treated with DAST and then demethoxytritylated with 
acetic acid to afford 3-fluoro-3-deoxythymidine (32) in 10% overall yield. 
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Scheme 4.16 Fluorination of 1-(5'-methoxytrityl-2'-deoxy-p-D-erythro- 
pentofuranosyl)thymine (30) with DAST 
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Although some destruction and demethoxytritylation was observed in the 
fluorination step, DAST is still the most favoured reagent for fluorination 
in the presence of acid-labile group (i. e. the glycosidic bond and the 
monomethyloxytrityl ether). The advantage of this reagent is that products 
of dehydration and carbonium ion rearrangement are formed in much 
smaller amounts than with other fluorination agents. 
The lone-pair of electrons on the secondary hydroxyl group attack the 
sulphur centre of DAST and displace a fluoride ion. This converts the 
hydroxyl group into a better leaving group which is subsequently attacked, 
with inversion of configuration in an SN2 displacement reaction, by a 
fluoride ion to afford the required 3'-exo fluorinated nucleoside. 
4.2.2: Synthesis of 3,3"-difluoro-3'-deoxythymidine (35)190 
The 5-tritylthymidine (33) was used as the starting material for this 
synthesis. Oxidation, fluorination and detritylation with acetic acid 
afforded 3', 3'-difluoro-3-deoxythymidine (35) in 17% overall yield. 
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Scheme 4.17 Synthesis of 3,3'-difluoro-3'-deoxythymi dine (35) 
Oxidation of the 5-trityl protected thymidine was accomplished in 73% 
yield using pyridinium dichromate (PDQ as the oxidising agent. This 
reagent is superior to pyridinium chlorochromate (PCQ, which has a 
mildly acid character and therefore precludes its use with acid sensitive 
substrates or products. On the contrary, PDC can be used with alcohols and 
ketones containing acid-sensitive functionality (i. e. the glycosidic bond 
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and the trityl ether). The Y-keto-derivative of thymidine has been 
reported to be quite unstable so careful reaction conditions must be 
employed to prevent any decomposition occurring. The addition of PDC 
(1-2mol equiv) and molecular sieve powder (0.5-1-Og per mmol of 
alcohol) to 5-tritylthymidine affected a quick and efficient oxidation. The 
molecular sieves catalyse the reaction by favouring the cleavage of the C- 
H bond from the alcoholic carbon. There is some controversy as to the 
mechanism of this reaction but an intramolecular proton transfer is 
postulated. 
R 
>< 
OH 
ýPYH+12 CV7 2- 
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R 
Scheme 4.18 Oxidation of alcohols with PDC/molecular sieves 
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Scheme 4.19 Oxidation of alcohols with PDC/molecular sieves 
Oxidation of the alcohols takes place at specific sites on the surface of the 
molecular sieve. The alcohol is bound to the sieves by the hydroxy 
function and the molecular sieves orientate the alcohol and the 
chromium species so that the hydrogen can be transferred. The sieves also 
stabilise the charges on the intermediate species which facilitates the 
reaction. 
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The 3" -keto-5'-tritylthymi dine (34) was then subjected to DAST in order to 
prepare the gem 3', 3'-difluoride derivative of thymidine. The lone-pair of 
electrons on the keto group attack the sulphur centre of DAST and 
displace a fluoride ion. This produces a trivalent, positively charged 
oxygen centre which is neutralised by the attack of a fluoride ion on either 
the cc- or the P- face of the sugar ring to afford the monofluorinated 
nucleoside. The ketone is thus converted into the same species as in the 
displacement of hydroxyl groups with DAST. This good leaving group is 
subsequently attacked, with inversion of configuration in an SN2 
displacement reaction, by a fluoride ion to afford the required gem-3', 3'- 
difluorinated nucleoside (35) in 16% overall yield. 
4.2.3: Synthesis of 2- de oxy-2'-fluorouri dine (39)191-193 
The addition of an excess of 2-acetoxyisobutyryl chloride to a suspension of 
cytidine in acetonitrile at 800C afforded the crystalline 2,2-anhydro-(3'- 
acetyl-o-D-arabino-furanosyl)cytosine hydrochloride (36) in 99% yield. 
Treatment with HCI in methanol at room temperature for 6 days removed 
the 3/-acetyl group to give 2,2'-anhydro-l-(P-D-arabino-furanosyl)cytosine 
hydrochloride (37). Fluorination with potassium fluoride in crown ether 
oPened the cyclic nucleoside to yield the required 2'-fluoro-2'- 
deoxycytidine (38) which was converted to the uridine derivative (39) in 
24% overall yield. 
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Scheme 4.20 Synthesis of 2'-deoxy-2'-fluorouridine 
The reaction of 2-acetoxyisobutyryl chloride with cytidine proceeds via the 
conversion of the 2', 3'-cis diol into a reactive 2', 3'-acetoxonium ion, which 
undergoes intramolecular attack by the C2 carbonyl group of the 
pyrimidine ring to initially form 2,2'-anhydro-(3"-acetyl-p- D-a ra bin o- 
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furanosyl)cytosine hydrochloride (36) which is then deacylated to give 2,2'- 
anhydr o- 1- (P-D-a ra b ino-furano syl)cyto sine hydrochloride (37)191. 
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OA 0. HO HO 0 0 
H OH OH 
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Scheme 4.21 Formation of 2.2' -anhydro- (3-a cetyl- P-D-a ra bin o- 
furanosyl)cytosine hydrochloride (36) 
The conversion of 2,2'-anhydro-l-(P-D-arabino-furanosyl)cytosine 
hydrochloride (37) to 2'-fluoro-2'- de o xycyti dine (38) was performed by 
activation of fluoride with crown ether under total exclusion of moisture. 
The crown ether forms a stable complex with the potassium ion to liberate 
the fluoride ion which has increased nucleophilicity. The crown ether- 
activated fluoride ion also has increased basicity which can lead to 
hydrolysis of the anhydro bond in the presence of moisture. Therefore, 
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only after complete elimination of traces of moisture by azeotropic 
distillation, with benzene from the reaction mixture, can the desired 
nucleophilic fluoride substitution take place192 
NH + 2 
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Scheme 4.22 Fluorination of 2,2'-anhydro-I-(P-D-arabino- 
furanosyl)cytosine hydrochloride (37) with KF/crown ether 
The final step is the conversion of the cytosine base to a uracil base by 
catalysis with bisulphite193. 
NH2 NH2 0 
1 
H20 OH- + HS03 + HN HN HN HN 1 
OH- 
1: ýk 
HS03- 
N NN SO37 0-ýý N S03 0 
RRRR 
H, Ribose, 2-deoxyribose 
Scheme 4.23 Conversion of cytosine into uracil 
The sodium bisulphite adds reversibly to the 5,6-double bond of cytosine, 
which then dearninates upon standing in aqueous solution. If the pH is 
adjusted to 10 then the equilibrium is moved to the right to afford the 
uracil derivative. 
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These compounds and the others listed in Materials and Methods were 
used in the v ariabl e- temperature 1H NMR conformational studies of the 
sugar rings. 
4.2.4: Conformational Studies of Nucleosides 
As discussed in Chapter 2, in the synthesis of deoxyribonu cleos ides using 
N-deoxyribosyltransferases from lactobacilli to catalyse the transfer of a 
deoxyribosyl residue or an analogue from a donor nucleoside to an 
acceptor base, it has been found that 2'-deoxy-, 2', 3'-dideoxy-, and 2', 5"- 
di deoxynucleos ides are efficient glycosyl donors but that Y-substituted 
21,3'-dideoxynucleos ides will not transfer their glycosyl residues to an 
acceptor base. Little is known about the active site of these enzymes, but 
major factors accounting for this lack of reactivity may be steric hindrance 
or dipolar effects that inhibit the binding of a substrate to the transferase. 
Another factor which may be important is the "flexibility" of the 
deoxyribose ring. As discussed in the introduction to this chapter, the 
flexibility, can be considered to be made up of three components: 
*rotation about the glycosyl bond; 
9 rotation about C-4'-C-5'; 
opseudorotation of the deoxyribosyl ring. 
The pseudorotation of ten 2"- and Y-substituted 2', 3'-dideoxynucleosides 
have been investigated because a substrate which adopts a "'rigid", 
unfavourable shape may not bind to the active site of the transferase and 
may be inactive as a substrate. It was hoped that these studies would yield 
some information on the binding of these compounds to enzymes 
in 
aqueous media. The technique selected for this investigation, variable 
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temperature 1H NMR, requires a solvent which remains liquid over as 
wide a temperature range as possible. Perdeuteromethanol was found to 
be a more suitable solvent than water, which is liquid over a 
comparatively narrow range of temperature, because it permitted the use 
of a much wider range of temperatures than is possible with water. It was 
found that the 1H NMR spectra of solutions of the nucleosides in water 
and in perdeuteromethanol were very similar, suggesting that they adopt 
similar conformations in the two solvents and thus allowing comparisons 
to be made between results obtained in perdeuteromethanol and aqueous 
solutions. 
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Fig. 4.24 Structures of 2'- and 3'- substituted 21,3'-dideoxynucleosides 
investigated by variable temperature IH NMR 
From the temperature dependencies of the N and S conformer equilibria 
for compounds 1,3,6,32,35,39,40,41,, 42,, 43, the conformer populations 
and equilibrium constants were determined. These were used then to 
calculate the enthalpy and entropy differences between the N and S forms. 
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In theory, it would appear possible to establish the complete conformation 
of a sugar ring from all the vicinal proton coupling constants. 
Unfortunately, such an approach is not possible because the sugar ring 
does not possess a unique rigid structure in solution but is in a dynamic 
equilibrium between at least two favoured puckered conformations, a type 
N conformer and a type S conformer. The rapid interconversion rate 
between these conformers results in the observed coupling constants being 
averages of the coupling constants of the individual conformers. 
However, methods have been developed for relating coupling constants to 
sugar ring conformation properties and of the empirical and semi- 
empirical methods available, those of Altona and Sundaralingam have 
194 been the most widely used186, 
4.2.4.1: Variable Temperature 1H NMR Studies 
The 1H NMR spectra of compounds 1,3,6,32,35,39,40,41f 42,, 43,, were 
measured between 190 and 330K. In high resolution proton NMR the 
most widely used proton "'NMR thermometers"' are methanol for low 
temperatures (175-330K) and ethylene glycol for high temperatures (310- 
410K) regions. In the temperature range of this investigation the probe 
temperature was calculated from the chemical shift separation of the 
resonances of the aliphatic and hydroxyl protons of methanol195. At low 
temperature, more hydrogen bonding occurs, and the OH peak shifts 
downfield. Conversely as the temperature rises, the amount of hydrogen 
bonding diminishes, and the OH proton resonance moves upfield towards 
the methyl resonance. 
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The temperature dependence has been determined by Van Geet at 60MHz 
and for methanol the least squares fit gives the empirical equation: 
T(K) = 403.0 - 0.491 
lAu 1- 66.2 [10-2AU]2 
Where A-o = chemical shift separation in Hz at 60MHz 
T= temperature in Kelvin 
More recent calibration of these shifts have been carried out and found to 
be in excellent agreement with the above equation196. It has been shown 
from work at 220MHz, that the Van Geet equation can be scaled to higher 
fields without any significant increase in error. Therefore, in the present 
study the internal temperature of the sample was determined by using the 
above equation with a scaling factor (60-400 = 0.15) as the chemical shift 
separations were measured at 40OMHz: 
T(K) = 403.0 - 0.491 
IAu 1- 66.2 [10-2AU]2 X 0.15 
4.2.4.2: Vicinal Spin-Coupling Constants 
From each spectrum the vicinal spin-coupling constants were determined 
and are tabulated in Appendix II. These vicinal spin-coupling constants 186 
were used to calculate the puckering equilibrium of the deoxyribose rings 
(Table 4.1 ), using the formula: 
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%S ý 100 x Jl'2/(Jl'2' + J34'). 
where %S = Type S conformer population 
ixty, = the coupling constants relating to the structure: 
Base 
Fig. 4.25 Coupling constants in the deoxyribose ring 
The equilibrium constant for each compound (Table 4.1) was calculated 
also by the use of these vicinal spin-coupling constants using the formula: 
KN ..: Jl'2'/J34' -` XS/XN 
where Keq = equilibrium constant 
Jxy = coupling constants relating to the above structure 
Xs = mole fraction of conformer type S 
XN = mole fraction of conformer type N 
The coupling constants due to protons in the glycosyl moieties of the 
nucleosides must obey inter-relationships governed by the laws of 
pseudorotation and, hence, the coupling constants cannot assume random 
values that are independent of each other. This situation allowed 
predictions to be made for values Of JH, H when fluorine atoms replaced 
hydrogen atoms in the glycosyl ring and only JH, F could be measured'97. 
When measuring the coupling constants for fluorinated deoxyribose 
moieties, it was assumed, where necessary., that the corresponding JH, H = 
1/2(JH, F). This adjustment of coupling constants was not required for the 
AH and AS calculations, but such a correction factor was required to 
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AH and AS calculations, but such a correction factor was required to 
estimate a value for the percentage of N- and S-character in the 
conformations adopted by fluorinated nucleosides. 
The puckering equilibrium values and the equilibrium constants, along 
with the vicinal spin-coupling constants used to calculate them, have been 
tabulated (Table 4.1): 
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Table 4.1 Variation in coupling constants in the deoxyribosyl ring of 
nucleosides with temperature 
J/I-lz 
Cormripotund pot Temp/K Hl', 2' H3'41 
4 
- 
%S 
F 
11 209 6.91a 2.70 2.56 74 237 6.80a 3.00 2.27- 69 
207ca 6.80a 
-- 
3.35 
- 
2.03 67 
315 F 6.78a r 3.46 1 1.96 1 67 
32 208 9.69 0 b >99 
259 9.60 0 b >99 
278 9.37 0 b >99 
297 9.25 0 b >99 
315 9.13 0 b >99 
40 208 6-33d 4.49 1.41 59 
233 6-36d 4.70 1.35 58 
259 6-38d 4.79 1.33 57 
279 6.40d 4.84 1.32 57 
302 6.43d 4.85 1.33 57 
310 6.43d 4.80 1.34 57 
42 234 6.47 3.90 1.66 62 
280 6.68 4.09 1.63 62 
296 6.69 4.16 1.61 62 
321 6.70 4.27 1.57 61 
41 208 16.76c 4.82 1.74 64 
259 16.85C 4.77 1.77 64 
279 16.94c 4.84 1.75 64 
300 17.03c 4.85 1.76 64 
319 17.09c 4.84 1.77 64 
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J/1-IZ 
Compound Temp/K 
Mý 
1 
Hl', 2' H3', 4' Keq %S 
43 208 18-69C 5.06 1.85 65 
234 18.22C 5.22 1.75 64 
259 17.85C 5-. 41 1.65 62 
279 17-62C 5.54 1.59 61 
297 17.42C 5.67 1.54 61 
320 17-35C 5.70 1.52 60 
6 209 2.30 8.82 0.26 21 
234 2.73 8.49 0.32 24 
260 3.12 8.74 0.36 26 
276 3.26 8.70 0.37 27 
297 3.49 8.68 0.48 32 
320 3.59 7.29a 0.49 33 
35 206 9.01 3.72d 4.84 83 
215 8.94 4.20d 4.26 81 
232 8.75 5.19d 3.37 77 
252 8.56 6.67d 2.56 72 
269 8.39 6.62d 2.53 72 
296 8.13 7d 7-3/-- 2.21 69 
317 7.54 7.93d 1.90 66 
39 211 <1.0 8.27 0.12 11 
235 1.19 8.09 0.15 13 
260 1.85 7.33 0.25 20 
278 2.15 7.27 0.29 23 
297 2.23 7.26 0.31 24 
307 2.34 7.23 0.32 24 
3 198 1.64 3.02 0.54 35 
214 1.86 2.95 0.63 39 
231 1.99 3.04 0.66 40 
249 2.17 3.12 0.70 41 
269 2.31 3.12 0.74 43 
296 2.52 3.12 0.81 45 
aAverage value determined from unresolved peak signals, bVery large as 
J3', 4' = OHz, cJl', F, dJ4', F. 
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For each compound,, the differences in enthalpy and entropy between the 
favoured conformations adopted over the range of temperatures studied 
were calculated from the temperature dependence of the equilibrium 
constants by using a weighted least-squares fit for the van"t Hoff equation: 
-log Keq = AH/RT - AS/R 
A graph was plotted of 1 /T in Kelvin versus In Keq and from this the 
intercept gave the value of AS and the gradient gave the value of AH 
which have been tabulated (Table 4.2): 
Compound EnthalPy differencea 
(kcal / mol) 
Entropy differencea 
(e. u. ) 
1 -0.43 (0-08) -0-50 (0-35) 
32 0.0(0.0) +9.13(0.0) 
40 -0.11 (0.02) +0-16 (0.08) 
42 -0-13 (0-01) +0.495 (0.04) 
41 +0-02 (0.01) +1.18 (0.02) 
43 -0-25 (0.01) +0.029 (0.02) 
6 +0-82 (0.14) +1.17 (0.49) 
35 -1-13 (0.08) -2-38 (0-34) 
39 +1.29 (0.19) +2.04 (0.70) 
3 +0-43 (0-03) +1.03 (0-13) 
aStandard deviations are given in parentheses. 
Table 4.2 Enthalpy and entropy differences between N and S 
conformations of nucleosides 
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These structures were then modelled on a Silicon Graphics workstation 
using QUANTA, which gave good agreement with the calculated 
conformations. 
The main interests of this study lay in determining the "flexibility' and 
preferred conformational type of each sugar ring in the 2'- and Y- 
substituted-2', 3'-dideoxynucleosi des. From the data it can be seen that the 
1H NMR spectra of 3" -f luoro-3'-deoxythymi dine (32) in 
perdeuteromethanol do not vary significantly over the temperature range 
208-315K (Table 4.1 and Fig. 4.26). The calculated difference in enthalpy 
between the N- and S-conformations of (32) over this temperature range 
is zero. On the other hand, there is a large entropy difference (+9.1e. u. ) 
between the N- and S-conformations over this temperature range (Table 
4.2). This finding suggests that the conformation of the deoxyribosyl ring 
in (32) has >99% S-character, implying that (32) adopts a "rigid" shape 
with an extreme S-conformation. When Van Roey and Schinazi198 
analysed the crystal structure of 3'-fluoro-3-deoxythymidine (32), they 
found that the conformation has a pseudorotation angle, P, of nearly 1800 
which corresponds to a nearly perfect C2'-endo/C3'-exo twist and agrees 
with our findings of a 99% S conformation. 
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The NMR spectra of 3'-azido-3-deoxythymidine (40), 5-deoxythymidine 
(42), and 2"-deoxy-2'-fluoro-5-methyl-arabinosyluracil (FMAU, 41) also 
changed little over this temperature range. Calculations indicate that there 
are small differences in enthalpy between the N- and S-conformations of 
the three compounds over this range of temperatures. However, the 
magnitude of the entropy differences between the N- and S- 
conformations increase with increasing S-character (40, +0.16 e. u., 59% S- 
character; 42, +0.495 e. u., 62% S-character; 41, +1.18 e. u., 64% S-character). 
The small entropy values for 3--azido-3-deoxythymidine (40) and 51- 
deoxythymidine (42) suggest that these compounds assume a favoured 
conformation which is unaffected by changes in temperature and is 
therefore "'rigid". On the other hand, for 2'-deoxy-2-fluoro-5-methyl- 
arabinosyluracil (FMAU, 41), there is a comparatively large difference in 
entropy (1.16 e. u. ) between the N- and S-conformations, which could 
make the deoxyribosyl ring relatively "inflexible", causing the molecule to 
have a nearly constant percentage (65%) of S-character over the 
temperature range studied. 
The NMR spectra of the other nucleosides studied changed with change in 
temperature, indicating that the sugar rings show some conformational 
mobility under these conditions. The enthalpy differences for 31- 
deoxythymidine (6), 2'-fluoro- 2'-deoxyuri dine (39), and 1-(2, -deoxy-P-D- 
erythro-pentofuranosyl)thymine (3) are +0.82, +1.29, +0.43 kcal/mol 
respectively, indicating that, for these compounds, the N-conformation is 
more stable than the S-conformation. As the temperature is lowered, so 
the favoured N-conformations become more prevalent, indicating that 
the deoxyribosyl rings are "flexible". 
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In contrast, for 3', 3-d ifl uoro-3-deoxy thymi dine (35), there was a large 
negative (-1.13 kcal/mol) difference in enthalpy between the two forms, 
showing that the S-conformation is significantly more stable (Table 4.2 
and Fig. 4.29). As the temperature is reduced, the flexibilty of the 
deoxyribosyl ring is again shown by the increase in S-character from 69% 
at 296K to 83% at 206K (Table 4.1). 
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Fig. 4.29 1H NMR spectra of 3,3-difluoro-3'-deoxythymidine (35) run at 
40OMHz in CD30D measured at 206,252,317K 
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The remaining compounds, thymidine (1) and 1-(2', 3-dideoxy-2-fluoro-P- 
D-threo-pentofuranosyl)uracil (43) show an increased percentage of the 
favoured S-conformation at low temperatures. The relatively small 
enthalpy and entropy values for these compounds suggest that the sugar 
rings are reasonably "'flexible". The conformations which were elucidated 
for all these compounds are in good agreement with those published in 
177,198-200 the literature 
The position and orientation of substituents have a definite and 
predictable influence on the conformation of the deoxyribose ring. Atoms 
or groups on the same side of the sugar ring as C-5' are designated endo 
and those on the opposite side of the ring to C-5" are exo. Those 
nucleoside analogues in which the Y-substituent is exo favour the S- 
conformation, whereas those analogues with the Y-substituent endo adopt 
N-conformations. These predictions can also be extended to the 2- 
position. An exo 2'-substituent appears to favour the adoption of the N- 
conformation, while an endo 2-substituent favours the adoption of the S- 
conformation. In 2', 3'-disubstituted compounds, the influence of the 
substituents is additive. For example, 2'-fluoro endo and Y-hydroxy exo 
substitution in 2'-deoxy-2'-fluoro-5-methyl-arabinosyluraciI (FMAU, 41) 
enhances the amount of S-character in the conformation and renders the 
sugar ring almost "'inflexible". However, as can be seen in 2"-fluoro-2'- 
deoxyuridine (39), the influence of the 2'-fluoro exo substitution over- 
rides the effect of the Y-hydroxyl exo substitution. The resulting 
nucleoside has the N-conformation and the sugar ring is still "flexible". 
This observation, that the most polar substituent pulls the pucker to its 
201,202 
side, has been investigated and discussed in several publications 
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As mentioned before, although the fluorine atom is only slightly larger 
than the proton,, it is considerably more electronegative. It appears, 
therefore, that the sugar conformation is essentially influenced by the 
polarity of the substituents. 1H and 13C NMR studies, which have been 
done to determine the relationship between electronegativity of 2' - 
substituents and conformation of the sugar moiety of adenosine, have 
found a linear correlation. When studying 2'-substituted 21- 
deoxyadenosine it was found that there is an increase in the contribution 
of the N-conformer with the increasing electronegativity of the 2'- 
substituent in the order F>N3>CI>Br>I. This pattern also corresponds to 
the atomic radii of these groups so steric hindrance may be occurring. 
However, the compounds substituted at C-2' by OH, OMe, N3 and NH2,, 
which are bulkier than H, have predominately more of the N-conformer 
than the H-substituted compounds, thus inferring that there is only a 
minor steric effect. 
These results show the dominant influence of the polarity of the 
substituent on the conformation of the sugar ring (Pauling"s 
electronegativites: F=4.0, OH = 3.5, N3 = 3.0, Cl = 3.0, NH2 = 3.0, H= 2-1). 
For the substituents at C-2' and C-3' the most electronegative substituents 
pulls the pucker towards its side. This is shown by 2'-deoxyadenosine 
having the highest preference for the S-form, while 2'-fluoro-2'- 
deoxyadenosine has the highest preference for the N-form. Hence, it 
appears that polar effects of the C-X bond rather than steric considerations 
are mainly responsible for the adoption of the preferred conformation. 
This preference for the electronegative substituents to be approximately 
gauche to the ring 04" rather than trans is known as the gauche effect 163 
However, the effects of hydrogen-bonding with the solvent must not be 
discounted as the binding will be different for every substituent. 
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4.2.5: Summary 
Those compounds which are active glycosyl donors with N- 
deoxyribosyltransf erases from lactobacilli, thymidine (1), 5'- 
deoxythymidine (42), and 3'-deoxythymidine (6), appear to have relatively 
flexible sugar rings. This property may allow them to adopt the "correct" 
conformation at the active site of the transferase without undue input of 
energy. Steric and dipolar constraints may become important in the case of 
3'-fluoro-3'-deoxythymidine (32) and AZT (40), making them inactive 
substrates for the transferases. Previous investigations found that 
although the sugar moiety of 3'-fluoro-3'-deoxy thymi dine (32) was not able 
to be transferred, some degree of hydrolysis was observed. This may 
indicate that the compound actually binds to the enzyme but the lack of 
any transfer may be due to the sugar binding weakly and the extreme 
114 
conformation preventing further reaction with the acceptor base 
Unfortunately, further theoretical investigations into the nucleoside- 
enzyme interactions at the active site seem superfluous now that the 
structure of the enzyme has been investigated. Sadly, only preliminary 
findings have been published116 and no crystal structure or other data are 
available. 
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The correlation of the shape of the sugar ring in a nucleoside in solution 
with antiviral activity is much more complex as several enzymic steps are 
involved before the nucleoside inhibits viral replication. That aside, it is 
of interest that three of the nucleosides in our study, Y-fluoro-Y- 
deoxythymidine (32), AZT (40), and FMAU (41), which have "rigid" ring 
conformations with a predominance of S-character present at 294K, are all 
active antiviral agents. However, it must be emphasised that the 
suggestion that an S-conformation is desirable for the anti-HIV activity of 
nucleosides'98 is not supported by the results found for 2', 3- 
di deoxynucleos ides. In this work, 2', 3'-dideoxythymidine was found to 
have 68% N-character at 297K and this preference for the N- 
conformation has been shown for the other natural 2', 3'- 
dideoxynucleosidesl99. 
4.2.6: Synthesis of (±)-l-[(2P', 4p')-2"-(hydroxymethyl)-4"-dioxolanylI 
thymine. [(±)-Dioxolane-T] (50)184 
Dioxolane-T (50) has been synthesised, in the literature, by two routes 
which both involve a key intermediate, (±)-4-acetoxydioxolane-2- 
substituted dioxolane (47), which is then condensed with a heterocyclic 
base and deprotected to afford the required nucleoside: 
*the method of Kim et a1203 synthesised the intermediate in nine 
steps from 1,6-anhydro-D-mannose; 
*the method of Norbeck et a1184 synthesised the intermediate in 
four steps which was the method employed in this study. 
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The following synthetic scheme was developed from the note by Norbeck 
et a1184 which did not give full experimental details: 
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Fischer esterification of (±)-calcium glycerate dihydrate gave (±)-methyl 
glycerate (44) which was condensed with benzyloxyacetaldehyde dimethyl 
acetal to give the basic dioxolane structure (45) in 74% yield as a racemic, 
1: 1 mixture of diastereisomers. Saponification of the dioxolane methyl 
esters (45) followed by acidification afforded the carboxylic acids (46) as an 
oil. Treatment of the carboxylic acids with 1.1 equivalents of pyridine and 
1.3 equivalents of lead tetraacetate in dry acetonitrile effected the oxidative 
decarboxylation to yield the acetates (47) in a 1.7: 1 mixture of cis and trans 
isomers as the intermediate for the condensation reactions with 
heterocyclic bases. There was also a very polar product which was a dimer 
resulting from self-coupling. The acetates (47) were then condensed with 
trimethylsilylthymine6l to yield a 1: 1 mixture of diastereisomers of the 
dioxolanes (48 and 49) which were separated on silica gel. The required P- 
dioxolane-T (50) was obtained in 19% overall yield by hydrogenolysis of 
the cis isomer. 
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Scheme 4.35 Condensation of benzyloxyacetaldehyde dimethyl acetal and 
W-methyl glycerate (44) 
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The initial condensation reaction to form the basic dioxolane structure 
produced methanol as a byproduct and in order for the reaction to go to 
completion the methanol was distilled off after one hour of the reaction, 
forcing the equilibrium towards products in 74% yield. Saponification and 
acidification of the esters (45) afforded the carboxylic acids (46). The 
oxidative decarboxylation of the acids (46) to the acetates (47) was 
accomplished using lead tetraacetate and pyridine. The mechanism is 
generally accepted to be of the free-radical type. 
Thymine was silylated using excess hexamethy1disilazane which was 
evaporated and the residue used immediately in the condensation 
reaction with the (±)-dioloxane esters (47) according to the general method 
of Vorbriiggen6l to afford a 1: 1 diastereisomeric mixture of 5-protected (±)- 
dioxolane-T (48 and 49) which, after separation, were hydrogenolysed to 
yield (±)-dioxolane-T (50). 
4.2.6.1: Variable Temperature 1H NMR Studies of (±)-Dioxolane-T (50) 
In order for a nucleoside to be an effective glycosyl donor in transfer 
reactions using N-deoxyribosyltransferase enzymes we believe that the 
sugar moiety of the nucleoside must be "'flexible" with a conformation 
near to 50: 50 N: S and so extremes of conformation and relatively "'rigid" 
structures are not glycosyl donors. Norbeck et a1184 and Kim et a1203 
reported that (±)-dioxolane-T (50) adopts an N-conformation so it was of 
interest to see the degree of flexiblity within the sugar moiety of this 
nucleoside. As there was no HY proton in the structure, the JH3'-H4' could 
not be measured and therefore the conformation was calculated using the 
186 approximation %S = 10JH1'-H2'a 
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j/ Fiz FTEMP/OK 
I H11,2a Hll, 2'b Keq 
- 
%N 
3 ., jq 23 1.86 
5.63 0.23 81 
313 1.78 5.61 0.22 82 
303 1.71 5.66 0.20 83 
294 1.56 5.62 0.19 84 
273 1.24 5.60 0.14 88 
263 1.09 5.56 0.12 89 
Table 4.3 Variation in coupling constants in the sugar moiety of (±)- 
Dioxolane-T (50) with temperature 
The results indicated that the N-conformation adopted by the sugar ring in 
(±)-dioxolane-T (50) was an extreme N-twist. The preference for the N- 
conformer was shown by the increase in the %N with the decrease in 
temperature. The spectrum was measured at lower temperatures than 
indicated in the table but the resolution was too poor to yield any useful 
information. From these results it was unlikely that (±)-dioxolane-T (50) 
would act as a glycosyl donor in the transfer reactions but several test 
reactions were set-up using adenine as the acceptor base and the reactions 
were followed by reverse phase HPLC for one week; as expected, no 
transfer was observed. For completeness (±)-dioxolane-T was also 
investigated as a donor nucleoside in transfer reactions which use 
nucleoside phosphorylases as the biocatalysts; again no reaction was 
observed. 
In summary, the synthesis of P-dioxolane-T (50) was successful but this 
nucleoside adopted an extreme N-conformation which was not accepted 
as a substrate by N-deoxyribosyltransferase from Lactobacillus leichmannii. 
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4.3: MATERIALS AND METHODS 
Nucleosides 
Thymidine (1), 3"-azido-3'-deoxythymidine (40) and 5-deoxythymidine (42) 
were obtained from Sigma Chemical Co., 2'-deoxy-2'-fluoro-5-methyl- 
arabinosyluracil (FMAU) (41) was a gift from Dr. J. J. Fox (Sloan-Kettering 
Institute for Cancer Research, New York), 1-(2', 3'-dideoxy-2'-f1uoro-P-D- 
threo-pentofuranosyl)uracil (43) was a gift from Dr. J. A. Martin (Roche 
Products, Welwyn, U. K. ). 1-(2'-deoxy-p-D-erythro-pentofuranosyl)thymine 
(3) and 3'-deoxythymi dine (6) were synthesised as described in Chapter 2 
and the other nucleosides (32,35,39) were prepared as described in the 
Experimental section. 
4.3.2: Variable Temperature IH NMR 
The 1H NMR spectra were measured on a Bruker WH400 spectrometer 
between 190 and 330 K. The probe temperature was calculated from the 
chemical shift separation of the resonances of aliphatic and hydroxyl 
protons of methanol' 95,196. 
The puckering equilibrium of the deoxyribose rings was analysed by the 
use of vicinal spin-spin coupling constants 186. These values were used in 
the calculation of the differences in enthalpy and entropy between the 
favoured conformations adopted over the range of temperatures studied. 
When measuring the coupling constants for fluorinated deoxyribose 
moieties, it was assumed, where necessary., that the corresponding JH, H ý 
1/2 GH, F) 197 . This adjustment of coupling constants is not required 
for the 
AH and AS calculations, but such a correction factor is required to estimate 
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a value for the percentage of N- and S-character in the conformations 
adopted by fluorinated nucleosides. 
4.4: EXPERIMENTAL 
4.4.1: Synthesis of 1-(2-deoxy-p-D-erythro-pentofuranosyl)thymine (31)73 
4.4.1.1: Synthesis of 5-methoxytritylthymidine (28) 
Thymidine (5.0g, 20.6mmol) and DMAP (10mg, catalytic amount) were 
dissolved in dry pyridine (30ml) and cooled to OOC in an ice-water bath. To 
the cooled solution was added p-anisylchlorodiphenylmethane (9.56g, 
31. Ommol) - The mixture was stirred under nitrogen at room temperature 
overnight before being poured into ice-water (500ml) with vigorous 
stirring. The solution was stirred for 1h and the precipitated white solid 
was collected by filtration through a glass sinter funnel, washed with water 
(50ml) and Iyophilised to give 10.04g (95% yield) of white crystals: Rf = 0.29 
MeOH/CH2CI, 1/9); 1H NMR (CDC13) 81.47 OH, d, J=1.14Hz, C5, -Me), 2.32 
(1H, ddd, J=2 x 6.92,14.8Hz, HTA 2.46 (IH, ddd, J=2.21,6.09,14.61-lz, H2'b), 
3.38 (1 H, dd, J=3.89,12.2Hz, H5'a), 3.48 (1 H, dd, J=2.92,12.2Hz, H5'b), 3.80 
OH, s, TrOMje, 4.11 (1H, ddd appears as quartet, J=3 x 3.52Hz, 1-14, ), 4.59 (1H, 
unresolved ddd, H3'), 6.45 (1H, dd appears as t, J=6.65Hz, Hl, ), 6.85-7-50 
(14H, m, Tr), 7.64 (1H, d, J=1.17F[z, H6),, 9.12 (1H, s, NH); MS (EI) m/z (%) 43 
(13), 55 (19), 69 (8), 81 (11), 98 (7), 126 (19, thymine+-), 152 (6), 165 (11), 197 
(12), 229 (6), 273 (63); (CI) m/z (%) 55 (1), 81 (1), 99 (1), 127 [5, (thymine+H)+], 
153 (1), 167 (1), 197 (1), 243 (1), 273 (4), 274 (3), 292 (1), 515 [1, (M+H)+]. 
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4.4.1.2: Synthesis of 3'-methanesulphonyl-5-methoxytritylthymidine (29) 
5'-Methoxytritylthymidine (2.0 g, 3.9mmol) and DMAP (4 mg, catalytic 
amount) were dissolved in dry pyridine (20 ml). Methanesulphonyl 
chloride (2.0 ml, 9.3mmol) was added to the cooled solution at OOC under 
nitrogen. The reaction mixture was stirred overnight at room temperature 
and then poured onto ice-water (200 ml), with vigorous stirring. The 
solution was stirred for 1h before the precipitate was collected by filtration 
through a glass sinter funnel, and washed with water (10 ml). The white 
precipitate was dissolved in acetone, filtered and reduced in vacuo before 
being Iyophilised to give 2.12 g (92% yield): Rf=0.51 (MeOH/CH2Cl2,, 1/9); 
1H NMR (CDC13) 5 1.49 (3H, d, J=1.12Hz, CF-Me), 2.53 (1 H, ddd, J=2 x 6.95, 
14.7Hz, H2'a), 2.67 (1 H, ddd, J=2.26,6.12,14.6Hz, H2'b), 3.05 (3H, S, S02Me), 
3.47 (1H, dd, J=3.84,12. lHz, H5'a), 3.48 (2H, dd, J=2.93,12. lHz, H5, b), 3.84 
OH, s, TrOMe), 4.32 (1H, ddd appears as quintet, J=2.96,3.87,6.84Hz, F14, ), 
5.45 (1 H, ddd, J=2 x 2.78,6.8OHz, HY), 6.49 (1 H, dd, J=6.15,7.99HZ, H10,6.85- 
7.68 (14H, m, Tr), 7.88 (1H, d, J=1.14Hz, H6), 9.70 (1H, s, NH); MS (EI) m/z 
M 55 (31), 81 (56), 93 (1), 126 (46, thymine+ -), 165 (33), 229 (20), 273 (100); 
(CI) m/z W 55 (7), 81 (12), 127 [38, (thymine+H)+], 165 (5), 225 (7), 273 (49), 
497 (2),, 593 [1, (M+H)+]. 
4.4.1.3: Synthesis of 1-(S'-methoxytrityl-2'-deoxy-p-D-erythro- 
pentofuranosyl)thymine (30) 
3'-Methanesulphonyl-5'-methoxytritylthymidine (2.12g, 3.6mmol) was 
dissolved in ethanol (40ml). To the solution was added water (20ml) 
containing LON NaOH (15ml) and the mixture was refluxed under 
nitrogen for 5 h. The solution was neutralised with LON HCI and the 
volume was reduced in vacuo to -5ml. The solution was extracted with 
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CH202 (2 x 20ml), water (150ml) was added and the solution was left to 
stand at 40C. The precipitated crystals were separated by filtration, washed 
with water (20ml) and Iyophilised before being purified by flash 
chromatography on silica gel (MeOH/CH2CI2,5/95) to give 1.38g (75% 
yield) of a white solid: IH NMR (CDC13) 6 1.79 (3H, s, CT-Me), 2.12 (1H, 
ddd appears as m, H2'a), 2.57 (1 H, ddd, J=5.42,8.31,14-3Hz, H2'b), 3.08 (1 H, s. 
OH), 3.49 (1H, dd, J=5.94, lO. 2Hz, HFa), 3.62 (1H, dd, J=4.85,10.2HZ, H5'b)., 
3.79 (3H, s, TrOýje), 4.02 (1H, ddd appears as quartet, J=3 x 5.08FIz, H4, ), 5.41 
(1 H, unresolved ddd, HT), 6.20 (1 H, dd, J=2.35,8.32Hz, Hl, ), 6.81-7.46 (14H, 
m, Tr), 7.66 (1H, s, H6), 8.66 (1H, s, NH). 
4.4.1.4: Synthesis of 1-(2'-deoxy-p-D-erythro-pentofuranosyl)thymine (31) 
1-(5'-Methoxytrityl-2"-deoxy-p-D-erythro-pentofuranosyl)thymine (1.30g, 
2-5mmol) was dissoved in 50% acetic acid (20ml) and refluxed for 20 min 
under nitrogen to remove the methoxytrityl group. The solvent was 
removed in vacuo and the residue was Iyophilised before being purified by 
flash chromatography on silica gel (MeOH/CH2Cl2,5/95) to give 0-51g 
(83% yield) of a white solid: 1H NMR (CD30D) 8 1.92 (3H, d, j=l. 20Hz, C51- 
Me), 2.05 (1H, ddd, J=1.00,2.55,14.9Hz, H2a), 2.68 (IH, ddd, J=5.38,8.25, 
14.9Hz, H2'b), 3.92 (IH, dd, J=6.65,11.56Hz, H5'a), 3.95 (IH, dd, J=2.58, 
11.6Hz, H5'b), 4.00 (1H, ddd appears as septet, J=3.21,4.32,6.68Hz, 1-14, ), 4.43 
OH, ddd, J=0.93,3.09,5.36Hz, HY), 6.19 OH, dd, J=2.52,8.24HZ, Hl, ), 7.98 
OH, d, J=1.22Hz, H6); MS (EI) m/z (%) 45 (65), 55 (100), 73 (80), 81 (34), 99 
(66), 110 (45), 117 (99), 126 (93, thymine+-), 127 (72), 153 (16), 242 (15, M+'); 
(CI) m/z M 55 (5), 81 (20), 98 (10), 99 (11), 117 (11), 127 [42, (thymine+H)+], 
144 (5), 153 (2), 207 (1), 243 [26, (M+H)+]. 
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4.4.2: Synthesis of 3'-fluoro-3"-deoxythymidine (32) 
4.4.2.1: Synthesis of 5-methoxytrityl-3'-fluoro-31-deoxythymidine 
1-(5'-Methoxytrityl-2'-deoxy-p-D-erythro-pentofuranosyl)thymine (1.40g, 
2.7mmol) was dissolved in dry CH202 (20ml) and the mixture was cooled 
to OOC in an ice-water bath. To the cooled solution, DAST (1.3ml, 
9.85mmol) was added slowly and the solution stirred for 3h at room 
temperature. The solution was poured into sodium bicarbonate solution 
(20ml), extracted with CH202 (2 x 20ml), dried over MgS04,, filtered and 
evaporated in vacuo. The residue was purified by flash chromatography 
on silica gel (MeOH/CH2CI2.5/95) to give 0.42g (30% yield) of a white 
solid: 1H NMR (CDC13) 8 1.43 (3H, s, CF-Me), 2.36 (1H, dddd, J=4.89,9.39, 
14-33,39.77Hz, H2'a), 2.69 (1H, dddd, J=2 x 5.55,14-50,20-18Hz, H2'b), 3.40 
(1H, dd, J=3.31,11.9Hz, H5a), 3.95 (1H, dd, J=3.07,11.9Hz, H5'b), 3.81 OH, s, 
TrOMe), 4.37 (1 H, dt, J=3.14,27.75Hz, H40,5.32 (1 H, dd, J=4.65,53.82Hz, HY), 
6.53 (1H, dd, J=5.46,9.37Hz, Hl, ), 7.65 (1H, s, M), 9.55 (1H, s, NH). 
4.4.2.2: Synthesis of 3"-fluoro-3'-deoxythymidine (32) 
5'-Methoxytrityl-3'-fluoro-3-'-deoxythymidine (0.40g, 0.78mmol) was 
dissolved in 50% acetic acid (10ml) and stirred at room temperature for 50 
min under nitrogen to remove the methoxytrityl group. The solvent was 
removed in vacuo and the residue was Iyophilised before being purified by 
flash chromatography on silica gel (MeOH/CH2CI2,5/95) to give 0-10g 
(53% yield) of a white solid: 1H NMR (CD30D) 8 1.92 (3H, d, J=1.21HZ, C5'- 
Me), 2.28 (IH, dddd, J=4.96,9.39,14-32,39.04Hz, H2'a), 2.37 (1H, dddd, J=2 x 
5.56,14.46,20.85Hz, H2'b), 3.80 (1H, ddd, J=1.18,3.36,11.94Hz, H5'a), 3.95 OH, 
dd, J=3.05,11.94HZ, HTO, 4.28 (1 H, dt, J=2 x 3.24,27.54Hz, 1-14, ), 5.15 (1 H, dd, 
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J=4.90,53.91 Hz, HY), 6.36 (1 H, dd, J=5.53,9.25Hz, Hl, ), 7.87 (1 H, d, J= I . 23FIz, 
H6); HRMS (EI) calcd (ClOH13N204F+*) 244-0859, found 244.0861. 
4.4.3: Synthesis of 3', 3-difluoro-3'-deoxythymidine (35)190 
4.4.3.1: Synthesis of 3'-keto-5-tritylthymidine (34) 
A slurry of 4A molecular sieve powder (1-50g) and pyridinium dichromate 
(1-50g, 3-99mmol) in CIj2CI2 (10ml) was magnetically stirred at room 
temperature. The flask was initially flushed with nitrogen and then 
maintained under an atmosphere of argon. 5'-Trityl thymi dine (1-25g, 
2.6mmol) was added in CH2CI2 (10ml) and the colour of the reaction 
mixture changed from light orange to dark brown within five minutes. 
The reaction was stirred for 2 h, then filtered on a Bilchner funnel 
through a celite pad. The collected solids were washed with CH2C12 (2 x 
20ml) and the filtrate was evaporated in vacuo to give a brown solid 
which was suspended in EtOAc (200ml) by sonicating the mixture for a few 
minutes. The suspension was filtered through 4A molecular sieve powder 
(deposited as a slurry with EtOAO on a glass sinter funnel and the solids 
were washed with EtOAc (25ml). The solvent was evaporated in vacuo to 
yield 1.03g of a light tan powder. The crude solid was recrystallised from 
CH2CI2/diethyl ether, 1/3 and the white crystals were separated by 
filtration and Iyophilised to yield and first crop of 0.60g and a second crop 
of 0.31g (73% yield): Rf=0.32 for the product and 0.71 due to decomposition 
which yielded 2-trityloxymethyl-3(2H)-furanone (MeOH/CH2CI2,5/95); 1H 
NMR (CDC13) 8 1.31 OH, d, J=1-141-1z, CF-Me), 2.76 (1H, dd, J=8.25,18-68HZ, 
H2'a), 3.08 (1H, dd, J=6.69,18.65Hz, H2'b), 3.41 (1H, dd, J=2.30,10.43Hz, H5'a), 
3.67 (1 H, dd, J=2.59,10.43Hz, H5b). 4.17 (1 H, dd appears as br t, H4, ), 6.57 (1 
H, dd, J=6.70,8-21Hz, HI, ), 7.23-7-37 (15H, m, Tr), 7.63 (1H, d, J=1.28Hz, H6), 
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8.61 (1 H, brs, NH); MS (EI) m/zM 52 (21), 63 (32), 71 (10), 89 (68), 107 (66), 
136 (93), 154 (100), 165 (27), 243 (74, Trityl+. ), 289 (8), 391 (4), 482 (4, M+ . ). 
4.4.3.2: Synthesis of 3,3-difluoro-3"-deoxythymidine (35) 
3'-Keto-5'-tritylthymidine (0-57g, 1-18mmol) was dissolved in CH202 
(20ml) and the flask was purged with nitrogen. DAST (0.48g, 0-39ml, 
4.14mmol) was added dropwise to the solution and the mixture was 
stirred for 24 h under nitrogen at room temperature. The solution was 
poured into a saturated aqueous solution of sodium bicarbonate (30ml) 
and then extracted with sodium bicarbonate (2 x 30ml), dried over MgS04 
and evaporated in vacuo to yield a yellow residue. The residue was 
lyophilised before being purified by flash chromatography on silica gel 
(MeOH/CH2CI2,5/95) to give 0.18g (31% yield) of a pale yellow solid: 
Rf=0.55 (MeOH/CH2CI2,, 5/95). 
The 5'-trityl-3', 3'-difluoro-3'-deoxythymidine (0.18g, 0-38mmol) was 
dissolved in 50% acetic acid (10ml) and the mixture was refluxed for 15 
min. The solution was evaporated in vacuo and Iyophilised before being 
purified by flash chromatography on silica gel (MeOH/CH2CI2,2/98) to 
give 0.07g (74% yield) of a pale yellow solid: Rf=0.38 (MeOH/CH2CI2,1/9); 
1H NMR (CD30D) 8 1.93 (3H, d, J=1.19Hz, CF-Me), 2.67 (1H, dddd, J=8-13, 
13-60,14.3,20.6Hz, H2'b), 2.86 (1 H, dddd, J=2 x 6.78,14.17,14.3Hz, H2'a), 3.85 
(1H, ddd, J=1.43,4.10,12.5Hz, H5'a), 3.90 (1H, dd, J=3.58,12.5Hz, H5'b), 4.28 
(I H, dddd, J=2 x 3.74,7.37,15.79Hz, H4, ), 6.35 (1 H, dd, J=6.46,8.13Hz, Hl, ), 
7.87 (1H, d, J=1.25FIz, HO; 19F NMR (CD30D) 5 -98-16 OF, dddd, J=2 x 15.14, 
21.41,238.44Hz, Fb), -109.89 OF, dddd, J=2 x 7.3,13.7,238.44Hz, Fa); MS (EI) 
m/zM 55 (72), 69 (20), 83 (43), 87 (76), 93 (20), 117 (74), 126 (100, thym ine+ *), 
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188 (23), 231 (11), 262 (12, M+'); (CI) m/z M 55 (6), 83 (2), 99 (6), 117 (5), 126 
(26), 127 [33, (thymine+H)+], 188 (1), 263 [57, (M+H)+]. 
4.4-4: Synthesis of 2'-fluoro-2-deoxyuridine (39) 
4.4.4.1: Synthesis of 2,2'-anhydro-l-(D-D-arabino-furanosyl)cytosine 
hydrochloride (37)191 
A suspension of cytidine (1.85g, 7-59mmol) and 2-acetoxyisobutyryl 
chloride (5.0g, 30-Ommol) in CH3CN (20ml) was stirred at 800C under 
nitrogen. After 3 min the solution cleared and this was shortly followed by 
the formation of some fine white crystals. After 30 min the mixture was 
cooled to room temperature and ether (50ml) was added to the stirred 
solution. The solid was collected by filtration, washed with ether (2 x 10ml) 
to yield 0.88g of crude product. The filtrate was evaporated in vacuo and 
the solid was redissolved in ether (20ml) and left at 40C to crystallise a 
further 1-41g of crude product: total 2.29g (99% yield). 
The crude product (2.20g, 7.24mmol) was dissolved in methanol (60ml) 
containing conc. HCl (1ml) and stirred under nitrogen at room 
temperature for 6 days during which time crystals of product separated. 
The crystals were separated by filtration to yield 1.10g and the filtrate was 
evaporated in vacuo. The solid was recrystallised from MeOH/acetone to 
give a total of 1.55g (82% yield) of white crystals: Rf=0.07 (MeOH/CH2CI2, 
1/9); m. p. =264-265OC; 1H NMR (d6-DMSO) 8 3.27 OH, dd, J=3.27,12.03HZ, 
H5'a), 3.40 (1 H, dd, J=2.85,12.12HZ, H5'b), 4.22 (1 H, unresolved ddd, FIC), 
4.47 (1H, unresolved dd, HY), 5.06 (1H, brs, OH), 5.39 (1H, d, J=6.02FIZ, H2'), 
6.16 (1 H, brs, OH), 6.54 (1 H, d, J=6.02Hz, Hl, ), 6.60 (1 H, d, J=7.32FIZ, H5), 8.28 
(1 H, d, J=7.29Hz, F16), 9.21 (1 H, brs, NH), 9.53 (1 H, brs, NH); MS (ED m/zM 
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55 (85), 69 (100), 81 (67), 97 (54), 112 (31), 135 (35); (CI) M/z M 69 (3), 81 (7), 
96 (5), 112 (5), 113 (34), 136 (10), 226 (3), 262 [1, (M+H)+]. 
4.4.4.2: Synthesis of 2'-fluoro-2-deoxycytidine (38)192 
A mixture of DMF (50ml), dicyclohexano-18-crown-6 (0.5ml, 1-34mmol), 
KF (1.25g, 21.6mmol, dried over P205,1000C/0.01torr) and benzene (50ml) 
was heated at 1350C and the benzene was slowly distilled off. On 
completion of distillation, 2,2'-anhydrocytidine hydrochloride (0.5g, 
1.92mmol) was added and the mixture was heated at 1200C under nitrogen 
for 5 h. The solvent was evaporated in vacuo and the pale brown oil was 
purified by flash chromatography on silica gel (MeOH/CH2Cl2,, 1/5) to 
give 0.19g (41% yield) of white crystals: Rf=0.38 (MeOH/CH2CI2,3/7); 
m. p. =165-167OC; 1H NMR (d6-DMSO) 8 3.58 (1H, dd, J=2.79,12.4Hz, H5'a), 
3.73 (1H, dd, J=3.01,12.4FIz, HTO, 4.87 (1H, unresolved ddd, H4, ), 4.10 (1H, 
ddd, J=4.65,7.46,22.44liz, HY), 4.86 (1 H, ddd, J= 1.50,4.35,53.32Hz, H2'), 5.72 
OH, d, J=7.46Hz, HO, 5.87 (1H, dd, J=1.53,17.99Hz, Hl, ), 7.89 (1H, d, 
J=7.46Hz, HO; MS (EI) m/z (%) 55 (15), 69 (10), 81 (6), 97 (4); (CI) m/z (%) 61 
(1), 85 (3), 96 (1), 111 M, 139 (1), 246 [1, (M+H)+]. 
4.4.4.3: Synthesis of 2'-fluoro-2'-deoxyuridine (39)193 
2'-Fluoro-2'-deoxycytidine (30mg, 0.12mmol) was dissolved in water 
(10ml) containing sodium metabisulphite (12mg, 1-2mmol) and the 
mixture was stirred under nitrogen overnight at room temperature. 
Unreacted sodium bisulphite was precipitated by the addition of barium 
hydroxide (3.15g, 10. Ommol) and the white solid was separated by 
filtration. The filtrated was purified by ion exchange chromatography on 
Dowex 50W H+ and the uridine nucleoside was eluted with distilled 
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water. The eluted aqueous fractions were concentrated in vacuo and 
lyophilised, before being purified by flash chromatography on silica gel 
(MeOH/CH2CI2., 1/9) to give 22mg (73% yield) of white crystals: Rf=0.13 
(MeOH/CH2CI2,2/8); m. p. =165-167OC; 1H NMR (CD30D) 8 4.24 OH, ddd, 
J=2.41,2.95,7.3Hz, 114, ), 4.25 (1H, dd, J=2.95,12. OHz, H5a), 4.39 OH, ddd, 
J=4.39,7.26,18.75fiz, HT), 4.42 (1 H, dd, J=2.41,11-86Hz, H5'b), 5.08 (1 H, ddd, 
J=2.31,4.43,52.62Hz, H2'), 5.78 (1H, d, J=8.13Hz, H5), 6.06 (IH, dd, J=2-30, 
16.5OHz, Hl, ), 7.99 (1H, d, J=8.14Hz, HO; HRMS (EI) calc (C9HllN205F+-) 
246.05077, found 246.0509. 
4.4.5: Synthesis of (±)-I-[(2p', 4p')-2'-(hydroxymethyl)-4'-dioxolanylI 
thymine. [(±)-Dioxolane-T] (50)184 
4.4.5.1: Synthesis of W-methyl glycerate (44) 
To a stirred suspension of (±)-calcium glycerate dihydrate (25.0g, 0.087mol) 
in methanol (500ml) was added 96% H2SO4 (10. Oml, 0.180mol) over a2 
min period. After 24 h at 250C, a trace of methyl orange was added, the 
reaction mixture cooled to OOC, and then rapidly neutralised with 50% 
sodium hydroxide to give an apparent pH of 6.0-6.5 (a colour change of 
pink to yellow). The solid material was removed by filtration through a 
celite pad which was washed with methanol (500ml). The combined 
organic fractions were reduced in vacuo before Kugelrohr distillation 
(150OC/O. 1mm Hg) to afford 17.98g (86% yield) of product as a clear oil: 1H 
NMR (CD30D) 5 3.79 (3H, s, OMe), 3.81 (2H, dd, J=3-97,4-66HZ, CH2), 4.26 
(1H, t, J=4.3OHz, CH); 13C NMR (CD30D) 52.49 (OMe), 65-00 (CH2), 73.28 
(CH), 174.53 (CO); HRMS (CI) calcd (C4H804+ + H+) 121-0501, found 
121-0500. 
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4.4.5.2: Synthesis of 
carboxylate (45) 
-M ethyl-2-b enzyl oxym ethyl di oxo lane -4- 
Benzyloxyacetaldehyde methyl acetal (24-53g, 0.125mol), (±)-methyl 
glycerate (44) (17.90g, 0.149mol) and p-toluene sulphonic acid (0.77g, 
4.03mmol) in CH3CN (50ml) were refluxed for one hour, after which 20% 
of the total volume was distilled off over a period of 45 min. The 
remaining solution was refluxed for a further 2 h, concentrated in vacuo, 
dissolved in CH2CI2 (50ml), extracted with NaHC03 (2 x 30ml) and dried 
over MgS04- The organic layer was separated by filtration and 
concentrated in vacuo to give 23-34g (74% yield) of a pale brown oil which 
was used without further purification: 1H NMR (CDC13) racemic 1: 1 
mixture of diastereomers 8 3.57-3.72 [2H, m, H5'a&b(Cc & PA, 3.69 & 3.73 [3H, 
2xs,, OMe(cc & PA, 4.05 [IH, 2x dd, J=5.34,8.26Hz & 7.36,8.61FIz, H2'a(()c & 
P)], 4.23 [1H, 2x dd, J=3.76,8.56FIz &2x7.27Hz, H2'b(Cc & P)I, 4.54-4-65 [3H/ 
m, H4, ((x & P) & C6H5-CH,? -O], 5.15-5.34 [1H, 2x dd, J=2 x 3.61Hz &2x 
4.28Hz, Hl, (cc & P)],, 7.22-7.41 [5H, M., C6H5(Cc & M; 13C NMR (CDC13) 51.94 
(OMe), 67.77,68.19 IC2'((X & P)I, 69.84,70.42 IC5'((X & P)1,73.19,73-23,73-37, 
73.52 IC4'(OC & P) & C6H5-QH2-01,103-82,104.35 [Cl, ((x & P)I, 127.31-127.99 
(C6H5); HRMS (EI) calcd (Cl3Hl6O5+*) 252-1004, found 252-1001. 
4.4.5.3: Synthesis of W-2-b enzyl oxym ethyl dioxolane-4-carb oxyl ic acid (46) 
Dioxolane methyl ester racemate (45) (23.0g, 0.0912mol) and UOH (4.28g, 
0.102mol) in THF/H20 (90ml, 4/1) were refluxed for 1.5 h. The solvent was 
removed in vacuo and the oil was redissolved in CH202 (50ml), extracted 
with LOM HCI (30ml), H20 (30ml) and dried over MgS04. The combined 
organic fractions were concentrated in vacuo to give 11.14g (51% yield) of a 
pale brown oil which was used without further purification: 
1H NMR 
198 
(CDC13) 1: 1 mixture of diatereomers 8 3.56 [1H, unresolved dd, H5'a(cc & 
PA, 3.72 [1H, unresolved dd, H5'b(cc & PA, 3.98 & 4.05 [1H, 2x dd, J=2 x 
7.47Hz &2x6.25Hz, H2'a((x & P)I, 4.28 [1H, 2x dd, J=2 x 7.26Hz &2x7.72Hz, 
H2'b(Cc & P)I, 4.57-4.70 [3H, m, 1-14, (a & P) & C6H5-CH2-0], 5.14-5-30 [IH, 2x 
br t, J=2 x 3.43Hz & unres., Hl, ((x & P)I, 7.21-7-35 (5H, M, C6H5), 10.05 (IH, 
brs, OH); 13C NMR (CDC13) 67.94,68-22 IC2((x & P)I, 70-07,70.15 IC5'(Oc & M, 
73.67 (C6H5-ýIH2-0), 74.06 IC4'(ICC & 0)], 104.14,104.20 [Cl, ((x & 0)], 127-81- 
128-66 (C6H5); HRMS (EI) calcd (C12H1405+-) 238-0853, found 238.0847. 
4.4.5.4: Synthesis of (±)-4-acetoxy-2-b enzyl oxym ethyl d ioxolane (47) 
Dioxolane carboxylic acids (46) (6.5g, 27.3mmol), lead tetraacetate (15-57g, 
35. Ommol), and pyridine (2.37g, 30. Ommol) in CH3CN (100ml) were stirred 
at 400C under nitrogen for 6 h. The solution was concentrated in vacuo 
and Iyophilised before being purified by flash chromatography on silica gel 
(MeOH/CH2CI2,2/98) to give 5.54g (80% yield) of the title compound as a 
clear oil: Rf = 0.86 (MeOH/CH2CI2,1/9), 1H NMR (CDC13) 1.7: 1.0 mixture of 
cis and trans isomers 8 1.94 [3H, s, Me ((x-form)], 2.00 [3H, s, Me (0-form)], 
3.53 [2H, 2x ddd, J=l . 30,3.83,0.51,3.99,11-06Hz, H5'a&b(p-form)], 3.59 
[2H, 
dd, J=2.79,4.24HZ, H5'a&b((x-form)], 3.86 [1H, m, HTA-form)], 3.90 [1H, m, 
HTA-form)], 4.13 [1H, d, J=10. OOHz, HTO-form)l, 4.17 [1H, dd, J=4.43, 
9.29Hz, H2'b(cc-form)1,4.55 [2H, S,, C6H5-_CH2-0(p-form)], 4.57 [2H, s, C6H5- 
. 
CH? -O(cc-form)], 5.24 [IH, dd appears as t, J=2 x 4.22Hz, H4, (cc-form)], 5.34 
[IH, dd appears as t, J=2 x 3.67FIz, H4, (P-form)], 6.27 [1H, d, J=3.66Hz, Hl, ((X- 
form)], 6.35 [1H, dd, J=2.08,4.42Hz, Hl, (P-form)], 7.20-7.35 (5H, m, C6H5); 
13C NMR (CDC13) 13-30 [Me(O-form)], 13.35 [Me(cc-form)], 62.43 IC5'(P- 
form)], 62.97 IC20-form)], 63.34 ICT(cc-form)], 63.47 IC2'((x-form)], 65.77, 
65-89 IC6H5-QH2-0(Cc & P-form)1,86.23 [Cl, (cc-form)], 86.73 [Cl, (P-form)], 
95.99 IC4'(C4'(P- form) 1,9 7.45 IC4, (a-form)], 120.01-120.70 (C6H5)/ 162.41 
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[CO(ß-form)1,162.45 [CO«x-form)]; MS (EI) in/z M 43 (89), 51 (11), 65 (33), 
77 (16), 91 (100), 107 (47), 131 (82), 149 (7), 162 (8), 192 (19), 207 (10), 219 (4), 
237 (6), 251 (1), 252 (1, M+. ); (CI) rn/z M 60 (2), 77 (1), 91 (8), 106 (5)120 (2), 
131 (3), 138 (1), 150 (3), 161 (1), 168 (2), 198 (3), 210 (5), 253 [3, (M+H)+]. 
4.4.5.5: Synthesis of trim ethylsilyl thym ine6l 
Thymine (1.0g, 7.9mmol), hexamethy1disilazane (8ml) and ammonium 
sulphate (4mg) were refluxed together under nitrogen for 16 h. Unreacted 
hexamethyldisilazane was removed in vacuo and the residue was co- 
evaporated twice with toluene (5ml). This compound was used 
immediately in the following coupling reaction without identification. 
4.4.5.6: Synthesis of (±)-l-(2"-benzyloxymethyl-4'-dioxolanyl)thymine (48 
and 49)61 
The acetoxy compounds (47) (1.03g, 4.08mmol), trimethylsilylthymine 
(2-14g, 7.94mmol) and trimethylsilyl triflate (0.29g, 0.25ml, 1.29mmol) in 
dry CH3CN (10ml) were stirred under nitrogen at room temperature for 1 
week. The solution was concentrated in vacuo and the residue redissolved 
in CH2CI2 (20ml), extracted with NaHC03 (2 x 20ml), dried over MgS04- 
The organic layer was concentrated in vacuo and Iyophilised before being 
purified by flash chromatography on silica gel to separate the 1: 1 mixture 
of (x- and P-anomers of the title compound [EtOAc/ petroleum ether(40- 
60), 7/31 to give a total of 1.01g (82% yield) of a white solid: 
Rf = 0.11 (P-anomer) (49) [EtOAc/ petroleum ether(40-60), 7/31; 1H NMR 
(CDC13) P-isomer, 8 1.61 (3H, d, J=l. loHz, C5, -Me), 3.81 (2H, d, J=2.24Hz, 
H5'a&b), 4.09 (1H, dd, J=5.21,10-05Hz, H2'a), 4.16 (1H, dd, J=1.86,10-05HZ, 
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H2'b), 4.61 (2H, s, C6H5-CH-9-O), 5.07 (1H, dd appears as t, J=2 x 2.24Hz, 1-14), 
6.36 (1H, dd, J=1.86,5.21Hz, Hl, ), 7.24-7-33 (5H, m, C6H5), 7.62 QH, d, 
J=1.12Hz, HO, 9.54 (1H, brs, NH); HRMS (EI) calcd (C16H18N205) 318.1216/ 
found 318.1?? 0. 
Rf = 0.17 ((x-anomer) (48), [EtOAc /petroleum ether(40-60), 7/31; 1H NMR 
(CDC13) oc-anomer, 8 1.89 (3H, d,, J=0.94Hz, C5, -Me), 3.54 (2H, d, J=3.72Hz/ 
H5'a&b), 4.00 (1H, dd, J=2.61,9.68Hz, H2'a), 4.37 OH, dd, J=5.21,9.68Hz, H2'b), 
4.58 (2H, S, C6H5-CH? -O), 5.57 (1H, dd appears as t, J=2 x 3.54Hz, H4, ), 6.28 
OH, dd, J=2.97,5.58Hz, Hl, ), 7.16 (1H, d, J=1.18Hz, HO, 7.17-7-33 (5H, m. 
C6H5), 10.21 (1H, brs, NH); HRMS (EI) calcd (C16H18N205) 318-1216, found 
318.1224. 
4.4-5.7: Synthesis of (±)-l-[(2p", 4p')-2'-(hydroxymethyl)-4-dioxolanylI 
thymine (50) 
The (±)-I-(2"-benzyloxymethyl-4' -dioxolanyl)thymine (49) (0-17g, 
0.54mmol) and Pd(OH)2 (20% on Q (0.486g, 0.70mmol) in ethanol (30ml) 
were shaken at room temperature in a Parr bomb at 20psi of H2 for 30 min. 
The catalyst was removed by filtration of the solution through a celite pad 
which was washed with ethanol (50ml). The solvent was removed in 
vacuo and Iyophilised before being purified by flash chromatography on 
silica gel (CH202) to elute the toluene byproduct and (MeOH/CH2CI2,4/6) 
to give 0.11g (91% yield) of white crystals: Rf = 0.23 (MeOH/CH2Cl2,, l/9): 
m. p. = 149-150OC; 1H NMR (CD30D) 6 1.91 (3H, d, J=1.07Hz, C5, -Me), 3.85 
(2H, 2x dd, J=2-20,2.21,13-6Hz, H5'a &b), 4.18 (1 H, dd, J=5.95,10-42HZ, H2'a), 
4.31 (IH, dd, J=1.49,10-05Hz, H2'b), 5.03 OH, dd appears as t, J=2 x 2.05Hz, 
H4'), 6.35 (1H, dd, J=1.49,5.59Hz, Hl, ), 7.91 (1H, d, J=1.49Hz, H6); 13C NMR 
(CD30D) 8 12-53 (C5-Me), 61.65 (CO, 72.10 (C2), 82.26 (Cl, ), 106-63 (C4'), 
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111.70 (C5), 138.35 (C6), 152.70 (C2), 166.44 (C4); HRMS (EI) calcd 
(C9HllN205) 228-0746, found 228.0737. 
4.4.6: (±)-Dioxolane-T (50) as a Glycosyl Donor 
4.4.6.1: N-Deoxyribosyltransf erase 
Five reactions were set-up with varying ratios of P-dioxolane-T and 
adenine in citrate buffer (50 mM, pH 6.0): 
i) P-dioxolane-T (0-5mM) + adenine (0.5mM) 
ii) P-dioxolane-T (l. OmM) + adenine (0-5mM) 
iii) P-dioxolane-T (1.5mM) + adenine (0.5mM) 
iv) P-dioxolane-T (2.5mM) + adenine (0.5mM) 
v) P-dioxolane-T (5-OmM) + adenine (0.5mM) 
The reactions were initiated by the addition of the crude enzyme 
preparation (50gl, 14.3mg ml-1 protein, OAU). The final volume of the 
reaction mixture was 0.5 ml and it was incubated at 400C with no shaking. 
The reactions were followed by reverse phase HPLC on a Techsphere 5C8 
column (25cm x 4.6 mm and a precolumn, 5cm x 4.6mm) as described in 
Chapter 2. No transfer was observed for any of the reactions. 
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4.4.6.2: Thymidine Phosphorylase 
Three thymidine phosphorylases, from the organisms named below, were 
investigated to see if they were able to cleave P-dioxolane-T95: 
i) Lactobacillus casei (rhamnosus) NCIMB 6557 
ii) Lactobacillus casei (rhamnosus) NCIMB 7473 
iii) Lactobacillus casei (casei) NCIMB 4113 
Each reaction contained P-dioxolane-T (10. OmM) and DTT (O. ImM) in 
sodium phosphate buffer (50 mM, pH 7.0) to a total volume of 0.5ml after 
the addition of a crude preparation of the thymidine phosphorylase (50ýtl). 
Each reaction was incubated at 400C with no shaking and was followed by 
reverse phase HPLC on a Techsphere 5C8 column (25cm x 4.6 mm and a 
precolumn, 5cm x 4.6mm) as described in Chapter 2. No cleavage of the 
glycosyl bond and release of thyrnine was observed for any of the reactions. 
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APPENDIX 1: RELATIVE RATES OF GLYCOSYL TRANSFER 
Table A. 1.1: Relative Rates of Glycosyl Transfer between 2'-deoxycytidine 
and 2 and 6-substituted purine bases. 
Compound C-6 C-2 Relative Rates 
Adenine NH2 H 1.00 
6-Methyladenine NHMe H 0.76 
2-Aminopurine H NH2 0.60 
6-Chloroguanine ci NH2 0.52 
Purine H H 0.35 
6-Chloropurine Cl H 0.27 
Isoguanine NH2 _-O 0.25 
N-1 oxide adenine NH2 H 0.14 
Hypoxanthine -_O H 0.13 
Xanthine -_O _-O 0.11 
2-Hydroxypurine H _-O 0.08 
2,6-dichloropurine cl cl 0.07 
2,6-diaminopurine NH2 NH2 0.07 
Reaction conditions: 2'-deoxycytidine (10mM) = 75ul 
Purine Base (10mM) = 25ul 
10% Ethylene Glycol = 50ul 
Citrate Buffer 0 mM, PH6.0) = 300ul 
Crude Enzyme(36U) = 50ul 
Total = 500ul 
Reaction mixture thermostated at 40'C for 10 min before addition of the 
crude enzyme. A 20ul aliquot of the mixture was applied to a Techsphere 
5C8 HPLC column at 0 min and again at 15 min. The initial rates were 
compared using the ratios of CAC after the 15 min reaction time and were 
scaled so that the fastest transfer had a corresponding value of 1.00. 
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Table A. 1.2: Relative Rates of Glycosyl Transfer between 2',, 3'- 
dideoxycytidine and 2 and 6-disubstituted purine bases. 
Compound C-6 C-2 Relative Rates 
Adenine NH2 H 1.00 
6-Methyladenine NHMe H 0.86 
2-Hydroxypurine H =0 0.79 
6-Chloropurine Cl H 0.78 
Isoguanine NH2 =0 0.65 
Purine H H 0.64 
Hypoxanthine =0 H 0.61 
2-Aminopurine H NH2 0.54 
Xanthine =0 =0 0.55 
6-Chloroguanine cl NH2 0.45 
2,6-dichloropurine cl cl 0.42 
2,6-diaminopurine NH2 NH2 0.36 
Reaction conditions: 2', 3'-dideoxycytidine (10mM) = 75ul 
Purine Base (10mM) = 25ul 
10% Ethylene Glycol = 50ul 
Citrate Buffer(lmM, PH6.0) = 300ul 
Crude Enzyme(180U) = 50ul 
Total = 500ul 
Reaction mixture thermostated at 40'C for 10 min before addition of the 
crude enzyme. A 20ul aliquot of the mixture was applied to a Techsphere 
5C8 HPLC column at 0 min and again after 5 d. The transfer rates were 
compared using the ratios of C: ddC after the 5d reaction time and were 
scaled so that the fastest transfer had a corresponding value of 1.00. 
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